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Abstract 
 
Metastasis Associated in Colon Cancer 1 (MACC1) is a newly discovered prognostic and predictive 
biomarker associated with tumor progression and metastasis development. Since our first report 
concerning MACC1 in 2009, MACC1-related research has been exponentially increasing. At present, 
MACC1 involvement in the progression of many cancer types has become increasingly clear. MACC1 
does not only promote invasion and metastasis formation, but it also induces angiogenesis, stemness 
and prevents apoptosis. Although in the last years our research concerning MACC1 gained new 
insights into cancer progression, little is known about its structural role and functions in physiological 
processes. 
In this thesis, I will address for the first time the role of MACC1 during CME (clathrin-mediated 
endocytosis). Importantly, MACC1’s role in CME was first suggested by interactome analysis. Thus, 
MACC1’s CME interactors (CLTC, DNM2, AP2α and TfR), were first identified and validated. In 
addition, MACC1’s impact on TfR endocytic traffic was addressed by studying its effect on surface 
distribution, uptake, recycling and degradation of the receptor with pioneering and newly 
established methods. As a result of this research, MACC1 shows a clear impact on TfR internalization 
and recycling. Thus, the present work dissects the MACC1 protein structure containing predicted 
CME domains such as clathrin box, NPFs and DPF. By deleting these domains, first the impact on the 
binding between MACC1 and CLTC, DNM2 and TfR were analyzed. Also, we characterized the 
distribution of MACC1 in the cell depending on the presence of its CME domains, and then I 
addressed their specific impact during TfR endocytic traffic. 
After we elucidated the MACC1-dependent increase in TfR recycling, we compared its newly 
discovered function during EGFR endocytic traffic. By analyzing TfR -EGFR coupled early endocytic 
traffic during EGF-stimulated internalization in MACC1 overexpressing cell lines, we discovered that 
MACC1 promotes faster recycling of EGFR to PM, in two different cell lines. In order to understand 
the MACC1 CME domains impact on EGFR endocytic traffic, we dissected not only EGFR endocytic 
fate in MACC1 CME mutant cell lines but also the impact on EGFR trans-activation after EGF-
stimulated internalization and downstream signaling, in particular, AKT and ERK1/2. To conclude with 
functional analysis, we also addressed MACC1 CME domains impact on cell proliferation revealing 
that CME domains integrity is important for efficient cell proliferation. 
The present work sheds new light on MACC1’s role during endocytosis, opening a possibility of 
intervention on metastasis development in CRC to improve the survival of patients. 
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Zusammenfassung 
Metastasis Associated in Colon Cancer 1 (MACC1) ist ein prognostischer und prädiktiver Biomarker 
für Tumorprogression und Fernmetastasierung von Darmkrebs. Der exponentielle Anstieg der 
MACC1-verbundenen Publikationen seit dessen Entdeckung im Jahr 2009 verdeutlicht Mitwirkung 
von MACC1 am Krankheitsfortschritt vieler solider Tumore. Dies umfasst sich nicht nur die erhöhte 
Tumorinvasion und Metastasierung, sondern ebenso erhöhte Tumorangiogenese, dessen 
Stammzellfähigkeit und die Vermeidung von Apoptose. Obwohl unsere Forschungsarbeiten in den 
letzten Jahren neue Erkenntnisse über die Auswirkung von MACC1 in der Tumorprogression 
brachten, ist über dessen Proteinstruktur und der damit verbundenen Funktion in physiologischen 
Prozessen wenig bekannt. 
In dieser Arbeit wird zum ersten Mal die Rolle von MACC1 in der Clathrin-abhängigen Endozytose 
(CME) untersucht. Nach massenspektrometrischer Analyse des MACC1-Interaktoms wurde die 
Proteinbindung von MACC1 und den CME-verbundenen Faktoren CLTC, DNM2 und AP-2α, bzw. dem 
CME-Cargo TfR experimentell bestätigt. Davon ausgehend wurde der Endozytoseweg von TfR und 
MACC1-abhängige Änderungen in dessen Oberflächenverteilung, Internalisierung, Recycling und 
Proteinabbau mittels neu etablierter Methoden untersucht und ergab einen deutlichen Einfluss von 
MACC1 auf die Internalisierung und das Recycling von TfR. Daraufhin wurden durch Sequenzanalyse 
der MACC1-Proteinstruktur vorhergesagte N-terminale Interaktionsbereiche mit CME-Faktoren 
betrachtet, die eine Clathrin-Box sowie NPF- bzw. DPF-Motive umfassen. Deletionsvarianten von 
MACC1 wurden zunächst auf ihre Interaktionsfähigkeit mit CLTC, DNM2 und TfR getestet, deren 
subzelluläre Lokalisation bestimmt, sowie deren Einfluss auf den Endozytoseweg von TfR geprüft. 
Das erhöhte Recycling von TfR in Abhängigkeit von MACC1 wurde für EGFR als wichtigen Vertreter 
von krebsrelevanten Rezeptor-Tyrosinkinasen überprüft. Die Analyse des TfR-EGFR gekoppelten 
frühen Endozytosewegs ergab eine erhöhte Recyclingrate des Rezeptors in verschiedenen MACC1-
überexprimierenden Zelllinien. Um den Einfluss der N-terminalen Interaktionsbereiche von MACC1 
auf den Endozytoseweg von EGFR zu verstehen, wurden die MACC1-Deletionsvarianten nicht nur auf 
Änderungen im Verlauf der EGFR-Endozytose geprüft, sondern ebenfalls auf die Aktivierung des 
Rezeptors sowie nachgelagerter Signaltransduktoren wie PI3K/AKT und ERK1/2. Die Wichtigkeit der 
Interaktionsbereiche von MACC1 wurde durch eine Analyse der EGF-induzierten Zellproliferation 
bestätigt. 
Die Ergebnisse dieser Arbeit, die die Rolle von MACC1 in der Endozytose beschreiben, erweitern die 
Interventionsmöglichkeiten gegenüber der Fernmetastasierung solider Tumore und könnten helfen, 
das Überleben betroffener Patienten zu verlängern. 
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1. Introduction  
 
1.1 CRC: incidence, mortality and risk factors 
 
Cancer represents an enormous burden on societies across the world. Generally, in less developed 
countries the incidence and mortality of cancer are higher than in developed countries, but both 
have increased over the last 20 years due to the growth and aging of populations and their increasing 
exposure to known and newly emerging risk factors. Global statistics estimated 18.1 million new 
cancer cases and 9.6 million cancer deaths worldwide in 20181. Cancer death rates are the most 
effective measure to understand research progress against cancer, and although they have been 
rising in the 20th century, the rates had dropped of 26% (2.3 million fewer cases in total between 
1991-2015) because of the early detection and targeted treatments2. Nowadays, colorectal cancer 
(CRC) is the sixth most common cancer in men for incidence and mortality, in new estimated cases 
worldwide. CRC dramatically strikes more women than men. In US for example, CRC is the third-
leading cause of cancer deaths (respectively 12% for women and 9% for men). Worldwide, CRC is the 
fourth most common cancer in new cases incidence and the fifth for mortality for women3.Estimated 
global numbers of CRC-related deaths in 2018 show the highest rates in Asia and Europe, in 
particular in the south. The 5-year survival rate for those with localized CRC, is 80% but declines to 
58%, 10 years after diagnosis. If the cancer has spread metastatically to nearby organs or lymph 
nodes by the time of diagnosis, 5-year survival drops to 15%2. The risk of CRC increases with age and 
drops dramatically starting around the age of 50. CRC also increases in incidence when considering 
factors such as obesity, physical inactivity, a diet high in red or processed meat and low in fruits and 
vegetables, alcohol consumption, and long-term smoking. There is a hereditary component; risk 
increases for those with a personal or family history of CRC and/or polyps, a personal history of 
chronic inflammatory bowel disease (e.g. ulcerative colitis or Crohn disease), some other inherited 
genetic conditions (e.g. Lynch syndrome), and type 2 diabetes2. 
 
1.2 Tumorigenesis and cancer progression 
 
Tumorigenesis and progression of CRC is a slow, multistep process driven by critical genetic 
alterations which can be inherited (germ-line mutations) or progressively acquired (somatic 
mutations). These lead to a high predisposition for CRC development, often resulting in metastasis. 
Hereditary CRC has been categorized into two basic types with different clinical and pathological 
features according to the genetic background: Familial Adenomatous Polyposis (FAP) and Hereditary 
14 
 
Non-polyposis CRC (HNPCC)4. FAP is typically characterized by the loss of the gatekeeper 
adenomatous polyposis coli (APC) gene, while HNPCC is characterized by genetic instability and 
mutations in the mismatch repair process and associated genes4. Understanding the molecular basis 
of CRC has been a long and challenging process which has still not been completed. However, huge 
improvements were achieved in the last years to comprehend the underlying mechanism of CRC 
progression. As many kinds of cancer, also CRC is marked by a loss-of-function defects in tumor-
suppressor genes functions or gain-of-function mutations in oncogenes. 
One of the best characterized features of CRC is genomic instability, which can occur through the 
physical loss of a wild-type copy of a gene and its structure (e.g. APC, cellular tumor antigen p53 or 
the small mother against decapentaplegic (SMAD) gene5. A subgroup of patients exhibit an 
inactivation of genes involved in the mismatch repair process, inherited inactivation somatically or 
through the germ line, as in Lynch Syndrome (2-4% of total CRC cases, for HNPCC)6. The most 
common genes responsible in this context, are DNA mismatch repair protein 1 and 2 (MLH1, MLH2); 
very recently, the mutY homologue gene (MYH) was added to this list. Gene inactivation participates 
in tumor progression by epigenetic silencing, which is mediated by the aberrant methylation of 
promoters in CpG islands.  
CRC develops through a sequential, multistep process, beginning with the mutational inactivation of 
tumor-suppressor genes, in some cases initially involving only APC, and then progressing to p53 and 
transforming growth factor β (TGFβ). A hyperactivation of oncogenes also contributes extensively to 
CRC development. RAS (small GTPase KRas) and BRAF (serine/threonine-protein kinase B-raf) are key 
regulators which promote tumor progression by triggering the downstream hyperactivation of the 
mitogen-activated protein kinase (MAPK) signaling pathway. In addition, somatic mutations of 
PI3KCA (the catalytic subunit of PI3K, phosphoinositide 3-kinase) and the loss of the phosphatase and 
tensin homolog (PTEN) account for one third of the mutations observed in CRC. The aberrant 
regulation of signaling pathways or receptors has also been commonly accepted as a critical step in 
causing adenoma to develop into carcinoma. An activation of the epidermal growth factor receptor 
(EGFR) or the vascular endothelial growth factor receptor (VEGFR) strongly influence the overall 
survival of CRC patients7.  
The last decade has seen mounting evidence that lifestyle and diet constitute risk factors for CRC. 
The increased consumption of red meat, for example, has been shown to increase consistently the 
risk of developing CRC, and this depends on heme (a combination of ferrous iron and a heterocyclic 
organic compound). Heme promotes cancer possibly through genetic alterations in the colorectum, 
affecting particularly the APC and p53 genes8. In particular, heme is degraded and processed by 
heme oxygenase, releasing free ferrous iron. This circulating iron promotes cancer in different ways, 
15 
 
such as, forming reactive oxygen species (ROS) and malondialdehyde via the fat peroxidation 
pathway9,10.   
16 
1.3 Adenoma-carcinoma sequence 
CRC development proceeds along two different pathways: the chromosomal instability (CIN, 
canonical pathway) or through microsatellite instability (MSI). However, only 15% of CRC gain a bi-
allelic inactivation of the mismatch repair genes expressed in MSI11,12. Approximately 85% of CRC are 
characterized by CIN generated during a step-by-step acquisition of mutations in several key 
regulators, which finally promote cell survival and growth by evading cell apoptosis. CRC progression 
overlaps with progressive and increasing CIN in the adenoma-carcinoma sequence. CIN involves not 
only mutations but also the loss of heterozygosity (LOH) of genes, epigenetic silencing through 
methylation, transcriptional upregulation of oncogenes, tumor suppressor repression, translocations 
or chimeric fusions, resulting finally in a loss or gain of function of specific genes. Moreover, CIN is 
the result of early somatic mutations that provide the cell with a survival advantage, resulting in a 
clonal expansion that initiates evolving stages of tumor formation13. The adenoma-carcinoma 
sequence was first hypothesized by Fearon and Vogelstein, who proposed that specific genetic 
events are accompanied by progressive alterations of tissue (Fig. 1). The principal genetic mutations 
of the sequence are briefly discussed below.  
Figure 1 The CRC Adenoma-carcinoma sequence. Brief description of the model of the adenoma-carcinoma 
sequence summarizing all the reported visible clinical pathological changes with the genetic aberrations during 
the early CRC stages and later CIN progression, resulting in a sequential loss or gain of function of several 
genes. The first steps of the adenoma formation are characterized by loss of APC. Sequentially, adenomas 
undergo several mutations, such as mutations in KRAS or BRAF. These events are followed by the loss of 
chromosome 18q and SMAD4, downstream of TGFβ, and mutations in p53. In parallel the MSI, is characterized 
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by the deficiency of the mismatch repair genes and system which results in microsatellite mutations. In the 
lower panel, histological aspects of CRC progression from normal epithelium to carcinoma are represented. 
Adapted from Walther et al., Nat Rev, 2009 and Li et al., Curr Mol Pharmacol, 2009. 
 
1.3.1 APC, β-catenin and Wnt signaling 
 
Early stages of CRC transformation are marked by the loss of the APC function, located on 
chromosome 5q21. Germ line mutations in the APC gene typically lead to FAP development and CRC 
in 90% of the cases 14,15. APC is the key regulator of a multi-protein complex together with the 
glycogen synthase kinase 3 β and axin (APC-GSK3β-axin complex) of the Wnt pathway. This complex 
regulates intracellular levels of β-catenin by phosphorylating it and leading the protein to the 
degradation in the proteasome, resulting in a modulation via Wnt signaling16,17. Mutations in APC 
result in a loss of β-catenin regulation by impairing and avoiding its degradation, migrating instead 
into the nucleus, and resulting in constitutively active transcription of the T-cell factor/lymphoid 
enhancer-binding factor (TCF/LEF) promoter and therefore enforced Wnt signaling18.  
 
1.3.2 KRAS, BRAF and MAPK signaling 
 
Further genetic alterations during early stages of the adenoma-carcinoma sequence involve the small 
GTPase KRas (KRAS). KRAS is a GTP-binding protein located on 12p12.1, whose GTPase activity serves 
as an effector of several downstream pathways19. The mutation status of KRAS is an established 
predictive marker for treating CRC and determines patients response to EGFR inhibitors20. The EGFR 
ligand EGF leads to a homodimerization of the receptor and consequently to transphosphorylation of 
docking sites of the cytoplasmic tail (phosphorylated tyrosine -pY- e.g. 1067/1068). The docking sites 
bind generally to GRB2 or GAB1. These adaptors recruit the guanine nucleotide exchange factor 
(SOS) to activate the small GTPase RAS. KRAS activates the mitogen-activated protein 3 kinase 
(MAP3K, RAF), which activates MAP2K (MEK1/2) in a sequential cascade and ends in the final 
activation of MAPK (ERK1/2)21–23 (Fig.2). This increases MAPK signaling and promotes cell 
proliferation, survival and metastasis24. Oncogenic mutations of these proteins are present in about 
40% of CRCs. Three mutations are the most frequent25, with different effects on the activating 
potential of KRAS and distinct responses to therapies26. KRAS mutations are independent prognostic 
markers in CRC associated with differential outcomes. The most studied and well-known mutations 
are in exon 2 (codon 12 and 13) and exon 3 (codon 61). A poorer prognosis has been associated with 
the glycine to valine substitution of codon 1227. Due to this convergence, CRC stage IV patients with 
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KRAS mutations react poorly to cetuximab and panitumumab and receive low benefits compared to 
patients with wild type KRAS28–33.  
Figure 2 EGF-stimulated signaling cascades and their effects. Upon EGF binding EGFR, the receptor 
homodimerizes activating the tail intracellular kinase domain. In particular, the KRAS signaling cascade is then 
activated by the binding of the adaptor proteins GRB2 and SOS to EGFR tail, leading to a progressive 
phosphorylation of the downstream kinases BRAF-MEK-ERK, leading to the final effect: cell growth, 
proliferation and metastasis development. KRAS mutational status is predictive for CRC patients, in particular 
because KRAS mutated patients are resistant to cetuximab and panitumumab therapies.  Adapted from 
Walther et al., Nat Rev, 2011. 
1.3.3 p53 gene and the DNA repair balance 
P53 is a tumor suppressor protein whose gene is located on the short arm of chromosome 17 (17p). 
P53 is the most frequently altered gene is many cancer types, also known as the “genome 
guardian”34. Its transcription is activated during cellular stress in non-pathogenic conditions, in 
particular, its stabilization leads to a specific DNA binding of target genes resulting in growth arrest 
and cell cycle arrest and cell death35–37 (e.g. cyclin-dependent kinase inhibitor 1 -p21-, growth arrest 
and DNA damage inducible alpha -GADD45A-, E3 ubiquitin-protein ligase -MDM2-). During oncogenic 
stress or DNA damage, P53 can promote the repair of DNA via several genes such as GADD4538. More 
interestingly, after DNA damage p53 is phosphorylated by ATM, migrates into the nucleus and binds 
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to the p21 promoter, leading to a block of the cell cycle via cyclin-dependent kinase 4/6 and D (cdk4-
cdk6/cyclin D)39. P53 is also able to promote cell death by promoting Noxa transcription when DNA 
damage is irreparable; when DNA is successfully repaired or in unstressed cell conditions, p53 is 
degraded from the proteasome after MDM2-mediated ubiquitination and the cell cycle is restored39. 
Pathogenic alterations of the p53 gene or the allelic loss of 17p is very common in CRC and 
determines the impact and potential of cancer therapy40. Mutations in the gene have been reported 
in 4-26% of adenomas, 50% in adenomatous polyps and in 50-75% of adenocarcinomas41. A loss of 
p53 is associated with the transition from adenoma to carcinoma and contributes to the late and 
aggressive stages of CRC. 
 
1.3.4 18q loss and the TGFβ signaling  
 
The deletion of the long arm of chromosome 18 is the most common cytogenetic disruption 
associated with a poor prognosis in CRC; 18q is lost in 10-30% of early adenomas and 60% of late 
adenomas41,42. The original candidate in this region is directly linked and responsible for CRC 
development, was thought to be the “deleted in CRC” (DCC) gene. Later, other tumor suppressor 
genes were identified in this region, including SMAD2 and SMAD4, which are involved in CRC 
development and as mediators of the inhibitory signal from the TGFβ signaling pathway43,44. 
Activated TGFβ signaling regulates features of the cell including growth, apoptosis, differentiation 
and matrix production through the transcription activation via SMAD2/4 of a myriads of target 
genes45. In CRC the deletion of SMAD2 and SMAD4, considered as tumor suppressors, or 
deregulation of SMAD7 (SMAD2/4 inhibitor) leads to a deregulation of the TGFβ signaling and 
resulting in  poor prognosis of CRC by increasing the epithelial mesenchymal transition (EMT) and 
migrative features of the cell46–48.  
 
1.3.5 EMT: how CRC metastases generate during cancer progression 
 
Surgery is still the main treatment for early stages of patients with tumors that have not yet 
metastasized. However, several factors influence the results, such as preoperative staging and the 
choice of treatment (due to UICC or TNM staging system), together with mutational screening49,50. 
CRC survival is highly dependent upon the stage and progression of the disease, and only 10% of 
patients show a 5-year survival rate when presenting metastasis51. 90% of cancer deaths overall are 
due to metastatic dissemination, compromising the outcome of treatments52. One of the hallmarks 
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of tumor progression is the ability to invade and metastasize53. Metastasis formation is an 
extraordinary complex process and underlies the ability of a cancer cell to disseminate through the 
blood flow or lymph nodes from the primary tumor to distant organs, to be able to form a clinically 
relevant lesion at the new secondary site54,55. This process is known as metastatic dissemination and 
is represented in Figure 3.  
Figure 3 Principal steps of EMT. Tumor cells are enabled to migrate and invade the stroma by transcription 
enhancement of several markers and genes for invasiveness such as N-Cadherin, Vimentin and mesenchymal 
integrins. Tumor cells degrade extracellular matrix (ECM) and disseminate into the blood stream or into 
lymphatic routes. After dissemination, tumor cells might target several sites, as bone marrow, lymph nodes or 
other organs. In this sites and organs tumor cells might follow different fates as shown, but principally arise and 
form growing micro metastases. From Aguierro, Nat Rev Cancer, 2007 
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Numerous molecular alterations accompany the metastatic dissemination process56. One of the first 
is the dissolution of the tight junctions, triggered by a decrease of claudin-1 and occludin which are 
degraded or delocalized along with E-cadherin. Coinciding with the molecular changes, cells in this 
phase lose apical-basal polarity57. The TGFβ receptor makes a major contribution by activating EMT 
driving factors: zinc-finger protein (SNAIL), zinc-finger E-box-binding (ZEB) and basic helix-loop-helix 
(bHLH, TWIST). These transcription factors can repress epithelial genes (e.g. E-cadherin) and activate 
genes associated with the mesenchymal phenotype (e.g. Vimentin). During EMT, metastatic cancer 
cells not only change their integrin repertoire to facilitate migration but also increase the production 
of metalloprotease 2 and 9 (MMP2 and 9), enhancing ECM degradation and permitting invasion58,59. 
As well, many receptors and pathways are involved in EMT. In particular, an activated RAS and RAF 
cascade or mutations in the MAPK pathway lead to continuous activity of SNAIL and Rho-GTPase 
activity and increased motility60. EGFR is also involved in the process and when stimulated via EGF, it 
induces the endocytosis of E-cadherin, favouring cell movement. It also induces TWIST expression, 
leading to a reduction of E-cadherin levels61,62 2 and 9, enhancing ECM degradation and permitting 
invasion.58,59 As well, many receptors and pathways are involved in EMT. In particular, an activated 
RAS and RAF cascade or mutations in the MAPK pathway lead to continuous activity of SNAIL and 
Rho-GTPase activity and increased motility.60 EGFR is also involved in the process and when 
stimulated via EGF, it induces the endocytosis of E-cadherin, favouring cell movement. It also induces 
TWIST expression, leading to a reduction of E-cadherin levels.61,62 
 
1.4 Current clinical intervention therapies for CRC 
 
 
The most important known prognostic marker for CRC is the pathological stage of the primary tumor 
at the time of diagnosis. Currently the tumor-node-metastasis (TNM) staging system of the Union for 
International Cancer Control’s (UICC) is used to analyze the disease and classify the extent of cancer 
invasion to the bowel wall and the metastatic dissemination to the lymph nodes. In particular, the 
primary tumor growth (T), lymph nodes infiltrations (N) or metastasis development (M) are 
associated with numbers (1-4 and letters a-b) to assess the CRC stage, prognosis and appropriate 
treatment. The 5-year survival rate for those with localized CRC, classified following the UICC staging 
system63, is 80% but declines to 58%, 10 years after diagnosis. If the cancer has spread metastatically 
to nearby organs or lymph nodes by the time of diagnosis, 5-year survival drops to 15%64,65.  
The most common line of diagnosis and treatment for CRC in the absence of metastatic 
dissemination is first, the correct staging and a subsequent resection/surgery (colectomy). Colectomy 
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is an efficient and curative method, if associated with a radiation pre- and post-operative 
(neoadjuvant and adjuvant therapies). Patients with early, localized stages of CRC (TNM 0-I) show a 
5-year survival of 90%52. For stage II-III patients, in whom the primary tumor has already invaded the
surrounding tissue and lymph node metastases, resection is followed by adjuvant chemotherapy
treatment. Milestones of CRC treatment have been the use of fluorouracil (5-FU) and leucovorin and
Capecitabine. Respectively the first two are administered together; 5-FU is a fluorinated pyrimidine,
that inhibits the thymidylate synthetase and consequently pyrimidine nucleotide synthesis. 5-FU is
normally administered together with leucovorin, a reduced folate that stabilizes the binding between
5-FU and thymidylate synthetase.
Their synergistic effect finally inhibits DNA synthetase and induces cell cycle arrest and apoptosis. 
Capecitabine is a pro-drug that undergoes enzymatic conversion to 5-FU. All three drugs cause major 
side effects including neutropenia, stomatitis, diarrhea, nausea and vomiting. Several other drugs 
have been approved by the FDA for later stages of CRC: Irinotecan stabilizes DNA breaks and 
oxaliplatin induces apoptosis via the formation of DNA bulky structures65.  
In advanced stages (IV) of CRC metastatic dissemination limits the success of the treatment and it is 
the cause of a severe drop in the 5-year survival rate, to 12-15%52. To improve this situation, the FDA 
has approved several other treatment combinations which are already in clinical use. The most 
common is FOLFOX (oxaliplatin, fluorouracil, and leucovorin). Unfortunately, it causes neuropathy in 
92% of patients. New targeted therapies involve monoclonal antibodies against specific targets such 
as EGFR on cancer cells, which aim to block or inhibit cellular pathways essential for tumor growth. 
Further FDA-approved therapies include cetuximab and panitumumab (ABX-EGF), monoclonal 
antibodies designed to target the extracellular domain of EGFR, inhibiting ligand-induced 
downstream signaling, and bevacizumab, targeting the vascular endothelial growth factor to inhibit 
tumor vascularization.66,67 
The aim of these inhibitors is to improve CRC treatment by targeting VEGF/VEGFR triggered 
PI3K/AKT- FAK- and MAPK signaling pathways at different levels affecting migration, cell cycle 
progression, survival and proliferation of tumor cells.68 Nevertheless, several studies conducted on 
cetuximab have revealed limitations. Cetuximab is effective only whether the patient bears a wild-
type form of KRAS or EGFR. When KRAS or EGFR are mutated at the onset of metastasis, resistance is 
dependent on the hyperactivation of the downstream cascade, due to constitutively active upstream 
KRAS.33,69,70 New targeted therapies are needed to overcome the effect of these mutations and 
constitutive hyperactivation of the EGFR pathway due to its negative impact on treatment outcomes. 
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1.5 MACC1: a newly identified prognostic and predictive marker for CRC 
 
 
In 2009, the group of Prof. Stein identified MACC1 (Metastasis associated in colon cancer 1) as a 
prognostic and predictive marker in CRC through a genome-wide RT-PCR analysis of the normal 
mucosa, primary tumors and metastases of patients. MACC1 mRNA expression is higher in malignant 
tissue than in adenomas or normal mucosa, and levels in the primary tumor correlate positively with 
metachronous distant metastasis formation and negatively with metastasis-free survival. The 5-year 
survival rate for stage I-III CRC patients with high MACC1 expression in the primary tumor is only 15% 
compared to subjects with low MACC1 expression which show a higher 5-year survival rate (80%). 
There is increasing evidence that MACC1 plays pivotal roles in development and progression of 
entities beyond CRC, particularly in lung adenocarcinoma, esophageal cancer, ovarian cancer, 
glioblastoma, glioma, pancreatic cancer, squamous cell carcinoma, renal pelvis carcinoma, bladder 
urothelial carcinoma, cervical cancer, osteosarcoma, breast, esophageal and gastric cancer71–78, 
totalizing 22 different entities. However, the underlying mechanisms by which MACC1 mediates 
progression in many of these solid tumor entities are still vague. Functionally, MACC1 regulates the 
mRNA expression of the HGF receptor MET, increasing its transcription via the MET promoter. Prior 
work has identified MACC1 as a prognostic and predictive biomarker, not only in CRC, but in diverse 
type of cancers. Its effects include increases of cell motility and migration via MACC1/HGF/MET, 
PI3K/AKT and MEK/ERK, Wnt/β-catenin axes coordinating EMT79,80 (Fig. 4).  
Furthermore, MACC1 overexpression leads to cell invasion and angiogenesis, and induces tumor 
growth and metastasis formation in xenograft mice 81,82. Recently our group proved also, that 
MACC1-dependent tumor progression depends on increased activation of pluripotency mediated by 
the MACC1/Nanog/Oct4 axis driven by Wnt-β-catenin signaling83. MACC1 overexpression appears to 
decrease 5-FU and cisplatin sensitivity in gastric cancer via MCT1-upregulated expression affecting 
the results of therapy and the relapse of the cancer, but showing treatment-predicting traits84–87. We 
recently used high-throughput screening to identify two new potent MACC1 transcriptional 
inhibitors: Rottlerin and Lovastatin, resulting in reduced MACC1 mRNA and protein expression and 
leading to reduced cell motility88.  
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Figure 4 MACC1 3D structure and impact on cancer hallmarks and associated pathways. MACC1 impact has 
been related to cancer hallmarks by characterizing its involvement in several signaling pathways and relating it 
to the biological characteristics of cancer. Many pathways are involved in the MACC1-mediated effect on 
cancer cells. From Radhakrishnan et al., Cancer and metastasis Review, 2018  
1.5.1 MACC1 structure and roles related to pathways 
The MACC1 gene is located on the human chromosome 7 (7p21.1)89. The unspliced MACC1 transcript 
contains seven exons and six introns, resulting after splicing in a final coding cDNA of 2,559 
nucleotides. The gene encodes for a protein of 852 amino acids. Several domains have been 
predicted in the protein structure of MACC1 (Fig. 6)90. 
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The N-terminal domain of the protein contains a clathrin box, two Epsin 15 Homology interaction 
motifs (NPF), and an interaction motif (DPF) for adaptor protein 2α (AP-2α). The N-terminal domain 
presents is then followed by domain present in zona occludens 1 (ZO-1) and uncoordinated-5 
proteins (ZU5 domain), and a domain conserved in ankyrins domain (UPA domain). These domains 
are shown in Figure 5.  
The C-terminal region of MACC1 includes a SH3 domain which is generally important for interactions 
between proteins in particular with the proline rich domain (KxxPxxP, PRD) and signalosome proteins 
such as growth factor receptor bound protein 2 (GRB2), E3 ubiquitin-ligase (c-Cbl), and proto-
oncogene tyrosine kinase (Src)91 (Fig.5). It is also known that the SH3 domain typically interacts with 
proline rich domains (PRD) of other proteins, such has dynamin92,93. Interestingly, the location of 
MACC1 on chromosome 7 is near the TWIST gene which is involved in CRC and tumorigenesis. 
MACC1 is able to upregulate the TWIST1/2 genes promoting vasculogenic mimicry, but also to induce 
the activation of the TWIST/VEGF signaling pathway in gastric cancer94,95.  
 
Figure 5 Schematic overview of MACC1 protein structure. MACC1 shows several clathrin-mediated 
endocytosis domains at its N-Terminus and C-Terminus. At the N-Terminus: the clathrin box, two NPFs motifs, 
and the DPF motif. Centrally: ZU5 and UPA domains. At the C-Terminus: the proline-rich domain (KxxPxxP), the 
SH3 domain and two death domains (DD). 
 
One of the recently discovered targets of MACC1 is β-catenin and Wnt signaling; in nasopharyngeal 
carcinoma and CRC, MACC1 and β-catenin are positively correlated; knocking down both inhibits 
proliferation, migration and invasion. Silencing MACC1 inhibits β-catenin and c-Myc but doesn’t 
affect ERK1/2 expression in NPC.  
Accordingly, in CRC MACC1 overexpression upregulates MET, β-catenin, c-Myc, cyclin D1 and MMP9 
expression and the upstream factor p-GSK3β. In HCT116 CRC cells, MACC1 overexpression causes a 
suppression of E-cadherin and increases vimentin, the first step for a cell undergoing EMT. Taken 
together these data show a prominent role of MACC1 in tumorigenesis and EMT via Wnt/β-catenin 
signaling72,96.  
Very recently, MACC1 has been characterized regarding another fundamental pathway: PI3K/AKT. 
Although no effect of MACC1 overexpression on the PI3K/AKT pathway has been shown in CRC89, 
another effect has been described in gastric cancer and hepatocellular carcinoma. In gastric cancer, 
MACC1 overexpression predicts poor prognosis and enhances proliferation, migration, invasion; 
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additionally, it induces trastuzumab resistance in GC cell lines, enhancing their resistance to the 
metabolic stress via the Warburg effect and activating PI3K/AKT signaling97,98.  
MACC1 is also involved in the HGF/MET pathway as a key regulator; our lab identified MET as a 
transcriptional target of MACC1. In CRC it is also known that MET-promoting tumorigenic progression 
depends on a collaboration and balance between MACC1 and miR-199. This microRNA has generally a 
suppressive role but Giordano’s group has shown that in metastatic tumors, its downregulation 
correlates with the overexpression of MET and MACC1, favoring MET-induced tumor growth99. 
Furthermore, MACC1 has been identified very recently as a regulator of the MAPK/ERK pathway; in 
pancreatic cancer MACC1 is not only an indicator of poor prognosis but its inhibition suppresses 
proliferation and migration.  
When MACC1 is downregulated, pancreatic cell lines are more sensitive to gemcitabine treatment via 
inhibition of the ERK signaling pathway100. In the ovarian cancer cell line SKOV-3, it has been shown 
that silencing MACC1 leads to a higher sensitivity of the cells to cisplatin, increased cisplatin-induced 
apoptosis, and decreases in p-ERK1/2 expression84. In gastric cardia adenocarcinoma, MACC1 might 
contribute to cancer progression as well; it has been predicted as a target of miR-141, which 
suppresses MACC1 by binding its 3’-UTR, leading to an effect on MAPK/ERK and P38 MAPK signaling 
pathway101. In summary, over the last 10 years the role of MACC1 has been dissected in several 
cancer types and has been implicated in pathways such as the HGF/MET axis, MAPK/ERK, VEGF, 
TWIST1/2, Wnt/β-catenin and PI3K/AKT. 
1.5.2 Role of MACC1 in cancer progression and metastasis 
MACC1 has been identified as a prognostic and predictive marker for many solid cancer entities. Its 
overexpression promotes proliferation, invasion, migration, and colony formation72,74,77,78,100,102–107. In 
vivo studies with several mouse models showed that the intrasplenic injection of SW480 cells 
overexpressing MACC1 clearly increases tumor growth and liver metastasis compared to the empty 
vector, confirming its tumorigenic and metastatic capabilities89. Recently, reports have shown that 
silencing MACC1 with target specific shRNA (SW620/shMACC1) decreases tumor formation and 
metastasis in xenografted mice81. MACC1’s role in cancer and its effect has been also investigated 
with regard to another characterized prognostic marker: the cysteine-rich protein 61 (CYR61). 
Silencing both by targeting them with miRNA (miR-100 and miR-143), inhibited the EMT process that 
promotes apoptosis in CRC cell lines and decreases tumor growth. Targeting MACC1 and CYR61 
decreased not only the rates of invasion and metastasis formation but also the size and growth of the 
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tumor, thereby increasing the overall survival of tumor-bearing mice. In conclusion, targeting MACC1 
in combination with CYR61 via miRNAs may be a useful therapeutic strategy to treat CRC in future 
years82.  
 
1.5.3 MACC1 is a target of many miRNAs 
 
An abnormal expression of specific miRNAs contributes to cancer development by regulating 
proliferation, apoptosis and drug resistance in cancer cells. A dysregulation of the silencing effects of 
other miRNAs may cause tumor progression and metastasis formation108. The relationship between 
MACC1 and miRNAs has been widely explored in the last 4 years. Many papers show direct miRNA 
effects on proliferation, invasion and migration via targeting MACC1. Recently, MACC1 was identified 
as a target of miR-994. In gastric cancer cells, miRNA-994 inhibits EMT and metastasis formation but 
the re-expression of MACC1 rescued the effect, restoring EMT probably via the MET/AKT pathway109. 
In CRC cells, MACC1 has also been shown to be a target of miR-433. The tumor-suppressive 
characteristics of this miRNA lie in its ability to reduce viability and promote apoptosis in CRC cell 
lines by targeting MACC1 expression110.  
A novel therapeutic approach for treating liver metastasis in CRC has been suggested through the 
negative regulation of MACC1 expression targeted by Hsa-miR-574-5p. After an in silico analysis this 
miRNA was identified as a negative regulator of MACC1; its knockdown increased colony formation, 
cell invasion and spheroid formation of HCT116 cells, compared to the control group. Mimic 
transfected SW1116 cells showed the opposite effect. Finally, these effects were studied in a mouse 
model of liver metastasis after intrasplenic injection of GFP-labeled SW1116 and HCT116 cells, and 
the incidence of liver metastasis was increased111.  
miR-338 has exhibited a prominent suppressive behavior by targeting MACC1 in several cancer types. 
In HCC, miR-338-3p shows a negative correlation with MACC1, VEGF and β-catenin; its suppression 
corresponds to an increase in angiogenesis. In normal brain and glioma tissues, miR-338-3p also 
regulates tumor progression by silencing MACC1. In glioma cell lines the miRNA increases apoptosis 
and slightly inhibits proliferation, while MACC1 partially rescues this effect. In conclusion, in glioma 
cells this miR regulates aggressive cancer by targeting MACC1, engaging a tumor-suppressive and 
balancing role. More relevantly, in gastric cancer miR-338-3p silences ZEB2 and MACC1, inhibiting 
migration and invasion and upregulating the expression of EMT markers such as E-cadherin. By 
targeting MACC1, miR-338-3p inhibits also the MET/AKT pathway, whereas a re-expression of MACC1 
and ZEB2 in this context reverted the cancer-inhibitory effects on EMT79,112,113. To conclude, MACC1 
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has become a widely studied prognostic marker and a number of aspects of its relationships to 
miRNAs remain to be explored. This suggests that targeted and combined therapies might constitute 
a promising avenue for new therapies.  
1.6 Hints about MACC1 functions from its homologue SH3BP4 
In this thesis, SH3BP4 was studied as an homologue of MACC1; they share a 43.7% sequence 
homology91. In particular, they own similar clathrin boxes NPFs motifs, DPF motif and a SH3 domain. 
In this study we dissected the role of MACC1 in endocytosis using SH3BP4 as reference and positive 
control, considering the homology. Other proteins with similar to MACC1 in the domain composition 
include ANK, UNC5, UNC5CL71,89,90. The MACC1 homologue SH3BP4 (also named Transferrin 
Trafficking Protein, or TTP), is a SH3-domain binding protein first identified in 1999 through a 
genome-screen in corneal fibroblasts114. It is expressed in pancreas, placenta, heart and kidney. Its 
localization has been studied via FISH and the gene for SH3BP4 was found in 2q37.1-q37.2. The 
translated protein contains 963 amino acids (107.5 kDa) and belongs to the EH–network family of 
endocytosis proteins. Its structure contains several motifs including three NPFs, a DPF and a P-x-x-P 
motif, two SH3 domains, several tyrosine phosphorylation sites and death domains at its C-
terminus115 (Fig. 6).  
Figure 6 Schematic structure of SH3BP4. In different colours from the N-Terminus: the CB, an SH3 domain, 
three NPFs, a PxxP domain, the ZU5 domain, the UPA domain, a second SH3 domain, two DD domains. 
The 1999 study suggested an involvement of SH3BP4 during endocytosis, a role confirmed in a 
number of subsequent studies. SH3BP4 localizes mainly at the plasma membrane (PM) and in early 
and late endosomes in retinal pigment epithelial cells. One of its identified regulators is the 14-3-3 
protein114. The two proteins interact directly at Ser245, a residue essential for their association. 
SH3BP4 is responsive to oxidative stress and is phosphorylated on Ser245 by the AKT kinase, the 
downstream target of PI3K, to promote the association with 14-3-3116–120. The first clear indication on 
SH3BP4 function was introduced by Tosoni’s group121. SH3BP4 interacts with clathrin, dynamin, epsin 
15, and the AP-2 complex. It has been found in transferrin receptor-clathrin coated pits and coated 
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vesicles (TfR-CCPs and TfR-CCVs), and the colocalization of SH3BP4 with CLTC and TfR within these 
vesicles is dependent on the SH3 domain of TTP. SH3BP4 specifically regulates TfR endocytosis 
without perturbing the internalization of EGFR and low-density lipoprotein receptor (LDLR). Its 
knockdown or overexpression leads to a decreased rate of TfR internalization without affecting the 
recycling route. SH3BP4 specifically regulates TfR cargo loading on the vesicle through 
phosphorylation events and it has also been hypothesized that this might exclude SH3BP4 from 
EGFR-containing pits. Three models have been proposed of SH3BP4 function during TfR 
endocytosis121 (Fig. 7) without perturbing the EGFR and LDLR. Its knockdown or overexpression lead 
to a decreased rate of TfR internalization without affecting the recycling route. SH3BP4 specifically 
regulates TfR cargo loading on the vesicle through phosphorylation events and it has also been 
hypothesized that this might exclude SH3BP4 from EGFR-containing pits. Three models have been 
proposed of SH3BP4 function during TfR endocytosis121 (Fig. 7) 
 
Figure 7 SH3BP4 functions and speculated working models during TfR-CCV formation. (A) Adaptor model: TTP 
links TfR to CLTC (directly, left) or via AP-2 (indirectly, center) or with AP-2 (right). (B) Scaffold coordinator: TTP 
recruits dynamin regulating the fission machinery, TTP might bind CLTC directly. (C) Vesicle loading model: TTP 
acts as in (B) but switches off dynamin until TfR is not loaded into the pit. After TfR is loaded TfR excludes TTP 
from the machinery, allowing the activation of dynamin. The three models are not exclusive, and have been 
adapted from Tosoni et al., Cell, 2005. 
 
Further work has shown that SH3BP4 has functions related to the fibroblast growth factor receptor 
2b receptor (FGFR2b). Olsen’s group showed that SH3BP4 acts as a molecular switch of the FGFR2b 
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receptor and is recruited at the signalosome of the FGFR2b receptor depending on whether the 
stimulus is FGF-7 or FGF-10. The result is two different but aggressive cellular outputs. When FGFR2b 
is stimulated with FGF-10, the receptor is phosphorylated at the cytoplasmic tail (on the tyrosine 
734), allowing the recruitment of PI3K via SH3BP4 at the signalosome. This stimulates the recycling of 
the receptor to the PM, leading to sustained signaling and cell migration as a final result. In contrast, 
when FGFR2b is stimulated by FGF-7, SH3BP4 is not recruited and PI3K does not phosphorylate Y734. 
This leads to transient signaling and to the degradation of the FGF2b receptor and the final outcome 
is a switch to cell proliferation122 (Fig. 8). 
Figure 8 SH3BP4 sustains migration, signaling and recycling of FGFR2b receptor. Schematic representation of 
the proposed model from the Olsen’ group. FGF10 ligand-mediated stimulation of the FGFR2b determines a 
phosphorylation of the Y734, and an interaction with the catalytic unit of PI3K (p85) and the subsequent 
recruitment of SH3BP4. SH3BP4 is responsible for the FGFR2b sorting at the endosomal level towards TfR-
positive compartments and endocytic recycling compartments (ERC). On the contrary, FGF7 ligand-stimulated 
clathrin-mediated endocytosis (CME) of FGFR2b only determines a transient signaling, the Y734 is not 
phosphorylated upon stimulation, and therefore p85 not recruited, together with SH3BP4, at the FGFR2b tail. 
The receptor is targeted to degradation. Adapted from Francavilla et al., Molecular Cell, 2013.  
A number of additional roles have been identified for SH3BP4. An active role for this protein has 
been hypothesized during apoptosis in ARPE-19 cells118. Transfection of these cells with its C-terminal 
DD-domains stimulates the cells to progress more quickly toward apoptosis. Furthermore, this
protein has been recently shown to be targeted by miR-125b as a novel melanogenesis-regulator
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gene in melanoma cell lines. miR-125b binds directly to the 3’-UTR of SH3BP4, thereby decreasing its 
expression. SH3BP4 is positively regulated by MITF, a master gene in melanocytic cells123.  
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1.7 Endocytosis: biological role and tumorigenic involvement 
Endocytosis is a physiological process by which cells takes up nutrients and material from the 
environment through well-organized structures. It regulates the lipid and protein composition of the 
plasma membrane. A number of endocytic processes have been identified over the last years and can 
be subdivided in two branches: CME and clathrin-independent mechanisms (NCE). The most studied 
clathrin-independent mechanisms in mammalian cells are those that are caveolin-dependent124,125, 
GRAF-1-dependent (CLIC/GEEC)126,127, flotillin- and Arf6-dependent128,129 and Il-2 receptor-dependent.  
Very recently, Di Fiore’s studies showed that NCE and CME are not exclusive, when considering the 
EGFR receptor. It is well-established that EGFR is internalized and targeted to degradation, mediating 
signaling attenuation. Di Fiore’s pioneering researched showed instead, that CME-internalized EGFR 
is targeted to recycling, while NCE-internalized EGFR is sorted for degradation, modifying the nature 
of the signaling attenuation or enforcement130.Thus, endocytosis controls numerous biological 
processes including cell signaling. In this thesis the focus will be CME-mediated signaling and its 
impact on cell physiological endocytic processes.  
CME is important for many reasons; it is fundamental to neurotransmission, signal transduction and 
the plasticity of the plasma membrane in response to distinct stimuli. The intake of receptors from 
the plasma membrane into the cells during CME results in the formation of vesicles in sequential and 
well-regulated steps that place the receptor in a protective “cage” along with adaptors; they are then 
transported into other organelles to perform their biological actions. Briefly, clathrin vesicle 
formation is divided into the sequential steps of nucleation, cargo selection, coat assembly, scission 
and uncoating 131–133.  
Figure 9 Clathrin coated vesicle formation stages. Sequential representation of the CCV assembly is shown. 
The formation of a CCV is divided in five stages, in total the entire process is carried out in 45-60 sec. ca. and 
involves more than 100 different proteins. In red, the proteins will be considered in this thesis: clathrin, AP-2, 
dynamin. Many other proteins have been identified in this process such as: intersectin, EPS15, F-BAR domain-
containing Fer/Cip4 homology domain-only proteins 1 and 2 bar domain only 1,2 (FCHO1,2), 
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Bin/amphiphysin/Rvs protein (BAR protein), Auxilin and the G-associated kinase (GAK). Adapted from 
McMahon et al., Nat Rev, 2011. 
The first stage of a CCV formation is nucleation and is characterized by proteins including FCHO1,2, 
intersectin and EPS15 (Fig. 9). These proteins are involved in the first step before the formation of 
the vesicle and are recognized as “nucleators”. They create a first interaction hub during the 
curvature of the plasma membrane while the “pit” is formed, preparing the plasma membrane 
before the main scaffolding “clathrin-AP-2” hub is constructed to finalize CCV formation134–136. During 
the cargo selection step clathrin and AP-2 cooperate simultaneously to orchestrate the maturation of 
the pit. AP-2 acts as a major hub to modulate the recruitment of several adaptors, the 
phosphatidylinositol 4,5-bisphosphate (PIP2) and the cargo receptor, and support the clathrin initial 
coating of the pit. During coat assembly and scission, dynamin and BAR proteins cooperate to 
mediate the curvature of the CCV and the neck formation, which allows the vesicle to be pinched off 
the cytoplasm. Sequentially Auxilin and GAK mediate the vesicle uncoating in the cytoplasm. Below 
the structures and roles of clathrin and AP-2 before describing the final stages of CCV formation will 
be briefly and concisely analyzed 131. 
 
1.7.1 Clathrin structure, biological and tumorigenic function 
 
Clathrin was first identified in 1975 by the postdoc Barbara Pearse. Her original aim was to identify 
and purify tubulin, but she then discovered and characterized clathrin coated cages (Fig. 10). CCVs 
are hexagonal and pentagonal lattices that can self-organize in cages of triskelia. Clathrin is a trimer 
made of three heavy chains (CHC; 190kDa) associated with three light chains (CLC; 23kDa). The most 
relevant part of clathrin is the terminal domain (CTD, Fig. 10), a region protruding inward from the 
clathrin cage which comes in contact not only with adaptors throughout CCV formation but also 
other membrane interacting proteins. The terminal domain is constituted by a β-propeller structure 
and can interact with a consensus motif (LΦXΦD/E, Φ hydrophobic residue), which is recognized as 
“the clathrin box“, on interacting proteins133,137–139.
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Figure 10 Clathrin structure. (A) The clathrin triskelion is represented. All the CHC domains are reported in the 
figure, including the most relevant one: the terminal domain. (B) 3D structure and packing of the CCV. Adapted 
from Kirchhausen et al., CSH Perspect Biol, 2014 
 
Clathrin's involvement in tumorigenic processes has not been fully clarified, but a direct involvement 
of clathrin in tumors was recently shown, providing evidence of chromosome fusion (chromosome 2 
and 17) in hemopoietic tumors. Further, an evidence for clathrin as an oncogenic-driving protein has 
been pointed out in the inflammatory myofibroblastic tumor (IMT) in which ALK and the clathrin 
heavy chain gene (ALK-CLTC) are fused140.  
 
1.7.2 AP-2 structure, biological and tumorigenic function 
 
The adaptor protein 2 (AP-2) was first identified 30 years ago, as a “basket assembly” protein, able to 
promote the formation of a clathrin coat from purified triskelia. Nowadays, AP-2 is known to be one 
of the major components of CCV but also the main driver of receptor internalization. The adaptor 
protein family is constituted of 5 members termed AP-1 to AP-5. Only AP-2 takes an active part in 
CCV formation during CME, while the others regulate the traffic between endosomes and the trans-
Golgi network141,142. AP-2 is associated with the plasma membrane and consists of two larges 
subunits (α and β2, 100-130 kDa), two medium (µ2, 50 kDa) subunits, and one small (σ2, 20 kDa) 
subunit. The main subunits conserve small flexible appendages which can associate with clathrin via 
their clathrin boxes or DPF motifs. In summary AP-2 is recruited to the PM and oscillates between a 
closed and an open conformation; the latter is able to bind PIP2 and exposes additional sites 
important for CCV formation. Interactions with cargos stabilize the open conformation of AP-2, 
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leading to clathrin recruitment. The entire sequence of events takes globally 2 minutes. During CCV 
formation, the coat undergoes maturation. BAR proteins mediate the invagination of the plasma 
membrane and dynamin regulates the final step of vesicle scission.  
 
1.7.3 Dynamin 2 structure, biological and tumorigenic functions 
 
The dynamin super-family comprises several multi-domain GTPases with low affinity for guanine 
nucleosides and a number of characteristics related to self-assembly. The dynamin protein weighs 
around 70kDa and has diverse functions in cells. Dynamin's main function is to participate in 
membrane-remodeling events by forming self-assembling rings/helix-like structures around the neck 
of vesicles. Dynamin regulates the rate-limiting step of CCV fission and the fusion of intracellular 
trafficking vesicle into other endosomal organelles, influencing strongly endocytic traffic. An example 
is the transport of recycling vesicles from the tubular endosome to the plasma membrane, as occurs 
with the TfR143–145.  
Several isoforms of dynamin are known; here the focus will be restricted to known functions of 
dynamin 2 (DNM2). DNM2 has been identified as an important player during CME, regulating the 
rate-limiting step in pinching off the CCV and therefore directly regulating endosomal trafficking (Fig. 
11). Alterations in the guanosine triphosphate hydrolase (GTPase activity) of DNM2 lead not only to 
aberrant CCV formation but also strongly impair downstream signaling of activated receptors (e.g. 
EGFR)146. Several isoforms of dynamin are known; here the focus will be restricted to known 
functions of DNM2.  
DNM2 has been identified as an important player during CME, regulating the rate-limiting step in 
pinching off the CCV and therefore directly regulating endosomal trafficking. This leads to a general 
dysregulation of the process and increases tumorigenic effects on cancer cells.147,148 Recently DNM2 
has been determined to regulate actin dynamics at lamellipodia/invadopodia and focal adhesions, 
leading to suggestions that DNM2 might become an interesting therapeutic target in metastasizing 
solid cancers. There the remodeling of cell architecture is promoted by migration and is the key to 
aggressiveness.149–152  
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Figure 11 Dynamin GTP-mediated fission of clathrin coated vesicle. Dynamin binding to GTP triggers the 
assembly of dynamin units in a neck. After the collar assembly, the dynamin-mediated hydrolysis of GTP in GDP 
changes, its transformation and conformation, closing the neck resulting in the CCV pinching off into the 
cytoplasm. From Mettlen et al., Biochem Soc Trans, 2009 
 
1.8 Endocytosis and Signaling 
 
Endocytosis has recently emerged as a crucial factor in cancer. The effective internalization and 
intracellular traffic of plasma membrane proteins such as receptors and their endocytic and signaling 
adaptors have long been considered critical check-points in mediating an attenuation of signaling 
after stimulation by an extracellular ligand. Considerable evidence has been gathered to show that 
cell proliferation and migration are also results of aberrant and derailed endocytosis, as shown in 
Figure 12. In the case of receptor tyrosine kinases (RTKs) and integrins, the recycling process has an 
impact on sustaining signaling during proliferation or mediating the turnover of anchoring sites, 
respectively. In the case of integrins this contributes to malignant transformation153,154.  
 
 
 
Figure 12 Derailed endocytosis in the biological processes of proliferation and migration. (Left panel) Derailed 
endocytosis is responsible for enhanced proliferation and cell migration. In particular, increased cellular 
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proliferation depends on aberrant receptor ubiquitination, which avoids the receptor target to degradation, 
increase receptor recycling to PM, or defects in endocytic adaptors. (Right panel) A derailed endocytosis 
enhances also the integrin-mediated migration of cancer cells. In particular, integrin increased recycling via 
RAS-related protein 4 or 25, or stabilized microtubular structures. From Mosesson et al., Nat Rev Cancer, 2008 
 
CME modulates signaling of receptors that have been stimulated at various stages. This guarantees 
different signaling outputs depending on the plasticity of endocytic compartments. As shown in 
Figure 13 the early endocytic control of signaling begins at the plasma membrane and typically 
depends on the fidelity of the endocytic machinery assembly during the fission of a CCV155156. Beyond 
the availability of the receptor and its ligand at the plasma membrane, the correct recruitment of the 
endocytic machinery during the formation and the fission of CCVs directly influences the 
prolongation of active signaling. This depends mainly on the recruitment of dynamin and AP-2. In 
more detail, dynamin recruitment is a prerequisite for a productive CCP maturation, while the role of 
AP-2 is dispensable157. 
 
Figure 13 Endocytic "check points" of the EGFR receptor. Representation of the EGFR signaling check point 
after EGF-stimulated endocytosis triggered both via CME and NCE. (Left) EGF-activated EGFR is internalized via 
CME, and regulates the signaling during vesicle formation, at endosomal sites and via recycling. EGF-triggered 
NCE endocytosis leads the EGFR to ubiquitination and degradation, attenuating the signal. P - phosphorylated 
receptor; Ub - ubiquitinated receptor. Adapted from Disanza et al., Molecular Oncology, 2009 
 
38 
 
The expression of specific mutants of dynamin or dynamin depletion leads to a complete disruption 
of the EGFR endocytosis and thus to the attenuation of EGF-dependent EGFR activation and 
degradation with consequent attenuation of ERK1/2 and PI3K downstream pathways146. This makes 
the internalization of EGFR an important step for a sufficient activation of signaling. Endosome-
associated internalized EGFR also supports cell survival by recruiting signaling machinery (such as 
GRB2, SHC and PI3K) to the endosome and sustaining the active signaling cascade directly from this 
compartment 158. 
 
1.9 Biology of the Transferrin receptor 
 
TfR is the most commonly used model to investigate the individual steps in CME and their regulation 
by the cell. TfR is a 90-95 kDa transmembrane glycoprotein involved in the cellular uptake of iron and 
thereby the regulation of cell growth159. Knockouts of TfR in early embryonic development lead to a 
severe dysregulation of erythropoiesis and neural development160. At the PM, TfR is present as a 
homodimer connected by disulfide bridges. The extracellular part of the receptor contains the 
binding site for transferrin (Tf)161,162. An overview of TfR protein structure can be seen in Figure 14. 
TfR expression is regulated at the post-transcriptional level in response to intracellular iron deposits. 
TfR is ubiquitously expressed at low levels in most cells but is highly expressed in cells with a high 
proliferative rate159,163–167. TfR expression in cancer cells is higher compared to healthy counterparts. 
This higher TfR expression has been shown to be due to an increased need for iron as a cofactor of 
the ribonucleotide reductase enzyme involved in DNA synthesis in highly proliferative cancer 
cells159,166–170. 
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Figure 14 The TfR structure. This scheme represents a type II transmembrane transferrin receptor homodimer 
consisting of two monomers linked by disulfide bridges at cysteines 89 and 98. The TfR1 contains an 
intracellular domain, a transmembrane domain, and a large extracellular domain. This structural model of the 
extracellular domain consists of three subdomains: apical (A, orange), helical (H, green) and protease-like 
domain (P, blue). Adapted from Luria-Perez et al., Biol Med Hosp Inf Mex, 2016 
 
TfR trafficking in the cell has been extensively explored; iron-binding transferrin (ferric transferrin, h-
Tf) binds the receptor and is internalized via CME. Through the acidification of pH in endosomes, Tf 
changes its conformation releases the bound iron and stays as apo-Tf bound to the TfR. This complex 
can be recycled back to the cell surface, where neutral pH triggers apo-Tf release162,171,172. In contrast 
to receptors such as EGFR, TfR is constitutively internalized independently of the binding of h-Tf. 
After internalization, TfR is sorted into early endosomes either for recycling or degradation. 95% of 
TfR/apo-Tf complexes are recycled back to the cell surface; the remaining 5% are degraded in 
lysosomes173.  
 
1.10 Involvement if TfR in CRC and targeted therapy 
 
Iron is a primary nutrient that regulates cell growth and proliferation, but an overload may cause 
accumulation/toxicity, mutations and oxidative stress. This has led to the identification of excess iron 
as a risk factor for CRC174,175. The overexpression of TfR on the surfaces of cancer cells confers a 
growth advantage and increases their malignancy168. The relationship between iron uptake in CRC 
and cell growth was first introduced by Zorbas’ group, who tested CRC cell lines (HCT116, RKO, CBS 
and GEO) for their growth sensitivity to Tf, EGF and insulin. Poorly differentiated HCT116 and RKO 
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cells acquire growth capability in the presence of Tf or insulin, or both, but only in combination with 
EGF; they are insensitive to EGF alone. More differentiated cell lines (CBS and GEO) still respond to 
EGF but require at least Tf and insulin to support their growth. Moreover, HCT116 cells respond to Tf 
and insulin in growth media by increasing the expression of EGF receptors at the cell surface.176  
TfR density has been studied to date in 23 colon tumors (adenoma and malignant villous tumors) and 
their respective healthy mucosa after surgical resection. Analysis of the Tf binding capacity of tumor 
cells has shown that it increases compared to the control mucosa, leading to the introduction of TfR 
as a reliable prognostic marker that can be used to estimate the growth rate of tumors in CRC. In 
contrast to this role for TfR in CRC, Zarkovic’s group has highlighted a differential expression of TfR: a 
higher expression of TfR in CRC samples classified as Dukes A and B (well differentiated) and a lower 
expression in carcinoma samples Dukes C and D (poorly differentiated), the prevalent types to 
develop metastasis177.  
A recent interesting study of 11 CRC carried out by the Tselepis’ group revealed a general increase in 
the expression of iron import proteins (e.g. DMT1 and TfR) in these tumors compared to the 
respective normal mucosa. In Caco-2 and SW480 cells, proliferation rates increase whether or not 
this is supported by loading the cells with iron along with an increased repression of E-cadherin at 
the protein and mRNA level178.  
Intensive studies of TfR has been accepted as a prognostic marker for several cancer types including 
CRC, and its high accessibility on the cell surface renders it a promising target for delivering cytotoxic 
agents specifically to tumor cells. The most studied intervention to inhibit proliferation or to 
stimulate apoptosis in cancer cells is an anti-TfR-targeted monoclonal antibody. From the early 
1980s, several murine antibodies have been used against TfR on the cell surface; some have been 
very efficient but not all of them are reliable in blocking uptake without causing secondary effects 
such as cytotoxicity162. However, the use of murine antibodies against TfR for targeted therapies in 
humans produce severe side effects. The short half-life of the murine antibodies requires continual 
administration that may cause the production of human anti-mouse antibodies (HAMA) and allergic 
reactions. Murine anti-TfR antibodies and chimeric fusion proteins are not the only targeted therapy 
being used to modulate TfR-mediated cell proliferation. The short half-lives of the antibodies and the 
limitations in direct conjugation, have made it mandatory to develop new delivery methods. A recent 
study has suggested the use of Tf-nanoparticles (100 nm ca.) and liposomes as directed delivery 
systems. Tf-nanoparticles that are doxorubicin-conjugated are the most developed class, generally 
leading to a higher intracellular uptake of doxorubicin with a strong reduction in tumor growth.179 In 
agreement with this, one of the most recent studies published on TfR-targeted delivery shows the 
importance of this receptor in its diffusing ability into the brain by overcoming the blood-brain 
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barrier. Because the inhibition of cell proliferation and growth is a primary aim for cancer therapy, 
TfR inhibition or targeted-drug delivery via TfR have emerged as promising anti-cancer therapeutic 
strategies which merit further development. 
 
1.11 The epidermal growth factor receptor, a prognostic marker for CRC 
 
EGFR, also known as ErbB1 belongs to the ErbB family receptors. This super-family of receptors 
includes three less studied members: ErbB2, ErbB3, and ErbB4. EGFR is a transmembrane receptor 
consisting of an extracellular ligand binding domain, a transmembrane domain and an intracellular 
domain with intrinsic tyrosine kinase activity180. It has recently been shown that upon EGF 
stimulation, the dimeric EGFR/EGF complex is internalized for intracellular sorting, a process which 
regulates downstream signaling pathways and cell fates181. Alongside EGF, ErbB receptors have also 
been shown to bind the transforming growth factor receptor α (TGFα). Both TGFα and EGF bind 
EGFR, albeit with different affinities that depend on the pH-determined sensitivity of the ligands. 
EGFR is influenced directly at the level of endosomal sorting, decreasing its ability to recycle back to 
the plasma membrane according to its binding stability181,182. EGFR's fate after ligand-stimulated 
internalization is determined by a series of events and recruitment that involve cargo adaptors, 
kinases and sorting proteins at the signalosome. A recent model of EGFR internalization and sorting 
has been proposed by Stang ’s group (Figure 15)183. 
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Figure 15 EGFR trafficking model. (1) Upon EGF-stimulated CME, EGFR is activated, ubiquitinated and 
transported into CCV. (2) The block of ubiquitination of the receptor inhibits its internalization. (3) During the 
trafficking in vesicles EGFR is partially deubiquitinated and reaches the endosomes (4) where the ligand-bound 
EGFR is re-ubiquitinated and interacting with the endosomal sorting complexes required for transport (ESCRT) 
machinery, is sorted to the inner vesicles of endosomes to MVB (5) and lysosome (6). Alternatively (7), if the 
EGF-ligand complex dissociates at low pH in endosomes the receptor is deactivated and deubiquitinated, 
transported to ERC and recycled back to PM (7-8). From Madshus et al., JCS 2009. 
Ligand-stimulated EGFR is internalized via CME and is targeted to early endosomes and later to 
sorting endosomes tubovesicular structures that dynamically matures mediating the receptor sorting 
into different routes. The receptor will be then delivered to ERC and recycled or degraded into 
lysosome-associated membrane glycorotein 1 (LAMP-1) marked compartments. Once at the sorting 
endosomes, EGFR is delivered to multi vesicular bodies (MVBs) for lysosomal degradation, leading to 
a downregulation of EGFR signaling and proliferation which ultimately segregates the kinase tail from 
the signalosome molecules. Recently it has also been shown that a monoubiquitination of RTKs upon 
ligand binding suffices to target the receptor to lysosomes184. Interestingly, mutations of c-Cbl on its 
binding site on EGFR (Tyr1045) impair the receptor ubiquitination, but not its internalization, leading 
to decreased degradation and increased recycling184. Alternatively, once EGFR is internalized and 
reaches the sorting endosomes, it might be targeted for recycling. This path is less that understood 
but it has become clear that EGFR fate depends on the endosomal sorting complexes required for 
transport  (ESCRT) complexes, in particular I and III185. EGFR fate also depends on the ligand stability. 
Initially the binding of EGF and TGFα to EGFR can promote polyubiquitination with the same intensity 
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at the PM. EGF remains stably bound to EGFR at endosomes, maintaining the kinase activity and the 
ubiquitination and degradation. TGFα does not, it dissociates from the receptor mediating a transient 
ubiquitination and thereby allowing EGFR recycling to PM. c-Cbl seems to dissociate from the 
receptor as well. Thus, the EGF-induced ubiquitination of EGFR is important in allowing the EGFR tail 
to stably bind c-Cbl and target EGFR for degradation. In contrast, TGFα leads to less stable binding to 
the receptor in acidic compartments, ultimately leading to a disassembly and to the recycling route 
of EGFR to the PM183. 
Until recently, EGFR internalization has been considered a well-known example of how CME works 
and how it influences receptor-intrinsic signaling by driving its phosphorylation. CME has long been 
recognized purely as a mechanism to attenuate signaling, but recent studies have led to the 
surprising suggestion that CME might not be a straightforward way to degrade EGFR130; depending 
on the concentration of the extracellular ligand (EGF), the fate of the receptor might change. These 
latest studies revealed the importance of the correct CME internalization of EGFR that happens for 
low doses of EGF-stimulated endocytosis (20 ng/ml), in contrast to a NCE which normally targets 
EGFR to degradation for high doses of EGF-stimulated endocytosis (100 ng/ml)130. Low and high EGF 
dose on EGFR show different consequences for EGFR activity and the downstream signaling. For low 
EGF-stimulated internalization, a sustained signaling is possible through the EGFR recycling to PM via 
CME. For high EGF-stimulated internalization, the internalized EGFR are targeted to degradation, 
resulting in an impairment of the signaling. Signaling induced by ligand-binding receptors drives cell 
type-specific responses such as cellular proliferation and differentiation, depending on the receptor 
involved. This has made it important to understand how EGFR CME influences signaling via its 
differential sorting. Ligand binding, the recruitment of specific adaptors and correct trafficking is 
fundamental for EGFR signaling, recycling and degradation. EGF-mediated EGFR signaling is further 
under strict regulation by dynamin. In cells overexpressing a dominant negative version of dynamin 
(dynamin-K44A), defective in GTP binding, the EGF-stimulated EGFR endocytosis was completely 
abolished compared to the control cell line overexpressing a wild type isoform of dynamin. This led 
to an intracellular accumulation of EGF that was degraded after 10 minutes. Furthermore, EGF 
stimulated endocytosis in dynamin-K44A overexpressing cells does not following the classical ligand-
induced trafficking to degradation but recycles instead. Importantly, dynamin-K44A overexpressing 
cells showed increased EGF-dependent proliferation compared to the wild type control186. Recently, 
Li’s group showed that EGFR cooperates with TfR via its activation to achieve an increased surface 
distribution of TfR in non-small cell lung cancer. More importantly, supplementing the cells with 
ferric citrate (non-Tf bound) iron rescued the inhibition of EGFR-promoted proliferation caused by 
tyrosine-kinase inhibitor treatment, concluding that the EGFR positively regulates intracellular iron 
levels and the membrane expression of TfR 187. To conclude, dynamin-defective CME and TfR have an 
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impact not only on EGFR routing and surface distribution in the cell, but also stimulate enhanced 
proliferation. This might be the mechanistic basis by which a cancer cell escapes the attenuative role 
of CME. 
2. Aims of the thesis
MACC1 has been identified in 2009 as a driver for cancer progression and metastasis formation for 
CRC, but also as a prognostic marker for metastasis and metastasis free survival89. In the last 10 
years, MACC1 has become a referring prognostic and predictive marker also for several other types 
of cancer188. Besides promoting cell proliferation, migration, and invasion, as well as regulating MET 
expression, MACC1 promotes epithelium dependent angiogenesis in gastric cancer via TWIST/VEGF-
A95. In addition, several studies highlighted the importance of silencing MACC1, resulting in 
decreased cell proliferation, migration, and invasion, as well as reduced tumour formation and 
metastasis in xenograft mouse models. However, little is known about the protein structure and 
function of MACC1, besides prediction analyses of structural domains and linear interaction motifs. 
Therefore, the main aims of this study are as follow: 
a. Elucidation of the role of MACC1 in TfR CME. The thesis will investigate first the
interaction of MACC1 with CME proteins (clathrin, dynamin, adaptor complex 2) and
then the impact of MACC1 on TfR endocytic traffic.
b. Identification and characterization of MACC1 CME specific domains and elucidation of
their importance in this physiological process. This part of the thesis will dissect first the
importance of the interaction of these domains (clathrin box, NPFs and DPF) in their
binding with MACC1 after deletion. In the second part, this thesis will characterize the
impact of MACC1 predicted CME domains deletions, during TfR CME.
c. To conclude, in the last part of this thesis, MACC1 impact on CME will be investigated
regarding an additional receptor (EGFR). Similarities between the MACC1 impact on TfR
and EGFR during the endocytic traffic will be analysed. Also, we will study the impact of
the CME domains of MACC1 on EGFR signaling during endocytosis.
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3. Material and Methods 
 
3.1 Cell culture 
Cell culture media, phosphate-buffered saline washing (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM KH2PO4 pH 7.4) and Trypsin/EDTA solution were obtained from Life Technologies. All 
human CRC cell lines used in our study (Table 3.1) were obtained from the American Type Culture 
Collection (ATCC). Cells were grown in RPMI-1640 or DMEM (Invitrogen), supplemented with 10% 
fetal bovine serum (FCS; Bio&Cell, Germany). All cells were maintained at 37°C in a humidified, 5% 
CO2 ventilated incubator. Cells were trypsinized and diluted in a 1:6-8 ratio every 2-3 days. All cells 
were negative for mycoplasma, verified regularly using the MycoAlert® Mycoplasma detection kit 
(Lonza). The cell lines used in this study were recently authenticated by short tandem repeat profiling 
(DSMZ, Braunschweig, Germany). 
Table 3.1 Summary of all CRC cell lines used in this study   
Cell line Medium ATCC number  
SW480 RPMI-1640, 10% FBS CCL-227  
SW620 
HCT116 
HCT15 
DMEM, 10% FBS  
DMEM, 10% FBS  
RPMI-1640, 10% FBS 
CCL-228 
CCL-247 
CCL-225 
 
All cell lines are registered in the American type culture collection (ATCC).  
 
3.2 Derivative cell lines 
 
The cell lines SW480/e.v., SW480/MACC1, and SW480/SH3BP4 were previously generated by stable 
transfection of SW480 cells with pcDNA3.1, pcDNA3.1-pCMV-MACC1-V5-His, and pcDNA3.1-SH3BP4 
plasmids, respectively, and antibiotic selection of G418, (ThermoFisher, 1 mg/ml) of single clones. 
SW620/sh control and SW620/sh MACC1 cells were obtained by lentiviral transduction of SW620 
cells with pRFP-CB-CMV-driven sh control, sh MACC1 tagged with RFP constructs (Origene, US), were 
kept under antibiotic selection of Blasticidin (Invitrogen, 1 mg/ml). The derivative cell lines are listed 
in Table 3.2. The description of the MACC1 CME mutants will be reported in the next paragraph.  
 
Table 3.2 Summary of derivative cell lines used in this study 
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Cell line Medium 
SW480/empty vector (e.v.) RPMI, 10% FBS 
SW480/MACC1 RPMI, 10% FBS 
SW480/SH3BP4 RPMI, 10% FBS 
SW620/sh control (sh cnt) DMEM, 10% FBS 
SW620/sh MACC1 
HCT116/GFP 
HCT116/MACC1-GFP 
DMEM, 10% FBS 
DMEM, 10% FBS 
DMEM, 10% FBS 
3.3 Cloning of MACC1 mutants 
Cell lines containing mutated versions of the MACC1 open reading frame (ORF) are listed in Table 3.3. 
The MACC1 N-terminal DNA fragment with deletions (ΔNT) of potential interaction motifs of factors 
associated with CME (clathrin box, NPFs and DPF) was synthesized ad hoc (gBlocks® Gene Fragment; 
Integrated DNA Technology, IDT). The DNA fragment was designed with 5’- and 3’- regions of 80 bp, 
homologous to the target vector, to enable homologous recombination. A schematic representation 
of the ΔNT fragment location within the MACC1 ORF can be found in Figure 16, all the deleted 
sequences are reported in Figure 17 and its newly generated (from gBlocks®) complete sequence is 
given in Table 3.5.  
Figure 16 Schematic representation of the MACC1 ORF. The appropriate location of the N-terminal DNA 
fragment with specific CME deletions is reported (in figure: ∆NT cassette, in grey; in brackets the sequential 
deletions of cassettes deleted: clathrin box, NPFs, DPF). 
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Figure 17 MACC1 N-terminal nucleotide sequence. The MACC1 deleted CME cassettes (in red) are reported. In 
order the MACC1 start codon (ATG, in green) as reference. Sequentially reported in red the clathrin box deleted 
sequence, the two NPFs and the DPF sequences. 
 
All plasmids and sequences used in this thesis are listed in Table 3.4. The lentiviral vector rc224774l2 
cmv-macc1-mgfp (OriGene, US) containing the MACC1 ORF tagged with GFP was digested with SfaAI 
and BseJI (Fast Digest, Thermo Scientific) following manufacturer’s instruction. All restriction 
enzymes used are listed in Table 3.6. Homologous recombination of the synthesized MACC1-DNA 
fragment with N-terminal deletions and the target vector occurred via Gibson Assembly® (New 
England Biolabs), according to manufacturer’s instruction. The reaction was incubated at 50°C for 65 
min, and was then chemically transformed into NEB® Stable competent bacteria (New England 
Biolabs). After shaking at 37°C for 1 hr, transformed bacteria were selected on LB agar plates (10 g 
Trypton, 5 g yeast extract, 5 g NaCl, 15 g Agar) containing chloramphenicol (1 μg/ml, Sigma Aldrich). 
Plasmid DNA, from overnight cultures of picked colonies grown at 37°C in 2 ml LB medium (10 g 
Trypton, 5 g yeast extract, 5 g NaCl), was isolated with the PureYield™ Plasmid Miniprep System 
(Promega). A control digestion of the resulting DNA with SfaAI and BseJI was tested on a 1% agarose 
gel (Roth) for specific bands that indicate the correct recombination of the DNA fragment, generating 
rc224774l2 cmv-macc1-deltaNT-mgfp (MACC1ΔNT-GFP construct). In a second cloning step, we 
chose the previously generated deleted SH3-domain of MACC189 construct (51–amino acid in-frame 
deletion), containing the unique restriction sites XhoI and PshAI of MACC1. This MACC1 fragment 
was amplified by polymerase chain reaction (PCR) using PfuUltra High-Fidelity DNA Polymerase 
(Agilent Technologies) according to the manufacturer´s protocol. The primers used for this reaction 
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are listed in Table 3.5. To insert the amplified region into the target vector by Gibson Assembly, 
homologous ends were attached by first amplifying short flanking DNA fragments with suitable 
overlaps for the site of insertion and the MACC1 SH3-deletion fragment in 2 sequential steps 
(primers for PCR amplification 1 are: Fwd_amplif sh3frag_PshAI/Primer_R; for the PCR amplification 
2 are Primer_F/Rev_amplif sh3frag_XHOI, all the sequences from BioTez, Berlin; reported in Table 
3.5). The flanking regions and the SH3-deletion fragment were mixed in stoichiometric amounts (3:1) 
and are fused by PCR amplification, using the primer set Fwd_amplif sh3frag_PshAI / Rev_amplif 
sh3frag_XHOI (PCR amplification 3). The PCR reaction was performed using using PfuUltra High-
Fidelity DNA Polymerase (Agilent Technologies) according to the manufacturer´s protocol with the 
following parameters:  
Step Cycles Temperature (°C) Time 
1 1 95°C 2 min 
2 30 95°C 45 sec 
63°C 30 sec 
72°C 2 min 
3 1 72°C 10 min 
4 1 4°C hold 
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The generation of the lentiviral vectors rc224774l2 cmv-macc1-deltaSH3-mgfp (MACC1ΔSH3-GFP 
construct, Figure 3) and rc224774l2 cmv-macc1-deltaNTdeltaSH3-mgfp (MACC1ΔNTΔSH3-GFP 
construct, Figure 18, upper panel) was again performed by homologous recombination of the 
amplified flanked SH3-deletion construct into the PshAI/XhoI digested target vectors rc224774l2 
cmv-macc1-mgfp and rc224774l2 cmv-macc1-deltaNT-mgfp, respectively (the enzymes used are 
listed n table 3.6).  
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Figure 18 Schematic representation of the MACC1 ΔSH3 mutant (top panel), and the MACC1 ΔNTΔSH3 (bottom 
panel) mutant construct. In the maps, all the primers location for the entire cloning of the ΔSH3 mutant (top), 
and (bottom) the location of the N-terminus deleted region together with the SH3-deleted region are reported.  
GFP and MACC1-GFP constructs were stably transduced by lentiviral particles (kindly provided and 
performed by Dr. Kobelt) and cells with high transgene expression levels were selected via FACS, 
generating SW480/GFP, SW480/MACC1-GFP, SW480/MACC1ΔNT-GFP, SW480/MACC1ΔSH3-GFP and 
SW480/MACC1ΔNTΔSH3-GFP cells, respectively.  
Table 3.3 Establishment of GFP-control, full length MACC1- GFP and mutants of MACC1 CME 
cassettes 
Cell line Medium 
SW480/GFP RPMI, 10% FBS 
SW480/MACC1-GFP RPMI, 10% FBS 
SW480/MACC1ΔNT-GFP RPMI, 10% FBS 
SW480/MACC1ΔSH3-GFP RPMI, 10% FBS 
SW480/MACC1ΔNTΔSH3-GFP RPMI, 10% FBS 
Table 3.4 Summary of plasmids and fragments 
Plasmid Company 
CME Deleted MACC1 N-Terminal Fragment (Gib_Frag_del_NT, gBlocks ®) IDT 
pcDNA3.1_ MACC1 his V5 7a5 del SH3 Amplification 
rc224774l2 cmv-macc1-mgfp Origene 
rc224774l2 cmv-gfp Origene 
Table 3.5 Sequences and primers for the generation of the MACC1 mutants 
Sequence or Primer Name Size Purpose 
5’-
GTGAACCGTCAGAATTTTGTAATACGACTCACTATAGG
GCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGG
AGATCTGCCGCCGCGATCGCCATGCTAATCACTGAAA
GAAAACATTTTCGGTCAGGAAGAATTGCACAAAGTAT
GTCTGAAGCAGCTGGAAAACTCTCAAAAAGTTGCAAT
ATTACAGAATGCCAGGACCCAGACTTGCTTCACAATTG
GCCGGATGCTTTCACCCTTCGTGGTAATAATGCTTCCA
AAGTTGCATGGAATCAACTGTCTGCTTCTTTGGATGAC
ATAACTCAACTAAGAAATAACAGGAAGAGAAATAATA
TTTCCATCTTAAAGGAACTTTTCTGTAGAGAAATAGAA
AATGGAAATTCTTTTGATTCCTCCGGTGATGAACTTGA
TGTGCATCAGTTACTTAGGCAGACTTCCTCAAGAAATT
CTGGAAGATCTAAAAGTGTTTCAGAACTTCTGGA-3’ 
Gib_frag_del_NT 512bp MACC1 N-terminus 
containing deletion of 
the clathrin box, two 
NPF sites and a DPF. In 
evidence: MACC1 
starting codon (green).  
PCR amplification 1: 51-amino acid in-frame mutated SH3 amplification 
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5’-CTTGGGTAAAGAAGGCCCTT-3’ 
5'-AGGCAGGTTTCCACATCATC-3' 
 
 
Fwd_amplif sh3frag_PshAI 
Primer_R  
 
 
 Amplification of the in-
frame mutated SH3 
domain upstream 
PshAI RS and XhoI from 
the original plasmid 
(Stein et al., Nature 
Med 2009) 
PCR amplification 2: MACC1 GFP ORF end amplification from the recipient GFP plasmid    
5’-GCTGTCAAGCTTGGAAAAGG-3' 
5'-GAACTTGTGGCCGTGCAC-3' 
 
Primer_F  
Rev_amplif sh3frag_XHOI 
 
Amplification of the 
region upstream the XhoI 
site and the end of the 
MACC1-GFP tag region 
PCR amplification 3: Amplification of the SH3 deletion fragment of the upstream and downstream 
flanking regions 
   
5’-CTTGGGTAAAGAAGGCCCTT-3’ 
5'-GAACTTGTGGCCGTGCAC-3' 
 
Fwd_amplif sh3frag_PshAI  
Rev_amplif sh3frag_XHOI 
 
Amplification of the fused 
DNA fragments using the 
complementarity of the 
overlapping region (139 
bp). The total 
amplification results in a 
1567 bp fragment. 
 
 
Table 3.6 Restriction enzymes and their reaction temperatures 
Restriction Enzyme Working temperature and thermal inactivation Company 
SfaAI  37°C (thermal inactivation 80°C 5 min) Fast Digest, Thermo Scientific 
BseJI 65°C (no thermal inactivation) Fast Digest, Thermo Scientific 
PshAI 37°C (thermal inactivation 80°C 20 min) Fast Digest, Thermo Scientific 
XhoI 37°C (thermal inactivation 80°C 5 min) Fast Digest, Thermo Scientific 
 
3.4 Gene expression analysis 
 
3.4.1 RNA isolation and reverse transcription 
 
Cells (3 - 5 x 105) were seeded into a 6 well plate, washed with PBS and trypsinized. Total RNA was 
isolated using TRIzol reagent (Invitrogen, Thermo Scientific) according to manufacturer’s instructions. 
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RNA concentrations were determined by spectrophotometry on a Nanodrop device (Peqlab, 
Erlangen, Germany). 50 ng of RNA was reverse transcribed with random hexamers in a reaction mix 
(10 mM MgCl2, 1 x PCR Buffer II, 0.25 µM pooled dNTPs, 1 U RNAse inhibitor, 2.5 U Moloney murine 
leukemia virus reverse transcriptase; all from Applied Biosystems). Reaction was performed at 42°C 
for 15 min, 99°C for 5 min, and subsequent cooling at 5°C for 5 min. Reverse transcripts were either 
stored at -20°C or directly used for quantitative real-time PCR.  
3.4.2 Quantitative real-time PCR 
Reverse transcripts were diluted (1:3) and amplified using the Go Taq® Master mix (Promega). 
Primers used for gene specific quantitative real-time (q)PCR amplification were obtained from Biotez 
(Berlin, Buch) and are listed in Table 3.7. Each PCR reaction was performed in a total volume of 10 µl 
in 96-well-plates in the LightCycler 480 (Roche Diagnostics). The PCR protocol includes a pre-
incubation step at 95°C for 2 min followed by 45 cycles of (a) denaturation at 95°C for 7 sec, (b) 
annealing at 60°C for 10 sec and (c) elongation at 72°C for 20 sec. Each qPCR reaction was performed 
in duplicates. In parallel, cDNA quantification of the housekeeping gene GAPDH was used for 
normalization of gene expression. Data analysis was performed with LightCycler 480 Software 
release 1.5.0 SP3 (Roche Diagnostics). Mean values were calculated from duplicate qPCR reactions. 
Each mean value of the expressed gene was normalized to the respective mean GAPDH expression. 
Data were analyzed using the ΔΔCt method for relative amounts of gene expression. All expression 
analyses were performed three times independently.  
Table 3.7: Primers used for quantitative real-time PCR 
Primer name    Sequence 
MACC1 Fwd 5‘-TTCTTTTGATTCCTCCGGTGA-3‘ 
MACC1 Rev 5’-ACTCTGATGGGCATGTGCTG-3’ 
TfR Fwd 5’-GGCTACTTGGGCTATTGTAAAGG-3’ 
TfR Rev 5’-CAGTTTCTCCGACAACTTTCTCT-3’ 
SH3BP4 Fwd 5’-ACAACACCACCGAAATGGG-3’ 
SH3BP4 Rev 
EGFR Fwd 
EGFR Rev 
5’-ATCATACCGCTGTCACTCAGT-3’ 
5’-AGG CAC GAG TAA CAA GCT CAC-3’ 
5’-ATG AGG ACA TAA CCA GCC ACC-3’ 
GADPH Fwd 5’-GAAGATGGTGATGGGATTTC-3’ 
GADPH Rev 5’-GAAGGTGAAGGTCGGAGT-3’ 
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3.5 Protein Analysis 
3.5.1 Protein extraction 
For total protein extraction, 3-5 x 106 cells per well were seeded in 6-well plates. After 48 hr, cultured 
cells washed in PBS were scraped off the well, collected in 1.5 ml tubes and pelleted at 1,200 rpm 
(161 rcf) for 5 min. The pellet was either frozen at -20°C or immediately subjected to protein 
extraction. For total protein extraction cells were lysed with RIPA buffer (50 mM Tris–HCl at pH 7.5, 
150 mM NaCl, 1% NP-40; supplemented with protease and phosphatase inhibitor cocktail tablets; 
Roche Diagnostics, Germany) for 30 min on ice. Cell debris was pelleted at 14,000 rpm for 15 min at 
4°C. The supernatant was transferred to a new tube, stored at -20°C or directly subjected to Western 
blot (WB) analysis.  
3.5.2 Protein quantification 
 
Protein concentration was determined before samples were applied to WB analysis. Quantification 
was performed with Bicinchoninic Acid Protein Assay Reagent (BCA; Invitrogen, Thermo Scientific), 
according to the manufacturer’s instructions, using serial dilutions starting from 2 mg/ml of BCA 
solution for the standard curve. BCA reaction was incubated at 37°C for 15 min and absorption was 
measured at 560 nm in a SpectraFluor Plus II (Tecan) plate reader. Samples of equal amount were 
boiled at 98°C for 5 min in NuPAGE loading buffer supplemented with 10% DTT (all Life Technologies, 
Thermo Scientific, Darmstadt, Germany) according to the manufacturer’s instructions. To analyze 
protein expression levels samples were separated with sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). 
 
 
3.5.3 Western Blot analysis 
 
Separation with SDS-PAGE and WB was used to analyze protein expression levels. Protein extracts 
were diluted with RIPA to obtain 10-20 µg of total protein in 1x NuPAGE® loading buffer and 10% 
DTT. Protein samples were loaded onto a self-casted 10% gel and calculated using an on-line 
calculator (https://www.cytographica.com/lab/acryl2.html). For the 6% stacking gel: 40% acrylamide, 
0.5 M Tris pH 6.8, 10% ammonium persulfate (APS), 10% sodium dodecyl sulfate (SDS), Tetramethyl 
ethylenediamine (TEMED) ddH2O; for the 10% separating gel: 40% Acrylamide, 1.5 M Tris pH 8.8, 
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10% APS, 10% SDS, TEMED, ddH2O). Protein electrophoresis was carried out in 1x Laemmli running 
buffer (25 mM Tris, 192 mM Glycine, 0.1% SDS) buffer at 120 V for 1.5 hr within the EasyPhor Page 
Mini system (Biozym®). Pre-stained Spectra™ Multicolor high Range Protein Ladder (Thermo 
Scientific) was used to determine the band size. Semi-dry electrotransfer blotting of proteins onto 
the nitrocellulose membrane (Amersham, GE healthcare) occurred in Trans-blot® Turbo system (Bio-
Rad) in Trans-Blot Turbo Transfer Buffer (at 25 V for 10 min. Quality of the protein transfer was 
analyzed by protein staining with Ponceau S solution (Sigma-Aldrich). The membrane was washed 
with TBS-T (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% tween 20,) and blocked for 1 hr at room 
temperature (RT) with blocking buffer (6% milk powder in TBS-T, Roth). Membranes were then 
incubated overnight at 4°C with primary antibody in 6% milk (Table 3.8) followed by 3 washes with 
TBS-T 0.05% tween and an incubation for 1 hr at RTwith horseradish peroxidase (HRP)-conjugated 
secondary antibody. Secondary Antibodies diluted in TBS-T with 5% BSA. Antibody-protein complexes 
were visualized with WesternBright (Advansta, Menlo Park, CA, USA) and subsequent exposure to 
Fuji medical X-ray film SuperRX (Fujifilm, Tokyo, Japan). WB for β-actin served as protein loading 
control.  
Table 3.8: Antibodies used for Western blot analysis, their dilutions and their origins 
Target Dilution Company 
Primary antibodies 
Anti-β-Actin (clone AC-15) 1:20.000 Mouse monoclonal, Pierce 
Anti-MACC1  1:1000 Rabbit polyclonal, Sigma 
Anti-TfR (13-6800) 1:1000 Mouse monoclonal, Thermo Scientific 
Anti-CLTC (c-20) 1:1000 Goat polyclonal, Santa Cruz 
Anti-DNM2 (c-18) 1:1000 Goat polyclonal, Santa Cruz 
Anti-AP2α (c-8) 1:1000 Mouse monoclonal, Santa Cruz 
Anti-SH3BP4  
Anti-EGFR (1005) 
Anti-EGFR (A-10) 
Anti-p-EGFR (Tyr 1068) 
Anti-AKT  
Anti-Phospho-AKT (Ser473) 
Anti-p44/42 
Anti- Phospho-p44/42 
1:1000 
1:1000 
1:1000 
1:1000 
1:1000 
1:1000 
1:1000 
1:1000 
Rabbit polyclonal, Thermo Scientific 
Rabbit polyclonal, Santa Cruz 
Mouse monoclonal, Santa Cruz 
Rabbit polyclonal, Cell Signaling 
Rabbit polyclonal, Cell Signaling 
Rabbit polyclonal, Cell Signaling 
Rabbit polyclonal, Cell Signaling 
Rabbit polyclonal, Cell Signaling 
Secondary antibodies 
Anti-rabbit-HRP (W401B) 1:10.000 HRP conjugated antibody, Promega 
Anti-mouse-HRP 1:10.000 HRP conjugated antibody, Pierce 
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Anti-goat-HRP (sc-2020) 1:10.000 HRP conjugated antibody, Santa Cruz 
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3.6 Co-Immunoprecipitation assay 
To analyze MACC1 interacting proteins, 80–90% confluent cells of 10-cm dishes were washed once in 
ice-cold PBS and then lysed in co-IP lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% NP40, 1 
mM EDTA, 1% Triton, supplemented with complete protease inhibitor tablets; Roche) for 30 min on 
ice. Extracts were centrifuged for 10 min at 14.000 rpm at 4°C and incubated overnight with 4 µg of 
target specific antibodies (listed in Table 3.9.). Antibody-bound protein complexes were pulled down 
using Protein G Agarose beads (Alpha Diagnostic), washed three times with ice-cold co-IP lysis buffer, 
and denatured in NuPAGE loading buffer at 98°C for 10 min. Interaction of the precipitated proteins 
with MACC1 was analysed by WB and immunostaining for MACC1.  
Table 3.9: Antibodies used for co-IP analysis, their dilutions and their origins 
Target Dilution Company 
Anti-Transferrin receptor (13-6800) 
Anti-EGFR (1005) 
4 µg 
4 ug 
Mouse monoclonal, Thermo Scientific 
Rabbit polyclonal, Santa Cruz 
Anti-Clathrin (c-20) 4 ug Goat polyclonal, Santa Cruz 
Anti-DNM2 (c-18) 4 ug Goat polyclonal, Santa Cruz 
Anti- AP2α (c-8) 4 ug Mouse monoclonal, Santa Cruz 
Anti-Met (25H2) 4 ug Mouse monoclonal, Cell Signaling 
3.7 Immunofluorescence and data analysis 
Cells were seeded onto glass coverslips (VWR ®, 13 mm diameter, 1.5 µm thickness) at 1 x 104 
cells/ml in 24 well plates. After 48 hr cells were starved in serum-free media (SF-MEM media, Life 
Technologies) without FBS supplement. Cells were treated depending on the experiment with human 
holo-Transferrin (h-TF, Sigma-Aldrich), or with EGF (Sigma-Aldrich), and then washed twice with PBS. 
Stained cells were fixed with 4% paraformaldehyde (PolyScience) in PBS for 15 min at RT. Fixed cells 
were quenched for 10 min with 0.1 M Glycine (Roth), washed twice with 0.2% tween 20 in PBS (PBS-
T) and permeabilized with 0.2% Triton X-100 in PBS (PBS-X) for 10 min. After washing with PBS-T, the 
coverslips were incubated 1 hr in 5% albumin IgG free in PBS (Roth) at RT, were washed twice with 
PBS-T, followed by the incubation with protein specific primary antibodies in 2.5% albumin IgG free 
in PBS at 4°C overnight. The antibodies used for the immunofluorescence are listed in Table 3.10. 
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After 3x washing with PBS-T, the coverslips were incubated with their respective secondary 
antibodies for 1 hr at RT. After 3x washing with PBS-T the coverslips were incubated with 4',6-
diamidin-2-fenilindolo (DAPI; Biosciences) for 3 min at RT, and washed twice with PBS-T before they 
were mounted with Dako Fluorescent mounting media (Agilent).  
Table 3.10: Antibodies used for immunofluorescence 
Target Dilution Company 
Primary antibodies 
Anti-MACC1 (D-15) 
Anti-MACC1 
1:50 
1:100 
Goat polyclonal, Santa Cruz 
Rabbit polyclonal, Sigma-Aldrich 
Anti-Transferrin receptor (13-6800) 1:50 Mouse monoclonal, Thermo Scientific 
Anti-Clathrin (X22) 1:400 Mouse monoclonal, Abcam 
Anti-Clathrin (CLTC) 1:100 Goat polyclonal, Sicgen antibodies 
Anti-Clathrin (D3C6) 1:100 Rabbit polyclonal, Cell Signaling 
Anti- α-Adaptin (AP6) 1:100 Mouse monoclonal, Abcam 
Anti-DNM2 (#3457) 1:100 Rabbit polyclonal, Abcam 
Anti-EGFR (1005) 
Anti-EGFR (A-10) 
1:50 
1:50 
Rabbit polyclonal, Santa Cruz 
Mouse monoclonal, Santa Cruz 
Anti-human HGF/c-MET (AF276) 
Endosomal markers kit (EEA1, RAB11, CLTC) 
Anti-Lamp1 (D2D11) XP® 
 
1:100 
1:100 
1:100 
 
Goat polyclonal, R&D Systems 
Cell Signaling 
NEB 
Secondary antibodies 
Anti-goat Alexa Fluor® 488 conjugated 1:200 Thermo Scientific 
Anti-mouse Alexa Fluor® 555 conjugated 1:200 Thermo Scientific 
Anti-rabbit Alexa Fluor® 647 conjugated 1:200 Thermo Scientific 
 
Slides were imaged with a Leica SP5 confocal microscope (Leica, Microsystem), equipped with 
an argon laser having a 488 nm emission, one helium neon laser with 633 nm emission, a diode 
laser with a 405 nm emission and a diode-pumped solid state (DPSS) with 405 nm emission. 
Images were sampled at a resolution of 1024 by 1024 pixels, using a 63x (NA 1.5) objective, a 5 
times software zoom and a 10-20 z-step size of 0.2-0.3 μm. Images were saved in the Leica 
image file (.lif) format and quantification was performed on a NDVIA GeForce GTX 1070 PC 
workstation with an Intelcore i7-4930, 64 GB, 3,4 GhZ using Imaris 8 (Bitplane, South Windsor, 
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CT, USA). Quantification of the fluorescence overlap was measured with IMARIS (v.8) using the 
background automatic threshold.  
3.8 Endocytic-related functional and trafficking assays 
3.8.1 Surface staining and uptake of TfR 
Cells (1 x 106) were cultured in 60 mm dishes until 80 –90% confluency and were starved in SF-MEM 
at 37°C before the assay to deplete the supply of culture-born Tf. Cells were then washed once in ice-
cold PBS, harvested and resuspended in cold RPMI supplemented with 0.2% bovin serum albumin 
(BSA) containing 25 mg/ml Alexa® Fluor 647-conjugated Transferrin (Tf-Alexa® Fluor 647; Life 
technologies). The cells were incubated for 1 hr on ice to stain the surface located receptors. 
Receptor internalization was allowed by shifting the pre-stained cells to 37°C. Mean fluorescence 
intensity (MFI) of internalized TfR was determined by stopping the internalization after 10 and 20 
min in ice-cold PBS. After cells were fixed (1 mM EDTA, 1% glutaraldehyde in PBS), Tf/EGF-Alexa® 
Fluor 647 fluorescence was analysed using the FACS LSR Fortessa™ (BD Bioscience), quantifying the 
signal intensities in the APC channel. Unstained cells were used as background while the internalized 
signal was calculated by virtual stripping of the surface signal. 
3.8.2 Surface staining and recycling of EGFR 
Cells (1 x 105) were cultured in 6-well plates and were starved in SF-MEM at 37°C before the assay to 
deplete the supply of culture-born EGF. For the EGFR surface quantification cells were washed once 
in ice-cold PBS, harvested and resuspended in cold PBS supplemented with 0.2% BSA containing 2.5 
mg/ml Alexa® Fluor 647-conjugated EGF (EGF-Alexa® Fluor 647; Life technologies). The cells were 
incubated for 1 hr on ice to stain the surface located receptors. Fluorescence intensity of recycled 
EGFR was determined by stopping the clathrin-mediated endocytosis with 20ng/ml EGF (Sigma) after 
30 min in ice-cold PBS and staining with 2.5 μg/ml Alexa® Fluor 647-conjugated EGF, with or without 
pre-treating the cells for 4 hr with monensin (10 μM, Sigma) as controls. After cell washing with cold-
PBS, cells were fixed (1 mM EDTA, 1% glutaraldehyde in PBS), and EGF-Alexa® Fluor 647 fluorescence 
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was analyzed using the FACS LSR Fortessa™ (BD Bioscience), quantifying the signal intensities in the 
APC channel. Unstained cells were used as background. 
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3.8.3 Transferrin and EGF receptor endocytic trafficking assays 
For analysis of internalized receptor/ligand complexes and their subsequent localization and 
quantification in acidic cellular compartments, we obtained Tf and EGF labelled with the pH-sensitive 
red fluorescent dye pHrodo™ (Tf-pHrodo™ and EGF-pHrodo™; Thermo Fisher Scientific). These 
innovative fluorogenic dyes enable to detect and measure the fluorescence increase of the complex 
(receptor/ligand) while trafficking into the cell when reaching compartments with increasing and acid 
pH. Cells were cultured in 96-well plates (Corning) until they were approximately 80–90% confluent, 
and were starved before the assay in SF-MEM overnight at 37°C to deplete the supply of culture-born 
Tf or EGF. Cells were washed twice in ice-cold PBS. pHrodo™ Red-labelled Tf/EGF in Live Cell Imaging 
solution (LCIS, Life Technologies) were added to the plate with the relative controls at the indicated 
concentrations (Table 3.11 and Table 3.12). The plates were transferred into the IncuCyte ZOOM® 
platform located in a cell culture incubator at 37°C/5% CO2. At least two images per well from at least 
two technical replicates were taken every 5-15 min for 3-4 hr, using a 20X objective lens and then 
analyzed using the IncuCyte™ Basic Software. The acquisition time for phase contrast and emission 
intensities in the red channel was set to 2200 ms. In phase contrast, cell segmentation was achieved 
by applying a confluence mask. An area filter was applied to exclude objects below 50 μm2. Red 
channel background noise was subtracted with the Top-Hat method of background, and the 
integrated fluorescence signal was quantified by the software after applying a mask. 
Table 3.11: IncuCyte® ZOOM Live-cell Analysis System compound working concentrations 
Target receptor Dilution Compound 
Tf receptor 
EGF receptor 
50 µg/ml 
5 ug/ml 
pHrodo™ Red-labelled Tf, Thermo Scientific 
pHrodo™ Red-labelled EGF, Thermo Scientific 
Table 3.12: IncuCyte® ZOOM Live-cell Analysis System used inhibitors and working concentrations 
Target receptor Dilution Compound 
Monensin 10 µM 
Control treatment for recycling inhibition, 
Sigma-Aldrich 
Bafilomycin 100 nM Control treatment for degradation 
inhibition, Sigma-Aldrich 
Dynasore 80 µM 
Control treatment for internalization 
inhibition, Abcam 
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3.8.4 Transferrin Recycling assay 
 
Cells were cultured in 100-mm dishes until they were approximately 80 –90% confluent and starved 
before the assay in SF-MEM for 1 hr at 37°C to deplete the supply of culture-born Tf. Cells were then 
washed once in ice-cold PBS, harvested and resuspended in cold RPMI with 0.2% BSA containing 25 
μg/ml Tf-Alexa® Fluor 647. Cells were incubated for 15 min at 37°C. The endocytosis was stopped 
with ice-cold PBS. Cells were centrifuged and washed with ice-cold PBS and resuspended in cold 
RPMI 10% FBS h-Tf (250 ug/ml). The reaction was stopped at indicated time points. The cells were 
collected and washed twice with ice-cold PBS and fixed (1 mM EDTA, 1% glutaraldehyde in PBS). Tf-
Alexa® Fluor 647 fluorescence was analyzed using the FACS LSR Fortessa™ (BD Bioscience), 
quantifying the signal intensities in the APC channel. Data were analyzed considering the 
endocytosed Tf-Alexa® Fluor 647 as 100% of the internalized TfR. A reduction of Tf-Alexa® Fluor 647 
signal intensity over time was used to evaluate the rate of TfR/ Tf-Alexa® Fluor 647 recycling to the 
plasma membrane, where the Tf-Alexa® Fluor 647 was released from TfR and washed off. The 
protocol has been kindly provided from Dr. Armin Rehm189. 
 
3.8.5 TfR degradation assay 
 
For the TfR degradation assay, cells were grown to 80–90 % confluency and starved at 37°C in SF-
MEM (Invitrogen). Cells were treated for 10 and 20 min with 50 µg/ml h-Tf (Sigma), with or without 
pre-treatment of bafilomycin A1 (100 nM; Sigma). Total TfR protein was immunoblotted as 
previously described. 
 
3.9 Proliferation assay  
For the determination of anchorage-dependent cell proliferation, 1 x 104 cells were plated into 96-
well-plates and were allowed to accommodate for 6 h before treatment. Treated cells were grown 
for 2-4 days in 20 ng/ml EGF RPMI supplemented with 2% FBS. The proliferation rate was observed 
via IncuCyte® ZOOM Live-cell Analysis System (Essen BioScience) at 37°C. Each cell proliferation 
experiment was performed in duplicates, for three independent times.  
3.10 EGFR downstream cell signaling analysis 
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For the signaling analysis, cells were seeded in 6-well plates for 48 h, and after starvation with SF-
MEM cells were stimulated with 20 ng/ml EGF in RPMI (Sigma) for the indicated time points. Cell 
lysates were subjected to WB and immunostaining as previously described.  
3.11 High throughput analysis for Mass Spec data and other software 
 
For identification of the MACC1 interactome by mass spectrometry (MS) (shot-gun proteomics), 
immunoprecipitation of SW620 cells with two polyclonal rabbit anti-human MACC1 antibodies 
(HPA020103, HPA020081, Sigma, St. Louis, USA, 2 µg) was performed 4 times independently. 
Samples were eluted from the affinity beads using denaturing buffer (6 M urea, 2 M thiourea, 20 mM 
HEPES, pH 8.0, Sigma). Proteins were converted to peptides in a two-step digestion using 
endopeptidase LysC (Wako, Japan) and trypsin (Promega, Madison, WI, USA). The peptides were 
desalted using Stage-Tips following a protocol by Rappsilber et al190. The purified peptides were then 
resuspended in 3% trifluor acetic acid / 5% acetonitrile buffer (Sigma, Merck) and separated on a 
reversed-phase column (20 cm length, 75 μm ID, 3 μm Reprosil-C18, Dr. Maisch) with a gradient from 
5 to 45% acetonitrile in 122 min. Peptides were ionized on a Proxeon ion source and directly sprayed 
into the mass spectrometer (Q-Exactive, Thermo Fisher). The recorded spectra were analyzed using 
the MaxQuant software package (Version, 1.2.2.5) with fixed modifications set to carbamylation of 
cysteines and variable modifications set to phosphorylation of serine, threonine, and tyrosine, and 
methionine oxidation. The false-discovery rate was set to 1% on protein and peptide level. Statistical 
analysis of the data set was performed using the R-statistical software package. These analyses were 
performed in cooperation with Dr. Gunnar Dittmar, MDC, Head of Mass Spectrometry Core Facility, 
before the start of this project. 
Interactors of MACC1 identified by mass spectrometry were classified by DAVID (Database for 
Annotation, Visualization, and Integrated Discovery) Bioinformatics Resources tool (v6.7)191. For 
functional annotation clustering of gene ontology terms (GO terms), we set the following 
parameters: classification stringency “medium” and EASE=1, interactors selected had a p-value<0.05. 
We set interesting clusters with a fold enrichment of log2>1.5. 
 
3.12 Statistical analysis 
 
Statistical analysis was performed using GraphPad prism software (v5.01, GraphPad software, La 
Jolla, CA, USA) using either unpaired two-tailed Student t-tests, one-way or two-way ANOVA 
followed by posthoc Bonferroni correction, depending on the obtained datasets. Signal half-lives 
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were calculated using non-linear regression. P-values below 0.05 were considered statistically 
significant.  
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4.Results 
 
4.1 Identification of MACC1 CME interactors  
4.1.1 MACC1 protein structure and CME interactome analysis 
 
MACC1 contains several putative domains as shown (Fig. 19, A) which have been predicted and 
identified in 2009 by our group89. ln order to study MACC1 interactome and its role in CME process in 
CRC cells, a pull down of MACC1 from SW620 cells was performed followed by mass spectrometry 
(MS). This analysis allowed us to identify MACC1 potential interacting proteins. Of note, the SW620 
cell line of metastatic CRC  was chosen as model system due to high endogenous MACC1 expression89 
(cooperation with G. Dittmar, head of mass spectrometry core facility, MDC). MACC1 interactors 
were categorized using DAVID (Database for Annotation, Visualization, and Integrated Discovery) 
Bioinformatics Resources tool (v6.7)191 (Figure 1; R analysis handled by Tommaso Mari, Prof. Selbach 
Group at MDC). Only proteins with a p-value<0.05 were considered and validated in further analysis.  
MACC1 interactome analysis showed 1103 potential interaction partners and 27 interesting GO 
Terms or gene clusters enriched (fold enrichment>0.5 (Log2)) in biological processes, cellular 
components and molecular functions, all related to endocytosis and vesicle transport (Fig.19, B). We 
focused our attention on a subcategory of proteins (in red, Fig.19), that were reporting CME 
interactors interesting for our research. These CME proteins of interest have been selected 
considering the presence of CME motifs MACC1 protein structure in particular the clathrin box, NPFs 
and DPF motifs (Fig. 19, A).  
Furthermore, to understand at which steps MACC1 might have been involved in CME processes 
MACC1 potential interactors were involved during CME we also analyzed the MS list using another 
reliable tool: the KEGG PATHWAY (https://www.genome.jp/kegg/pathway.html). This is a reference 
database system for pathways mapping. The MS list analysis showed MACC1 enrichment in many 
different pathways, showing also several MACC1 potential CME interactors. The specific GO terms 
containing MACC1 CME interactors considered in this thesis are marked with red stars 
(Supplementary Figure 1, and 10). In conclusion, MACC1 shows GO enrichment in CME-related 
proteins which have been identified as potential interaction partners.
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Figure 19 MACC1 protein structure and CME interactome analysis. (A) MACC1 and SH3BP4 protein 
structures are shown; MACC1 and SH3BP4 share a 43.7% protein homology and several endocytosis cassettes.  
MACC1 (in color) motifs at the N-terminus: clathrin box (binds clathrin terminal domain, CTD); NPF, the Epsin 
15 homology motif interacting site (Asn-Pro-Phe motif binds epsin homology (EH) domain); DPF, α-adaptin 
binding domain of AP-2α, Asp-Pro-Phe motifs are shown. Motif at the C-terminus: SH3, SRC homology 3 
domain (interacts with proline-rich domains, PRD is shown. (B) Endogenously expressed MACC1 was pulled 
down via coimmunoprecipitation (coIP) in SW620 cells and its interactome was analyzed via DAVID. In (B) 
MACC1 endocytosis-related GO term enrichment analysis is shown and subdivided in cellular compartments, 
biological processes and molecular functions categories. The GO terms containing the CME proteins discussed 
in this thesis are shown in red. 
66 
 
4.1.2 MACC1 interacts with several CME factors and with TfR in different CRC cell lines  
 
The previous data indicates a possible role for MACC1 during CME traffic. In order to investigate and 
characterize MACC1 protein interactors and its involvement in CME process, we choose a set of CRC 
cell lines (SW480, SW620, HCT15, HCT116) as a model system. At first, we confirmed the expression 
of CME related proteins in all the chosen cell lines. The following Figure (20, A) shows indeed that 
CME related proteins such as: CLTC, DNM2, and AP-2α are highly and similarly expressed across all 
the cell lines. Thus, to identify and assess MACC1 involvement in CME, we further validated our MS 
results via coIP. For this purpose, CME proteins were pulled down and used as bait in three different 
CRC cell lines, respectively: SW620 (endogenously overexpressing MACC1), SW480/MACC1 
(ectopically overexpressing MACC1), SW480/MACC1-GFP (ectopically overexpressing GFP-tagged 
MACC1). As shown (Fig. 20 B-D), MACC1 coimmunoprecipitates with CLTC, DNM2, AP-2α and TfR. 
Globally, these data confirm the direct or indirect interaction of MACC1 with CLTC, DNM2, AP-2α and 
TfR in different CRC cell lines.
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Figure 20 MACC1 interacts with several CME factors and with TfR in different CRC cell lines. (A) CME-involved 
proteins were evaluated for their protein expression via WB, in different CRC cell lines (SW620, SW480, HCT15, 
HCT116). After seeding (3 x 105), cells were harvested, lysed in RIPA buffer and the cell lysates were 
immunoblotted for CLTC, DNM2, AP-2α and β-actin as a loading control. Represented (A, left panel) are the 
protein expressions of CLTC, DNM, AP-2α in SW480 and SW620 cells. In parallel (A, right panel) protein 
expressions of CLTC, DNM2 and AP-2α in HCT15 and HCT116 cells. (B-E) MACC1 CME binders validated via coIP 
in three different cell lines: SW620, SW480/MACC1, and SW480/MACC1-GFP. After seeding, cells (4 x 106) were 
harvested and lysed in coIP lysis buffer (see material and methods for details). Cell lysates were coIP with 
control IgG or indicated against individual CME proteins and immunoblotted for MACC1. The binding of MACC1 
and CLTC (B), DNM2 (C), AP-2α (D) is shown, while the binding between MACC1 and TfR (E) has been also 
determined. 
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4.1.3 Ligand-stimulated TfR internalization alters MACC1 colocalization and correlation 
with CME proteins  
 
Plasma membrane receptors play a key role in cell homeostasis by regulating cell signaling (in both 
attenuation and enforcement) and nutrient uptake132,192,193. Receptor fate changes dynamically 
during the principal steps of CME such as internalization, recycling and degradation. Hence, it has 
become pivotal to decipher the role of CME-associated proteins in deciding receptor routes during 
endocytosis. A first effective adopted approach was to investigate their recruitment to the endocytic 
machinery, in order to understand their impact during receptor fate decision. For this end, we 
elucidated MACC1 impact on CME regulation, in particular we analysed MACC1 changes in 
distribution, correlation and colocalization with CME interactors validated beforehand (CLTC, DNM2, 
AP-2α, TfR). 
TfR is a well-known model receptor that is constitutively internalized via CME194. To confirm MACC1 
involvement during CME and to investigate its correlation with CME proteins belonging to early or 
late stages of CCV formation, SW480/MACC1 cells were treated with h-Tf for 15 min following 1 h 
starvation (to deplete circulating TfR). After triggering TfR internalization and trafficking to 
endosomes (within 15 min of stimulation), MACC1 correlation with CME proteins, before and after 
TfR-stimulated internalization, was screened via immunofluorescence (IF) and analyzed using 
confocal microscopy. All the screened IFs are representative of a central section of the cell (Figure 21, 
top panel).  
Interestingly, both colocalization and correlation of MACC1 with TfR and the CME-associated factors 
CLTC and DNM2 changes upon ligand-stimulated TfR internalization (Fig. 21, A-C). More specifically, 
the Pearson’s correlation increased significantly for MACC1 colocalization with TfR and CLTC after the 
stimulation. In contrast, the Pearson’s correlation for MACC1 colocalization with DNM2 or AP-2α 
decreased. Furthermore, MACC1 colocalization with TfR and CLTC, as shown in Figure 21 (A-B) is 
strikingly increased in punctate structures in the cytoplasm. While, MACC1 and DNM2 initially 
colocalizing at PM (Figure 21, C) show a decreased correlation and distribution at PM after ligand-
stimulated TfR internalization. MACC1 and AP-2α correlation decreased upon TfR stimulated-
internalization, leading us to exclude this protein from any further analysis in this thesis, because of 
the secondary and probably indirect role with MACC1. 
Together, our data show that upon Tf-triggered internalization of TfR, MACC1 changes its distribution 
and correlation with different endocytic proteins. In particular, MACC1 colocalization was found 
increased with DNM2 at the PM before the stimulation and decreased after the stimulation. In 
contrast, after TfR-stimulated internalization MACC1 colocalization is increased in the cytoplasm with 
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CLTC and TfR and displayed in punctate structures. In conclusion, MACC1 shows a stimuli-dependent 
changes in the localization and correlation with several CME proteins confirming its involvement 
during CME and in CCPs or CCVs. 
 
Figure 21 Ligand-stimulated TfR internalization alters MACC1 colocalization and correlation with CME 
proteins. A confluent monolayer of SW480/MACC1 cells (1x104) was seeded, serum starved (1 hr) and treated 
for 15 min h-Tf (250 ug/ml) in order to measure the distribution and correlation of MACC1 with endocytic 
proteins by immunofluorescence. (A-D) Colocalization of MACC1 and TfR (A), CLTC (B), DNM2 (C) and AP-2α (D) 
in SW480/MACC1 cells before (upper panel) and after (lower panel) 15 min stimulation of TfR internalization 
with h-Tf. Scale bar = 10 µm. Indicated regions are displayed enlarged (10x). Statistical analysis of Pearson 
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correlation coefficients (n > 60 cells, mean ± SEM, n=3) are performed by Student’s t-tests. Single channel 
images are provided in Supplementary Figure 2. 
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4.1.4 MACC1 marks TfR containing vesicles and colocalizes with endosomes and TfR, 
upon h-Tf triggered TfR CME internalization  
 
TfR has been widely characterized for its internalization process, and together with LDLR they 
represent the classic examples for CME195. TfR receptor recycling to the PM after internalization 
seems to be the default path171. Moreover, in order to be recycled back to the PM, TfR does not 
require any specific consensus sequence on its cytoplasmic tail.196 Thus, considering its simplicity and 
its extensive characterization in literature, we focused on understanding MACC1 impact on TfR 
endocytic trafficking.  
TfR is internalized in CCVs, that after their uncoating, fuse with highly dynamic compartments known 
as endosomes, marked by EEA1162,171. SW480/MACC1 cells were used to accurately assess and screen 
the MACC1 involvement in the first endocytic steps and during TfR sorting. For this purpose, 
SW480/MACC1 cells were stimulated to induce the TfR-selected internalization with h-Tf, and 
immunostained with fluorescence-labelled antibodies for the vesicle compartment (CLTC) and the 
endosomal compartment (EEA1) (Figure 22, A-B). Triple colocalization has been spatially analyzed by 
measuring and representing the three different fluorescence intensities (red, blue, green), on the 
histogram in the lower panel (Figure 22, A-B), while the unstimulated condition is represented in the 
upper panels of Figure 22 (A-B). Our data show that MACC1 not only marks TfR-containing CCV 
(Figure 22, A), but also colocalizes with TfR at the endosomal compartment after 15 min stimulation 
(Figure 22, B). To conclude, MACC1 was found in TfR-containing vesicles and endosomes, therefore, 
it is involved in the earliest and later stages of TfR internalization. MACC1 might shuttle from the PM 
to endosomes in CCV together with TfR. Thus, MACC1 follows the TfR internalization from the PM to 
CCVs, towards endosomes as a cargo protein.    
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Figure 22 MACC1 marks TfR-containing vesicles and TfR-containing endosomes, upon h-Tf triggered TfR CME 
internalization. A confluent monolayer of SW480/MACC1 (1x104) was seeded, serum starved (1 hr) and treated 
for 15 min with h-Tf (250 ug/ml) (A-B) Colocalization of MACC1, TfR and CLTC (A) or EEA1 (B) after triple-
staining of SW480/MACC1 cells before (upper panel) and after (lower panel) 15 min stimulation of TfR 
internalization with h-Tf. Scale bar = 10 µm. Indicated regions are displayed enlarged 10x, and histograms show 
the spatial distribution of the signal intensities across indicated sections (n = 30 cells). All panels show merged 
images. Single channel images are provided in Supplementary Figure 3.  
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4.2 Characterization of MACC1 involvement during TfR endocytosis  
 
4.2.1 MACC1 overexpression and knockdown are not affecting TfR nor SH3BP4 mRNA 
expression  
 
Several proteins have been identified as receptor-fate “switchers”, but for our purpose we will focus 
on the well-characterized SH3BP4. SH3BP4 regulation of TfR, via DNM2, has been already 
elucidated121. MACC1 and SH3BP4 share 43.7% protein homology (Fig. 23, A) and several CME-
involved domains, together with the protein signature. To exclude any biological interdependence or 
effect of MACC1 overexpression and knockdown on TfR or SH3BP4 gene expression, we assessed 
their mRNA expression in these two MACC1 conditions. 
We first analyzed the expression of MACC1, SH3BP4 and TfR in SW480/e.v., SW480/MACC1 and 
SW480/SH3BP4, via qRT-PCR and WB. We observed no altered expression levels except for MACC1 in 
SW480/MACC1 and SH3BP4 in SW480/SH3BP4 as compared to SW480/e.v. (Fig. 23, A-B). Similarly, 
we evaluated MACC1, SH3BP4 and TfR gene expression in SW620 control cells (SW620/sh cnt) and in 
the MACC1 knock-down (KD) cell line (SW620/sh MACC1).  we observed only an altered gene 
expression level of MACC1 in the KD cell lines while no alteration in the protein levels was detected 
(Fig. 23, C-D). 
Tumors differently express TfR depending on their stage and their aggressive nature. TfR mRNA and 
protein levels are important to understand the endocytic receptor dynamics in terms of 
internalization, recycling and degradation. As previously reported for CRC, TfR is differently 
expressed in well (Dukes A and B) or poor differentiated (Dukes C or D) carcinoma samples or cell 
lines177. Therefore, to compare the CRC cell lines in focus (SW480 and SW620) and their TfR 
expression, we employed qRT-PCR and WB. As previously reported, we could confirm an altered CRC 
stage-dependent TfR mRNA expression in SW480 (Duke B) and SW620 (Duke C). These cell lines 
originate from the same patient and from primary lymph node metastasis respectively (Fig. 23, E-F). 
TfR is abundantly expressed in SW480 cells, confirming previous data177, however, an even higher 
expression of TfR was found in SW620 cells. Also, a reduced TfR protein expression in SW480 as 
compared to SW620 cells was observed, matching the TfR/CRC staging only in SW480 cells, as 
previously mentioned177. 
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Figure 23 MACC1 overexpression and knockdown are not affecting TfR nor SH3BP4 mRNA expression. 
MACC1, TfR and SH3BP4 mRNA and protein expression were studied in SW480/e.v., SW480/MACC1, 
SW480/SH3BP4 (A-B) and SW620/sh cnt, SW620/sh MACC1 (C-D) and SW620 and SW480 (E-F) to exclude any 
MACC1-interdependence or MACC1 dependent-effect on mRNA and protein expression levels. Thus, 48 hr after 
seeding cells (3x105), total RNA was extracted, reverse transcribed and quantified by real time q-PCR. (A, C, E) 
MACC1, TfR and SH3BP4 mRNA expressions were validated in SW480/e.v., SW480/MACC1, SW480/SH3BP4 and 
SW620/sh cnt, SW620/sh MACC1 and SW480 and SW620 cells. Results are first normalized to GADPH and then 
represented as n-fold of the control cell line respect to the gene of interest. Results are shown as means ± SEM 
of three independent experiments. (B-D-F) For the MACC1, TfR and SH3PB4 protein expression analysis, after 
seeding (3x105), cells were harvest, lysed in RIPA lysis buffer (see material and methods for details). Cell lysates 
were quantified and each sample immunoblotted on nitrocellulose membrane, for MACC1, TfR, SH3BP4 and β-
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actin as loading control. A representative blot of three independent experiments is shown. *p < 0.05, **p < 
0.01, ***p < 0.001 
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4.2.2 Ectopic overexpression of MACC1 decreases TfR surface distribution and affects 
TfR internalization in SW480 cells 
 
SH3BP4 involvement during CME has been already reported from Tosoni’s group and from Olsen’s 
group121,122. Briefly, SH3BP4 perturbation affects TfR during internalization121. The SH3BP4-mediated 
impact on TfR internalization is SH3-domain dependent and is rescued by DNM2 overexpression. This 
finding confirms the mutual action of SH3BP4 and its SH3 domain during the DNM2- mediated rate 
limiting step of endocytosis121,122. To investigate the role of MACC1 in the CME-dependent 
internalization of TfR, in comparison to the reported effects of SH3BP4, we analyzed SW480 cells 
with MACC1 ectopic overexpression (SW480/MACC1), of SH3BP4 (SW480/SH3BP4), and SW480 cells 
harboring the empty vector (SW480/e.v.), using both respectively as controls. 
 Surface abundance of TfR and its rate of internalization were determined by indirectly labeling 
extracellular surface TfR with fluorescence-labeled Tf-647 at 0°C to impede endocytosis, and for the 
time resolved uptake of the receptor-ligand-complex, after shifting the cells to 37°C (Fig. 24, A-B). 
Signal has been detected using FACS.  
After carrying out the assay we observed a reduced surface abundance TfR-Tf-647 complex in 
SW480/MACC1 cells (Fig. 24, A), as well as in SW480/SH3BP4 cells but not relevantly, compared to 
SW480/e.v. cells. After shifting surface-marked cells to 37°C, the TfR uptake resulted in a significant 
interference in SW480/MACC1 cells, compared to SW480/e.v. cells, with a similar tendency in 
SW480/SH3BP4 cells at the time points 10 min and 20 min (Fig. 24, B). SW480/SH3BP4 cells were 
used as a positive control as previously reported121.  
To conclude SW480/MACC1 and SW480/SH3BP4 cells show a significantly lower internalized Tf-647 
after 20 min, compared to SW480/e.v.. MACC1 overexpression affects, as SH3BP4, TfR-Tf-647 
internalization, and this suggest MACC1 might participates during TfR internalization. However, 
further experiments are required to understand how MACC1 affects TfR endocytic traffic, and at 
which step. 
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Figure 24 Ectopic overexpression of MACC1 decreases the surface distribution of TfR and affects TfR 
internalization. After cell seeding (1x106) and starvation, cells were harvest and marked with Tf-647 (25 μg/ml) 
at 0°C on ice to impede endocytosis and then shifted at 37°C (see Material and Methods for details). (A) 
Surface staining of TfR with Tf-647 (25 μg/ml) of SW480-derived cell lines is represented. Total surface Tf-647 
signal intensities were determined by FACS. (B) Internalized Tf-647 signal intensities after temperature shift for 
subsequent time points. Data represent mean ± SEM of three independent experiments. *p < 0.05, **p < 0.01, 
***p < 0.001 
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4.2.3 MACC1 overexpression prevents the endocytic TfR traffic into degradative 
compartments 
 
To investigate the role of MACC1 during TfR internalization, we extended our previous knowledge by 
further validating our results (Figure 25 A-C) using a newly established technique: IncuCyte®. After 
the establishment of the technique, we could carry out live-cell imaging and time-dependent analysis 
by using the transferrin pH sensitive compound (pHrodo-Tf). As previous works showed already, the 
compound is able to track the internalization of TfR, in particular in endosomes and in more 
acidic/late endocytic compartments187,197–20. The TfR-Tf complex is normally 95% recycled back to the 
PM where it dissociates and releases (apo-)Tf into the medium171.  
The compound is designed to be brightly fluorescent and activated at low pHs, especially in 
degradative compartments such as MVBs and lysosomes. We adjusted the protocol to our 
conditions:  after starving and feeding the cells with the compound, we moved the samples in the 
IncuCyte® shifting the temperature from 0°C to 37°C and the live-cell fluorescence signal was 
detected in a time-dependent manner (0-180, every 30min).  
We observed an increased integrated fluorescent signal and accumulation in acidic compartments of 
the pHrodo-Tf in SW480/e.v. cells after 180 min (Fig. 25, A, B-1). In contrast, SW480/MACC1 cells 
showed a reduced intensity of the signal (Fig. 25, A, B-2), diverging from the control after 1 h. 
Moreover, a decreased red fluorescence signal was detected after 180 min (Fig. 25, B-2) in 
SW480/MACC1 cells as compared to the control cell line (Fig. 25, B-1).  
In conclusion, our data show that MACC1 overexpression avoids the accumulation over time of the 
pHrodo-Tf-TfR complex in low pH and degradative compartments, while in the control (SW480/e.v.), 
a relevant accumulation of the pHrodo-Tf-TfR and the red fluorescence signal was observed after 180 
min.  
However, further experiments are required to understand whether MACC1 impact by avoiding TfR 
accumulation in acidic compartments in due to its intervention on the internalization, recycling or 
degradation step.   
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Figure 25 MACC1 overexpression prevents the endocytic TfR traffic into degradative compartments. Cells 
were seeded (1x104) in a 96-well plate and after starvation, were fed with pHrodo-Tf (50 ug/ml) and the 
integrated fluorescence signal was observed in a time-dependent manner. (A) Integrated pH-sensitive signal 
intensities of internalized pHrodo-Tf over time. Results are shown as means ± SEM of four independent 
experiments. ***p < 0.001. (B) Representative pictures from IncuCyte® live imaging system of SW480 e.v. (1) 
and SW480/MACC1 (2) and the pHrodo compound after 3 h of the endocytic assay.  
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4.2.4 MACC1 overexpression mediates a faster TfR recycling leaving RAB11 expression 
unaltered, while in the control cell line is degraded 
 
The MACC1 overexpression prevents the TfR-pHrodo-Tf complex from being processed towards low 
pH and degradative compartments (Fig. 25). Hence, to understand whether MACC1 was also involved 
in the recycling of TfR to the PM we studied the recycling rate (observable as a loss of fluorescent 
signal and measured by FACS) of the TfR-Tf-647 marked complex over time. As shown (Fig. 26, A), 
MACC1 overexpression in SW480 generates the faster signal loss of Tf-647, compared to the control 
cell line SW480/e.v..  
SW480/SH3BP4 cells showed no enhanced TfR recycling as compared to SW480/e.v. which is in line 
with previous data which showed no recycling effect of SH3BP4 ovexpression121. Moreover, when 
internalized, the TfR can be processed via two different recycling routes: a fast RAB4-mediated 
processing route directly from endosomes, and a slow RAB11-mediated route from ERC195,196,203. In 
our MACC1-CME interactome analysis we could find a putative interaction of MACC1 with a Ras-
related protein (RAB) (Supplementary Figure 1, 10), in particular RAB11A.  
Therefore, to exclude a RAB11A-altered activity on the TfR faster recycling to the PM, we checked 
the protein level in SW480/e.v and SW480/MACC1 cells and as reported (Fig. 26, B), no difference in 
RAB11 protein expression was observed between SW480/MACC1 and the control cell line.  
Moreover, we also studied TfR degradation over time by analyzing the loss of TfR total protein after 
stimulation with h-Tf. SW480/e.v. cells show decreased total TfR protein levels over time (Fig. 26, C-
D) following the stimulation of TfR uptake. On the other hand, SW480/MACC1 cells did not show 
apparently any loss of the protein over time. To conclude, these observations lead us to speculate a 
MACC1-mediated increased of TfR recycling in RAB11 endocytic recycling compartments. 
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Figure 26 MACC1 overexpression mediates a faster TfR recycling leaving RAB11 expression unaltered, while 
in the control cell line is degraded. (A) After seeding and starving cells, the recycling assay was carried out as 
previously described189 (see Material and method for details). Briefly, after marking cells surface with 
fluorescence-labelled Tf-647 (25 ug/ml), the shift of the cells from 0°C to 37°C in the incubator, allowed the 
loading of endosomes with Tf-647. Signal loss over time, due to recycling of the TfR to the PM has been 
quantified via FACS (MFI). (B) RAB11 protein level has been checked at steady state in SW480/MACC1 and 
SW480/e.v. cells. Representative Western blot of three independent experiments, β-actin has been used as 
loading control. (C) TfR degradation was studied, after seeding and starvation, cells (3x105) we fed with h-Tf (50 
ug/ml) for 10 and 20 min. Representative Western blot of three independent experiments. (D) Quantification 
of TfR/β-actin ratio level upon h-Tf stimulation, after quantification of WB signal intensities and normalization 
to t = 0 min. MFI – mean fluorescence intensity; RAB11 – Ras-related protein Rab11; **p < 0.01, ****p<0.0001 
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4.2.5 MACC1 recruitment during TfR-stimulated CME increases the receptor 
colocalization into RAB11-marked compartments and decreases its colocalization in 
LAMP1-marked degradative compartments 
 
Once we established a faster MACC1-induced recycling effect (Fig. 26, A), we confirmed and tested 
the ability of MACC1 to lead TfR to target RAB11 recycling compartments. To understand the fate of 
the internalized TfR, we compared TfR localization in SW480/e.v. and SW480/MACC1 cells, not only 
in RAB11-marked compartments, but also in degradative compartments, marked with the lysosomal 
membrane protein (LAMP1). For this purpose, immunofluorescence and confocal microscopy 
approaches were used. 
In the end, to confirm a role of MACC1 during internalization, we blocked both the slow and fast 
recycling routes with the ionophore monensin and analysed the TfR endosomal accumulation after 
treatment 158,195–197. Our data show that upon TfR-stimulated internalization, MACC1 overexpression 
in SW480 cells drives TfR to increased colocalization in RAB11-marked compartments, compared to 
SW480/e.v. cells (Fig. 27, A-D).  
Accordingly, the results showed that in SW480/MACC1 cells TfR colocalization with LAMP1 decreased 
after 30 min of TfR internalization with h-Tf as compared to SW480/e.v. cells (Fig. 10, B-D). 
Furthermore, observing both SW480/e.v. and SW480/MACC1 cells, the overall colocalization of TfR in 
LAMP1 compartments is lower than in RAB11 compartments, supporting the classical sustained TfR 
routing into recycling compartments in both the cell lines.  
However, we also used the recycling inhibitor monensin to evaluate the TfR accumulation in EEA1-
marked endosomes overtime, thus, blocking both the recycling routes. As expected, considering the 
MACC1-mediated interference on the TfR uptake (Fig. 6, A-B-C), no accumulation between 
SW480/e.v. or SW480/MACC1 was observed whilst a decreased colocalization of TfR in EEA1 
compartments was noticed. This confirms the MACC1-mediated interference on TfR uptake (Fig. 6). 
To conclude, our findings show a MACC1-mediated enhancement of the TfR trafficking into RAB11 
recycling compartments and its interference during ligand-stimulated TfR internalization.  
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Figure 27 MACC1 recruitment during TfR-stimulated CME increases the receptor colocalization into RAB11-
marked compartments and decreases its colocalization in LAMP1-marked degradative compartments. A 
confluent monolayer of SW480/e.v. and SW480/MACC1 cells (1x104) was seeded, serum starved and treated 
for 30 min with h-Tf (50 ug/ml) to measure the immunofluorescence distribution of TfR in RAB11 or LAMP1 
marked endocytic compartments. (A-C) Colocalization of MACC1 and RAB11 (A), LAMP1 (B), EEA1 (C) in 
SW480/e.v. and SW480/MACC1 cells after 30 min stimulation of TfR internalization with h-Tf. Scale bar = 10 
µm. Indicated regions are displayed enlarged (10x). (D) Statistical analyses of Persons correlation coefficients 
(mean ±SEM), are performed by Student’s t-tests. Single channel images are provided in the supplementary 
Figures 4. RAB11 – Ras-related protein Rab11; LAMP1 – lysosomal membrane protein; EEA1 – early endocytic 
antigen 1; **p < 0.01, ***p < 0.001 
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4.2.6 MACC1 knockdown is not altering TfR surface abundance in SW620 cell lines but 
interferes with the TfR uptake 
 
After we assessed the effect of MACC1 overexpression on TfR endocytic traffic (Fig. 25, A-B-C), we 
tested the effect of MACC1 knockdown (KD) on TfR internalization and surface distribution, using cell 
lines previously established in our lab81: SW620/sh cnt and SW620/sh MACC1 respectively. After 
lentiviral transduction, SW620 cells displayed a stable silencing for MACC1 mRNA expression 
(SW620/sh MACC1) (Fig. 23, C-D).  
No MACC1 KD dependent alterations of mRNA and protein levels of TfR and SH3BP4 were observed 
in SW620/sh MACC1 cells and the respective control cell line (SW620/sh cnt) (Fig. 23, C-D). Hence, 
the surface abundance of TfR at PM in SW620/sh MACC1 and SW620/sh cnt cells was indirectly 
assessed. As shown (Fig. 28, A), no difference was observed for the TfR-Tf-647 bound to PM in 
SW620/sh MACC1 and the control cell line.  
Consequently, the MACC1 KD-dependent effect on TfR CME uptake was elucidated. The 
internalization was determined by specifically labeling indirectly the TfR at PM with Tf-647 at 0°C to 
impede endocytosis, and the time resolved uptake of the receptor-ligand-complex was determined 
after shifting the cells to 37°C, (Fig. 28, A-B). As expected, MACC1 KD interferes with TfR 
internalization after 20 minutes, (Fig. 28, B). These data confirm MACC1 as a regulator of the TfR 
internalization.  
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Figure 28 MACC1 knockdown is not altering TfR surface abundance in SW620 cell lines but interferes with the 
TfR uptake. After cell seeding (1x106) and starvation, cells were harvested and marked with Tf-647 (25 μg/ml) 
at 0°C and then shifted at 37°C for determining the internalized signal (see Material and Methods for details). 
(A) Surface staining of TfR indirectly marked with Tf-647 of SW620-derived cell lines is represented. Total 
surface Tf-647 signal intensities were determined indirectly by FACS. (B) Internalized Tf-647 signal intensities 
after temperature shift for subsequent time points. Data represent mean ± SEM of three independent 
experiments. *p < 0.05.
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4.2.7 MACC1 knockdown targets TfR to degradative compartments  
 
As previously shown, MACC1 recruitment during TfR internalization generates a faster TfR recycling 
to PM which is independent from changes in RAB11 protein expression (Fig. 26, A-B). To complete 
our knowledge on TfR fate after internalization in MACC1 overexpressing and knock-down 
conditions, we used the IncuCyte® Live-imaging system, with the pH sensitive compound pHrodo-Tf.  
As expected, after feeding the cells with the pHrodo-Tf and shifting them from 0°C to 37°C, live-cell 
fluorescence signal was detected in a time-dependent manner. We observed a significantly increased 
integrated fluorescence signal in SW620/sh MACC1 cells after 180 min as compared to 
SW480/MACC1 cells, indicating a pHrodo-Tf accumulation into degradative and low pH 
compartments (Fig. 29, A). 
Moreover, the fluorescence signal was observed after 180 min of assay in SW620/sh MACC1 cells as 
compared to the control (Fig. 29, B-2). To conclude, our findings show that MACC1 KD leads to the 
accumulation of pHrodo-Tf-TfR complex in low pH and degradative compartments over time (Fig. 29, 
A and B-2).  
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Figure 29 MACC1 knockdown targets TfR to the degradative compartments. Cells were seeded (1x104) in a 96-
well plate and after starvation, were fed with pHrodo-Tf (50 ug/ml), and the integrated fluorescence signal was 
observed in a time-dependent manner. (A) Integrated pH-sensitive signal intensities of internalized pHrodo-Tf 
over time. Results are shown as means ± SEM of four independent experiments. ****p < 0.0001. (B) 
Representative pictures from the IncuCyte live imaging system of MACC1 SW620/sh cnt (1) and SW620/ sh 
MACC1 cells (2) and the pHrodo-Tf compound after 3 h of endocytic assay. 
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4.2.8 MACC1 knockdown leads TfR to degradation following specific internalization 
stimuli 
 
Our results show increased TfR trafficking into low pH and degradative compartments in SW620/sh 
MACC1 cells as compared to the control cell line (Fig. 29, A-B). Therefore, to confirm the MACC1-
mediated effect on TfR targeted traffic to degradative compartments, we measured the TfR total 
protein level after ligand-stimulated CME.  
After seeding and starving cells, TfR internalization was specifically stimulated with h-Tf. Cells were 
lysed after 10 or 20 min of stimulation and the total TfR protein was measured by SDS-PAGE and WB. 
In line with previous data (Fig.29), MACC1 KD increases TfR degradation after 20 min of h-Tf 
stimulation (Fig. 30, A-B). Hence, to check whether the MACC1-dependent degradation could be 
reverted, cells were pre-treated with Bafilomycin A1, an inhibitor of lysosomal degradation.  
Stimulation of TfR internalization for 10 and 20 minutes with h-Tf after Bafilomycin A1 leads to an 
accumulation of the TfR total protein in both cell lines (Fig. 30, C-D). We therefore conclude that 
MACC1 KD leads to TfR degradation via degradative compartments, while inhibition of lysosomal 
degradation results in a TfR protein accumulation in SW620 sh MACC1 cells, similarly to SW620/sh 
control. 
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Figure 30 MACC1 knockdown leads to TfR degradation following specific internalization stimuli. (A, C) TfR 
degradation was studied after seeding and starvation (with or without pre-treatment with bafilomycin A1 for 4 
h), cells (3x105) were fed with h-Tf (50 ug/ml) for 10 and 20 min and total protein changes were checked over 
time. Representative blot of three independent experiments. (B, D) Quantification of TfR/β-actin ratio upon h-
Tf stimulation, after quantification of WB signal intensities and normalization to t = 0 min.; *p < 0.05 
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4.2.9 Endogenously overexpressed MACC1 increases the endocytic traffic of TfR in 
SW620 cells compared to SW480 cells, virtually non-expressing MACC1  
 
To understand the general MACC1-dependent effect on TfR endocytic traffic we analyzed it from 
another point of view. A reported correlation between Dukes cancer staging and altered TfR 
expression and distribution in patients tissue raised the question as to whether we could detect an 
altered TfR surface distribution and internalization in CRC cell lines employed in this thesis, i.e. 
SW480 cells (Duke B, low MACC1 expression) and SW620 cells (Duke C, high MACC1 expression), 
originating from the primary tumor and a lymph node metastasis respectively, from the same 
patient177.  
Gene expression of MACC1, SH3BP4, and TfR in both cell lines were analyzed via gene specific qRT-
PCR and WB. Altered expression levels of MACC1 and TfR were observed (Fig. 23, E-F). Thus, to find 
out the MACC1 overall effect on TfR endocytic routing, we studied the surface distribution of TfR as 
well as TfR internalization by indirectly labeling extracellular TfR with Tf-647 at 0°C, and for the time 
resolved uptake of the receptor-ligand-complex at 37°C (Fig. 31, A-B), observing the surface and 
internalized signal via FACS.  
As expected, our data show increased PM-bound Tf-647 in SW620 cells in accordance with previous 
data (Fig. 23, E-F). On the other hand, increased TfR internalization was also observed in SW620 
highly expressing MACC1, we speculate it might depend from the increased TfR expression and 
surface distribution in SW620 (Figure 31, A). 
Next, we used the IncuCyte® Live-imaging system to elucidate the overall effect of the endogenously 
high expression of MACC1 on the TfR traffic, taking into consideration the MACC1-dependent fast 
recycling of TfR (Figure 26, A). The overall effect, as expected, shows a sustained endocytic traffic of 
TfR in SW620 cells towards low pH compartments (Fig. 31, C-D).  
To conclude, SW620 cells show increased PM distribution of TfR, indirectly measured. Depending on 
the PM distribution, the internalized TfR-Tf-647 complex is increased in SW620 compared to SW480 
low-MACC1 expressing cells. We conclude that MACC1 is regulating both TfR internalization and 
recycling. In SW620 cells this overall increases in the endocytic rate of TfR traffic in low pH 
compartments, might depend on the TfR higher expression together with MACC1 increased effect on 
TfR recycling. 
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Figure 31 Endogenously overexpressed MACC1 increases the endocytic traffic of TfR in SW620 compared to 
SW480, virtually non-expressing MACC1. After cell seeding (1x106) and starvation, cells were harvested and 
marked with Tf-647 (25 μg/ml) at 0°C and then shifted to 37°C (see Material and Methods for details) (A) 
Surface staining of TfR marked with Tf-647 of SW620 and SW480 cell lines is represented. Total surface Tf-647 
signal intensities were determined by FACS. Results are shown as means ± SEM of three independent 
experiments. (B) Internalized Tf-647 signal intensities after temperature shift for subsequent time points. (C) 
Cells were seeded (1x104) in a 96-well plate and after starvation, were fed with pHrodo-Tf (50 ug/ml) and the 
red fluorescence signal was observed in a time-dependent manner. Integrated pH-sensitive signal intensities of 
internalized pHrodo-Tf over time are reported. Results are shown as means ± SEM of four independent 
experiments. (D) Representative pictures from the IncuCyte® live imaging system of SW620 (1) and SW480 (2) 
cells and the pHrodo-Tf compound (in red) after 3 h of endocytic assay. *p < 0.05, **p < 0.01, ***p< 0.001. 
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4.3 Characterization of the impact of MACC1 CME domains 
 
4.3.1 Generation and characterization of the MACC1 mutants  
 
After observing the MACC1-dependent effect on TfR internalization and routing into later 
compartments, we decided to define the contribution of MACC1 CME domains (Fig.19, A) in order to 
dissect their impact and relevance during TfR CME. The in silico analysis of MACC1 amino acid 
sequence, focusing on putative structural domains and linear protein interaction motifs, revealed 
several N-terminally located interaction motifs for CME factors, and the SH3 domain.  
We thereby generated the MACC1∆NT-GFP construct by deleting all putative N-terminal interaction 
sites for CME factors (clathrin box, NPFs, DPF, Fig. 19 A) in a CMV-promoter-driven-MACC1-GFP 
fusion construct. Similarly, the SH3 domain was deleted, generating the MACC1∆SH3-GFP construct, 
and a combination of both deletions were structurally converged, generating the MACC1∆NT∆SH3-
GFP mutant.  
Structures of the deleted cassettes and the generated constructs are schematically represented (Fig. 
32, A). Expression levels of the mutated constructs of MACC1, as well as SH3BP4 and TfR were 
determined by qRT-PCR and WB (Fig. 32, B-C), to exclude again any MACC1-dependent effect at the 
mRNA and protein level. All MACC1-constructs presented increased expression as expected, and we 
did not observe any change in mRNA and protein expression of the indicated genes, compared to 
SW480/GFP.  
Globally, data show that the establishment of SW480/MACC1∆NT-GFP, SW480/MACC1∆SH3-GFP 
and SW480/MACC1∆NT∆SH3-GFP cell lines for our further purposes was successful, and 
overexpression of MACC1 deleted versions in the cell lines was not influencing mRNA and protein 
expression of both TfR and SH3BP4. 
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Figure 32 Generation and characterization of the MACC1 mutants. (A) Schematic overview of MACC1 mutants 
with deleted N-terminal CME-related interaction motifs (MACC1ΔNT, top), deleted SH3 domain (MACC1ΔSH3, 
middle), and a combination of both deletions (MACC1ΔNTΔSH3, bottom), C-terminally tagged with GFP. 
MACC1, TfR and SH3BP4 mRNA and protein expression were checked in all cells harboring the MACC1 deleted 
versions. (B) Thus, after seeding cells (3x105), total RNA was extracted, reverse transcribed and quantified by 
real time PCR. Results are first normalized to GADPH and then represented as n-fold of the control cell line with 
respect to the gene of interest. Results are shown as means ± SEM of three independent experiments. (C) For 
the MACC1, TfR and SH3PB4 protein expression analysis, after seeding cells (3x105), cells were harvested, lysed 
in RIPA lysis buffer (see Material and Method for details). Proteins of the cell lysates were quantified and each 
sample was immunoblotted on nitrocellulose membranes, for MACC1, TfR, SH3BP4 and β-actin as loading 
control. A representative blot of three independent experiments is shown. NPF – interaction motif for EPS15-
homology domains; DPF - interaction motif for adapter-protein 2 complex; ZU5 – domain present in zona 
occludens 1 and uncoordinated-5; UPA – domain found in uncoordinated-5, p53-induced death domain protein 
1 and ankyrins; SH3 – Src homology domain 3; DD – death domain. ***p < 0.001 
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4.3.2 The SH3 domain is pivotal for MACC1 distribution at PM and relevant for the 
binding with TfR 
 
To clarify the importance of MACC1 CME domains, and their role in the protein distribution, MACC1 
localization was analysed via confocal microscopy (Figure 33, A). As shown, the full-length MACC1-
GFP protein is distributed and accumulated at PM, as well as the in the MACC1ΔNT-GFP mutant cell 
line (second panel from left).  
Strikingly, MACC1 distribution at PM is completely lost when the MACC1 SH3 domain is deleted, 
resulting in a dispersed MACC1 localization throughout the cytoplasm (third panel, Figure 33). 
Moreover, a dispersed localization of MACC1 in the cytoplasm was noticed not only in 
SW480/MACC1ΔSH3-GFP but also SW480/MACC1ΔNTΔSH3-GFP cells.  
Our findings show that MACC1 SH3 domain determines its distribution and accumulation at PM, 
suggesting a stronger and predominant role for SH3 domain in the TfR endocytic traffic. To define the 
relevance of MACC1’s CME-domains in the interactions with CLTC, DNM2 and TfR, we studied the 
loss of binding between MACC1 and these proteins in the MACC1 deleted mutant cell lines (Figure 
33, B-D). MACC1 binding to CLTC and DNM2 was lost in all deleted mutant (Figure 33, B-C). Also, 
MACC1 binding with TfR was completely lost in the SH3-deleted cell line while was still observed in 
the NT-deleted cell line (Figure 33, D).  
Together, these findings confirm a strong and predominant role of the SH3 domain for the MACC1 
localization at the PM in SW480/MACC1-GFP cells. Moreover, our results confirm the involvement of 
both the MACC1 CME domains (at the N-terminus) and the SH3 domain in the binding with CLTC and 
DNM2. Also, our observations point out that MACC1/TfR interaction is mediated by the SH3 domain 
but it might be linked to the endocytic machinery via the N-terminal interaction motifs. 
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Figure 33 MACC1 SH3 domain is pivotal for its distribution at PM the binding with TfR. A confluent monolayer 
of MACC1 CME deleted mutant cells (1x104) was seeded. (A) Cellular localization of MACC1-GFP and all deleted 
mutants were assessed by confocal microscopy. Arrows indicate the loss of the MACC1-GFP localization at the 
PM. Nuclei were stained with DAPI. Scale bar=10µm (B-D) Pull-down of MACC1 deletion variants with CLTC, 
DNM2 and MACC1 antibodies and immunostaining for MACC1 (B and C) or TfR (D). 
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4.3.3 CME-related domains of MACC1 regulate the TfR distribution at the PM and the 
first steps of TfR CME 
 
To understand how the MACC1 deleted cassettes were impacting the TfR endocytic traffic, we 
employed the previously introduced methods for the following experiments. Surface located TfR was 
indirectly marked with fluorescence-labeled transferrin (Tf-647, at 0°C) in MACC1 mutated cell lines, 
and quantified by FACS analysis as already introduced for previous experiments. Our findings show, 
that the SH3-domain deletion on MACC1 caused accumulation of TfR at PM (Fig. 34, A) compared to 
the overexpressing MACC1-GFP full-length cell line.  
Accordingly, to understand whether the loss of MACC1 SH3-domain was also impacting the TfR 
uptake, surface-marked mutant cells were shifted from 0°C to 37°C, and TfR uptake displayed a 
significant and progressive decrease in all deleted mutant cell lines as compared to the full-length 
SW480/MACC1 and the control cells (Figure 34, B).  
Furthermore, we verified via confocal microscopy the SH3-deletion-dependent impairment during 
TfR-Tf-647 uptake. For this purpose, the full-length MACC1-GFP and the SH3-deleted mutant cell 
lines were fed with Tf-647 for 15 min and stained for EEA1. As shown (Fig. 34, C), SW480/MACC1-GFP 
shows not only a prominent MACC1 PM distribution as compared to the SH3 deleted construct (in 
line with previous data in Figure 33, A), but also overlaps with Tf-647 at the PM (shown in cyan in 
Figure 34, C). These data were confirmed by measuring the Tf-647 integrated intensity in both the 
cell lines (Figure 34, D). 
Furthermore, we used pHrodo-Tf to study the endocytic fate of the receptor. After feeding the cells 
with the pH sensitive compound, the TfR fate was monitored for 180 min. As a result, we observed 
increased internalized fluorescence signal in the control SW480/GFP cells, and decreased but still 
detectable signal in SW480/MACC1-GFP cells (Figure 34, E). Only weak increase of the signal was 
detected for the SW480/MACC1∆NT-GFP mutant cell line and no increase in signal could be detected 
for the SW480/MACC1ΔSH3-GFP and SW480/MACC1ΔNTΔSH3-GFP cell lines (Fig. 34, B).  
To conclude, our data show that the SH3 deletion of MACC1 is dominantly causing an excess of TfR at 
the PM. Moreover, the MACC1 SH3 deletion impairs strikingly the TfR uptake compared to full-length 
MACC1 and the ∆NT-GFP deletion construct. These data suggest that the SH3 domain of MACC1 is 
pivotal in the TfR-Tf-647 complex uptake.
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Figure 34 CME-related domains of MACC1 regulate the TfR distribution at the PM and the first steps of TfR 
endocytosis. (A) After cell seeding (1x106) and starvation, cells were harvested and marked with Tf-647 (25 
μg/ml) at 0°C for 1 h (see Material and Methods for details). Surface staining of TfR indirectly marked with Tf-
647 of MACC1 CME mutants is represented. Total surface Tf-647 signal intensities were determined by FACS. 
Data represent mean ± SEM of three independent experiment (B) Internalized Tf-647 signal intensities after 
temperature shift for 20 min. Data represent mean ± SEM of three independent experiment (C) A confluent 
monolayer of SW480/MACC1 cells (1x104) has been seeded, serum starved and treated for 15 min with Tf-647 
(25 ug/ml) to measure by immunofluorescence (SP5, Leica) sensible changes in the colocalization with 
endocytic markers (EEA1, in particular) after TfR specific stimulated internalization. Single channel images are 
provided in Supplementary Figure 5 for EEA1, Tf-647 in SW480/MACC1-GFP and SW480/MACC1∆SH3-GFP cells. 
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Scale bar = 10 µm. Indicated regions are displayed enlarged (10x). (D) Integrated intensity of the internalized 
Tf-647 is reported for SW480/MACC1-GFP and SW480/MACC1∆SH3-GFP cells (E) Cells were seeded (1x104) in a 
96-well plate and after starvation, were fed with pHrodo-Tf (50 ug/ml). The red fluorescence signal was 
observed in a time-dependent manner. Integrated pH-sensitive signal intensities of internalized pHrodo-Tf over 
time are represented. Data represent mean ± SEM of three independent experiment *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001 
99 
 
4.4 Characterization of MACC1 impact on RTKs endocytic traffic 
 
4.4.1 Investigating MACC1 impact on other RTKs: MACC1 binds both EGFR and MET 
 
After we validated MACC1 interactions with proteins involved in CME and with TfR (Fig. 20, B-D), we 
asked whether other CME-dependent tyrosine kinase receptors were also affected in a MACC1-
driven manner. Therefore, to validate other receptor-MACC1 interactions we coimmunoprecipitated 
the EGFR and MET receptors, and we searched for the MACC1 binding in SW620, SW480/MACC1 and 
SW480/MACC1-GFP (as previously shown in Fig.2 B-E). Both receptors show an interaction with 
MACC1 screened as a band on the immunoblot (Fig.35, A-B). Our data confirm that MACC1 binds 
directly or indirectly to these two RTKs.  
 
 
Figure 35 Investigating other cancer-related cargoes: new insights, new cargoes and a long way to go. (A-B) 
The validation of MACC1 binding to RTKs was carried out via coIP and immunoblot, in different CRC cell lines 
(SW620, SW480/MACC1 and SW480/MACC1-GFP). After seeding (4x106), cells were harvested after 48 h, lysed 
in coIP lysis buffer and the cell lysates were pulled down with EGFR (A) and MET (B) antibodies and 
immunoblotted for MACC1. IgG control was used as a negative control.  
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4.4.2 MACC1 overexpression determines EGFR and TfR associated cargo selection in 
CCV, upon EGFR-stimulated internalization 
 
After confirming MACC1’s role during TfR endocytosis (see, Chapter 4.2), we investigated its function 
during RTK endocytosis. On the one hand, it is known that TTP is behaving as endocytic adaptor for 
TfR via its SH3 domain collaborating predominately with DNM’s PRD domain121. On the other hand, 
SH3BP4 endocytic role has been dissected during FGFR endocytosis, concluding that SH3BP4 
regulates FGFR fate by directing it towards recycling or degradative routes depending on the p-
85/SH3BP4 complex recruitment at FGFR tail, after ligand-induced CME122.  
Also, it is known that TTP selectively joins TfR-marked CCV, depending on the cargo, but did not 
interact with the oncogenic driver EGFR198. Considering the difference between these two receptors 
(TfR and EGFR), it was speculated that inclusion or exclusion of RTKs from TfR-marked vesicles would 
depend on the phosphorylation of TTP or dynamin121. Nevertheless, literature search revealed that 
TfR and EGFR cooperate in non-small lung cancer (NSLC)187. In particular, the kinase activity of EGFR 
controls TfR distribution at PM.  
Considering what we found so far, our next step was to determine whether MACC1 could also 
mediate the inclusion/exclusion of EGFR from TfR-marked CCV, upon specific stimulation of the 
receptor in CRC cell lines. To address this issue, we used a concentration of EGF (20 ng/ml) that 
allowed us to exclude any NCE130 and checked whether in the absence or presence of MACC1 we 
could find EGFR in TfR-marked CCV.  
We treated SW480/e.v. and SW480/MACC1 cells with EGF for 8 min and we searched for 
colocalization of the three proteins respectively, MACC1, EGFR and TfR. As shown the colocalization 
between EGFR, TfR and CLTC was found (represented in white spots) in SW480/MACC1 EGF-
stimulated cells, while it was not found in control cells (SW480/e.v.) (Fig. 36, lower left panels).  
As control for the induced EGF-internalization, both cell lines were previously treated with dynasore, 
which prevents dynamin GTPase activity while pinching off CCV into cytoplasm, creating an 
accumulation of vesicles at PM (with “long neck” shape as shown in Fig. 36, lower right panels). 
Concluding, our findings show that EGFR colocalization into TfR-marked vesicle is MACC1 dependent. 
Moreover, we assumed that, likewise SH3BP4 (for TfR and FGFR), MACC1 might selectively choose 
cargoes to be included in TfR-marked CCV vesicles, following them in the first endocytic steps. 
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Figure 36 MACC1 overexpression determines EGFR and TfR associated cargo selection in CCV, upon receptor-
stimulated internalization. A confluent monolayer of SW480/e.v. and SW480/MACC1 (1x104) has been seeded, 
serum starved and treated for 8 minutes with 20 ng/ml EGF in presence or absence of the dynasore inhibitor 
pretreatment (80 μM). The three fluorescence signals from CLTC, EGFR and TfR, were measured by 
immunofluorescence (SP5, Leica) to observe changes. (A) Colocalization of EGFR, TfR and CLTC after triple-
staining of SW480/e.v. cells treated (left panel) and untreated (right panel) respectively with 8 min with EGF 
with or without pretreatment with dynasore (80 μM). (B) Colocalization of EGFR, TfR and CLTC after triple-
staining of SW480/MACC1 cells treated (left panel) and untreated (right panel) respectively with 8 min with 
EGF or 8 min with EGF after pretreatment with dynasore (80 μM). Indicated regions are displayed enlarged 10x, 
and histograms show the spatial distribution of the signal intensities across indicated sections. Representative 
pictures of three independent experiments. All panels show merged images. Single channel images are 
provided in Supplementary Figure 6. Scale bar = 10 µm 
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4.4.3 MACC1 overexpression increases the presence of EGF in low pH compartments 
 
Our previous results demonstrate the MACC1-dependent selection of the EGFR into TfR-marked 
vesicles (Fig.36, A-B). For this reason, we choose to further study the EGFR in order to deepen our 
knowledge with respect to MACC1´s impact on CME of RTKs receptors. In our previous studies, we 
found that in EGF-stimulated SW480/MACC1 cells TfR and EGFR were colocalizing with TfR-marked 
CCVs, which was not the case in SW480/e.v. cells (Fig. 36, A-B). Thus, to understand whether MACC1 
might regulate EGFR internalization we used pHrodo-EGF and measured the integrated fluorescent 
signal as shown in the experiments before, and using the IncuCyte® system199–202.  pHrodo-EGF allows 
to measure the release of the compound into acidic pH compartments in case of recycling200,203 or 
the progressively increased fluorescence in case of degradation of the receptor203,204, depending on 
different pH and compartments.  
Considering this, we expected the fluorescence signal weaker or stronger dependent on the pH of 
endosomes and ERC204,205 (pH 6.5-6.0) or MVBs and lysosomes (pH 5-4.5) hence, revealing the 
sorting route of EGFR/pH-EGF complexes to different endocytic pathways. To determine whether 
MACC1 might also influence EGFR endocytic traffic, we detected the integrated fluorescence 
intensity of pHrodo-EGF in a time-dependent manner. Our data revealed an enhanced internalization 
of pHrodo-EGF-EGFR complexes in SW480/MACC1-GFP cells as compared to SW480/GFP control 
cells, relevant only after 3h of compound accumulation in acidic compartments (Fig. 37).  
As controls for the correct uptake of the pHrodo-EGF-EGFR complex and delivery towards endocytic 
compartments, SW480/e.v. and SW480/MACC1 cells were also pre-treated with the endocytic 
inhibitors dynasore and bafilomycin A1. As shown, the dynasore and bafilomycin pre-treatments 
decrease strongly the integrated fluorescence signals. Therefore, we concluded that pHrodo-EGF, is 
endocytosed in a dynamin-dependent manner, and it is correctly targeted to low/acid pH 
compartments (Figure 37).   
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Figure 37 MACC1 overexpression increases the presence of EGF in low pH compartments. Cells were seeded 
(1x104) in a 96-well plate and after starvation, were fed with pHrodo-EGF (5 ug/ml) and the integrated 
fluorescence signal was observed in a time-dependent manner for 180 min. Integrated pH-sensitive signal 
intensities of internalized pHrodo-EGF over time are represented here for SW480/GFP and SW480/MACC1-GFP 
cells, pre-treated for 4 h or not with Dynasore (80 μM) and Bafilomycin A1 (100 nM). Results are shown as 
means ± SEM of three independent experiments. **p < 0.01. 
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4.3.4 MACC1 overexpression increases the recycling pool of EGFR at PM thereby 
targeting slow and fast recycling pathways  
 
Our results so far revealed that the overexpression of MACC1 enhances the presence of pHrodo-EGF 
in acidic compartments, which in our case might result in the accumulation of pHrodo-EGF within 
endosomes, recycling endosomes and lysosomes (Fig. 37). EGFR is normally targeted for degradation, 
but the EGF remains bound to the receptor when reaching very low-pH compartments183,205. 
Moreover, the latest EGFR endocytic model shows that EGFR releases the bound EGF in recycling 
endosomes (pH 6.5) while it is disassembled in order to be recycled back to the PM182,183,205. 
 Therefore, to clarify the mechanism behind MACC1-mediated increase in pHrodo-EGF within acidic 
compartments (Fig. 37), we indirectly measured via FACS the effect of MACC1 overexpression on the 
receptor recycling back to PM. The EGFR pool available at the PM (surface signal at time point 0) was 
indirectly marked with EGF-647 of HCT116/GFP and HCT116/MACC1-GFP cells, as well as SW480/e.v. 
and SW480/MACC1 cells, at 0°C. To quantify the recycled pool present at the PM after ligand-
induced internalization via CME, the receptor pool at PM was indirectly measured by re-probing the 
surface with EGF-647 at 0°C after 30 min of EGF-stimulated internalization (20 ng/ml)130 (Figure 38, 
A-B and D). SW480/MACC1 cells but not HCT116/MACC1-GFP cells showed a decreased surface 
distribution of EGFR as compared to the respective control cell line SW480/e.v. Interestingly after 30 
min of EGF-stimulated internalization, the EGFR recycled pool available at PM is significantly 
increased in HCT116/MACC1-GFP and in SW480/MACC1 cells (Figure 38, A-D). These data confirm 
the MACC1-mediated increase on recycling rate of EGFR to PM. 
 In order to understand whether the increased pool of EGFR at PM was caused by the MACC1-
mediated effect on internalization and recycling, we repeated the previous assay, and we pre-treated 
the cells with monensin, an inhibitor of both the fast (RAB4) and slow (RAB11) routes of recycling for 
EGFR206. As shown (Fig. 38, B) the EGFR recycled pool at PM after EGF-stimulated-CME endocytosis, is 
significantly decreased in the monensin-treated HCT116/MACC1-GFP cells compared to HCT116/GFP 
cells (Fig. 38, B).  
These findings confirm that MACC1 overexpression in HCT116 cells mediates the faster EGFR 
recycling to PM, via both the recycling routes (slow and fast). The absence of changes of the EGFR 
recycled pool at the PM in HCT116/GFP still remains unclear, but we assumed a slower/decreased 
response to EGF-stimulated CME in this cell line, compared to SW480. This observation might be 
further confirmed considering the complete absence of change in the EGFR pool at PM before and 
after EGF-stimulated CME (Figure 38, B). To conclude, our findings show that MACC1 overexpression 
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enhances the EGFR available pool at the PM via MACC1-mediated CME and by targeting EGFR to PM 
via slow and fast recycling routes. 
 
 
Figure 38 MACC1 overexpression increases the EGFR recycling pool at the PM in two different cell lines via 
targeting both the recycling slow and fast pathways. (A, D) After cell seeding (1-3x105) and starvation, cells 
were harvested and marked with EGF-647 (2.5 μg/ml) at 0°C for 1 h, without (for the surface EGFR pool) or 
with (for the recycled EGFR pool) ligand-stimulated CME for 30 min with 20 ng/ml EGF. After staining and 
fixation, the indirect surface fluorescence signal of EGFR of HCT116-derived (A) and SW480-derived (D) cell 
lines is represented. Total surface EGF-647 signal intensities were determined by FACS. Data represent mean ± 
SEM of three independent experiments. (B) After cell seeding (1-3x105) and starvation, cells were harvested 
and marked with EGF-647 (2.5 μg/ml) at 0°C for 1 h after 30 min of EGFR specific CME, stimulated with 20 
ng/ml EGF, in presence or absence of Monensin pre-treatment (10 μM) of 4 h. After staining and fixation, the 
indirect surface fluorescence signal of EGFR of HCT116-derived cell lines is represented. Total surface EGF-647 
signal intensities were determined by FACS and normalized to the initial surface signal beforehand. Data 
represent mean ± SEM of three independent experiments. (C, E) For the steady state MACC1 and EGFR protein 
expression analysis in the considered cell lines, after cells were seeded (3x105), harvested, and lysed in RIPA 
lysis buffer. Proteins in cell lysates were quantified and each sample was immunoblotted on nitrocellulose 
membranes for MACC1, EGFR and β-actin as loading control. A representative blot of three independent 
experiments is shown. 
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4.3.5 MACC1-mediated CME sustains EGFR routing into recycling compartments and it is 
dependent on its SH3 domain 
 
After we showed increased uptake of the pHrodo-EGF-EGFR complexes in SW480/MACC1-GFP cells 
compared to SW480/GFP cells (Fig. 37), we were curious to understand whether MACC1 was also 
regulating the PM distribution and uptake of EGFR as for TfR (Fig.39, A-B) with its CME cassettes. 
Therefore, as previously shown, we stained the surface of cells expressing MACC1-deleted constructs 
with EGF-647 to test indirectly the EGFR distribution at PM. A progressive accumulation of EGFR at 
the PM is observed in MACC1-CME deleted mutants cell lines. In particular, the EGFR accumulation at 
PM is increased in SW480/MACC1ΔSH3-GFP as compared to SW480/MACC1-GFP cells (Fig. 39, A). 
Furthermore, a decreased EGFR PM distribution was observed in SW480/MACC1-GFP as compared to 
the control cell line SW480/GFP, coherently with previous results (Fig.34, A-B).  
After we observing a progressive deletion-dependent accumulation of EGFR at PM, our next step was 
understanding whether MACC1 CME mutant cells were differing in EGFR uptake, comparing them 
also to our previous results. Indeed (Fig. 39, B-D), the MACC1 CME deleted MACC1 cell lines showed 
increased integrated fluorescence signal, statistically relevant for the SH3-deleted and the double-
deleted mutant cell lines compared to the full-length SW480/MACC1. As control, we also pre-treated 
the MACC1 mutant cell lines with dynasore and compared to the untreated mutants, observing no 
internalization of EGFR-pHrodo-EGF complexes (Fig. 39, C).  
These data show that MACC1 SH3 domain is likely regulating not only EGFR distribution at the PM, 
but also mediates the dynamin-dependent EGFR endocytic delivery of the EGFR-EGF-pHrodo 
compound into later endocytic compartments after internalization. Comparing the difference in 
signal intensity between the cell lines (Fig. 39, D), the MACC1-mediated EGFR distribution at PM and 
routing into degradative compartments is SH3-domain regulated and dependent.   
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Figure 39 MACC1-mediated CME sustains EGFR routing into recycling compartments and it is dependent on 
its SH3 domain. (A) After cell seeding (1x106) and starvation, cells were harvested and marked with EGF-647 
(2.5 μg/ml) at 0°C for 1 h, (see Material and Methods for details). Surface staining of EGFR indirectly marked 
with EGF-647 of MACC1 CME mutants is represented. Total surface EGF-647 signal intensities were determined 
by FACS. Data represents mean ± SEM of three independent experiments (B) Cells were seeded (1x104) in a 96-
well plate and after starvation, were fed with pHrodo-EGF (5 ug/ml) and the red fluorescence signal was 
observed in a time-dependent manner. Integrated pH-sensitive signal intensities of internalized pHrodo-EGF 
over time are represented. Results are shown as means ± SEM of four independent experiments.  *p < 0.05, 
**p < 0.01, ***p < 0.001. (C) Cells were seeded (1x104) in 96-well plate and after starvation, were pre-treated 
for 4 h with dynasore to impede dynamin scission of the vesicle into the cytoplasm (80 μM), then fed with 
pHrodo-EGF (5 ug/ml) and the fluorescence signal was observed in a time-dependent manner. Integrated pH-
sensitive signal intensities of internalized pHrodo-EGF over time are represented. Results are shown as means ± 
SEM of four independent experiments.  *p < 0.05, **p < 0.01, ***p < 0.001. (D) Representative pictures of the 
MACC1 CME mutant cells before and after 3 h of pHrodo-EGF endocytic traffic assay. 
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4.3.6 EGFR transphosphorylation upon EGF-stimulated CME and downstream signaling 
cascade is regulated by MACC1 CME cassettes 
 
Receptor internalization, recycling and degradation can differentially affect the strength and duration 
of signalling36. In particular, increased receptor recycling sustains and prolongs the signaling122. 
Besides SH3BP4, several other selective cargo proteins are known to prolong signaling 122. Thus, after 
we elucidated MACC1’s role in EGFR recycling, we decided to investigate the impact of MACC1 CME 
cassettes on different signaling cascades. Therefore, we induced the EGFR CME by specifically 
treating serum-starved MACC1 CME mutant cells with low concentrations of EGF (20 ng/ml) for 
different time intervals (0-90 min).  
In order to check the activation, signal prolongation and transphosphorylation of EGFR after ligand-
induced CME stimulation, we studied the phosphorylation of tyrosine 1068 (Y1068) located on the 
cytoplasmic tail of EGFR. As expected, (Fig. 40, A, C) SW480/GFP cells, show EGFR activation (pY1068) 
progressively increasing after EGF-stimulation, while SW480/MACC1 cells show a sustained 
activation and transphosphorylation (pY1068) after 8 and 30 min of stimulation.  
Regarding the downstream targets of the ligand-activated EGFR, MACC1 overexpression increased 
and sustained ERK1/2 and AKT phosphorylation (Fig. 40, A, C, D) until 90 min after stimulation. The 
impact of MACC1 overexpression EGFR downstream targets was also compared between the full-
length MACC1 overexpressing cell line and the MACC1-deleted mutant cell lines (Fig. 40, B). As 
shown, the loss of MACC1 N-terminal CME domains as well as the SH3 domain strongly impairs the 
EGFR activation after EGF-stimulation, comparable to the GFP control (Fig. 40, B, C). 
Also, in both the SH3-deleted mutant and the double mutant cell lines we observed a weak EGFR 
activation as compared to SW480/MACC1-GFP, which, however, was stronger compared to 
SW480/MACC1∆NT-GFP and the GFP control cell line.  
Looking into the AKT-downstream cascade, SW480/MACC1 cells show increased phosphorylation of 
AKT compared to the control cell line at any time point (SW480/MACC1-GFP). In contrast, both 
SW480/MACC1ΔSH3-GFP and SW480/MACC1∆NTΔSH3-GFP show a sustained AKT phosphorylation 
still 90 min after EGFR ligand-stimulated CME. SW480/MACC1∆NT-GFP cell line show similar 
downstream activation of AKT to the GFP control. The AKT downstream activation is overall impaired 
compared to the full-length MACC1 expressing cell lines (Figure 40, B, D). 
Regarding the ERK1/2- phosphorylation profile, SW480/MACC1-GFP, SW480/MACC1∆NT-GFP show a 
similar ERK1/2 activation to GFP. On the contrary, downstream activation of ERK 1/2 in 
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SW480/MACC1ΔSH3-GFP and SW480/MACC1∆NTΔSH3-GFP is strikingly impaired, compared to the 
full-length MACC1 (Fig. 40, B, E). These data suggest that MACC1 CME cassettes are important for 
downstream activation of ERK1/2 
To understand the functional relevance of the MACC1 CME cassettes loss, we studied the mutants 
cell lines proliferation in presence of low EGF concentrations (20 ng/ml) continuously for 72 h. The 
different activation patterns of EGFR (pY1068) in SW480/mutant-MACC1 cell lines are preserved in 
the proliferation assay. 
 The full-length MACC1 overexpression in SW480 cells significantly increased the cell confluence after 
3 days of ligand-stimulated proliferation (Fig. 40, F). In addition, the SW480/MACC1ΔSH3-GFP and 
the double mutant cell lines consistently show a similar proliferation rate to SW480/GFP.  
Our findings show new insights on MACC1 as endocytic protein. Our data suggest that MACC1 has a 
role during the EGFR activation via its SH3-domain as we observed by monitoring the docking-site 
(pY1068) transactivation during the EGF stimulated CME.  
Although downstream phosphorylation of ERK1/2 and AKT diverge in MACC1-mutant cell lines 
compared to control and the full-length cell line, only the MACC1 wild type overexpression in SW480 
guarantees the efficiency of ERK 1/2 and AKT-signalling cascades resulting in increased proliferation. 
These results were also confirmed by the decreased proliferation observed in 
SW480/MACC1ΔSH3-GFP and SW480/MACC1∆NTΔSH3-GFP cell lines. 
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Figure 40 EGFR activation and downstream cascade is regulated by MACC1 CME cassettes. (A-B) After seeding 
(3x105) and serum-free starvation, MACC1 mutants were stimulated with low concentration of EGF (20 ng/ml) 
for an interval 0-90 min, to induce EGFR-specific internalization. After stimulation, cells were harvested and 
lysed in RIPA lysis buffer (see Material and Method for details). Proteins of the cell lysates were quantified and 
each sample was immunoblotted for different cascade antibodies and β-actin as loading control. A 
representative blot of four independent experiments is shown. Western blot analysis of EGFR, activated and 
phosphorylated EGFR (Tyr1068), ERK 1/2 and phosphorylated ERK (Thr202/Tyr204), AKT and phosphorylated 
AKT (Ser473) was performed in SW480 overexpressing MACC1 deletion constructs. (C-E) Quantification of 
pEGFR/EGFR, pAKT/AKT, pERK/ERK ratio upon EGF (20ng/ml) stimulation, after quantification of WB signal 
intensities; *p < 0.05, **p < 0.01, ***p < 0.001 (F) Proliferation of the SW480 cell line overexpressing MACC1 
deletion construct was measured for 72 h in presence of continuous EGF treatment (20 ng/ml) in RPMI 2% FBS. 
The data shown are the mean ± SEM of four independent experiments. *p<0.05, **p<0.01, *** p<0.001  
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4.5 Supplementary Figures and Tables 
Supplementary Figure 1. List of the involved proteins in CME, found by KEGG Pathway Analysis. After 
analysing our IPI_IDs from the MS list with DAVID bioinformatic tool, we also extracted a representative figure 
of the involved pathway, in our case “Endocytosis”. Together with the representative positions (red stars, on 
Figure 1) of MACC1 potential interactors in the endocytic pathway, the KEGG analysis also provides a list of the 
involved proteins, including ENSEML and ENTREZ gene ID, represented above (for the graphical screen, see 
supplementary figure 10).  
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Supplementary Figure 2. MACC1 changes colocalization with validated CME interactors upon ligand-
stimulated TfR CME. A confluent monolayer of SW480/MACC1 (1x104) has been seeded, serum starved and 
treated for 15 min with an excess of h-Tf (250 µg/ml) in order to measure by immunofluorescence (SP5, Leica) 
changes in the protein distribution and correlation at steady state and after TfR specific stimulated 
internalization. (A-D) Single channel images of the colocalization studies of MACC1 and TfR (A), CLTC (B), DNM2 
(C) and AP2 (D) in SW480/MACC1 cells before (upper panel) and after (lower panel) 15 min stimulation of TfR 
internalization with h-Tf. Scale bar = 10 µm.  
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Supplementary Figure 3. MACC1 marks TfR-containing vesicles and TfR-containing endosomes, upon h-Tf 
triggered TfR CME internalization. A confluent monolayer of SW480/MACC1 cells (1x104) has been seeded, 
serum starved (1 hr) and treated for 15 min with h-Tf (250 µg/ml) in order to measure by immunofluorescence 
(SP5, Leica) changes in the protein distribution and correlation at steady state and after TfR specific stimulated 
internalization. (A-B) Single channel images of the colocalization of MACC1, TfR and CLTC (A) or EEA1 (B) after 
triple-staining of SW480/MACC1 cells before (upper panel) and after (lower panel) 15 min stimulation of TfR 
internalization with h-Tf. Scale bar = 10 µm.  
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Supplementary Figure 4. MACC1 recruitment during TfR-stimulated CME increases the TfR receptor 
colocalization in RAB11-marked compartments and a decrease of TfR in LAMP1-marked degradative 
compartments.  A confluent monolayer of SW480/e.v. and SW480/MACC1 cells (1x104) has been seeded, 
serum starved and treated for 15 min with h-Tf (50 µg/ml) in order to measure by immunofluorescence (SP5, 
Leica) changes in the protein distribution and correlation with different endocytic compartments. (A-C) 
Colocalization of MACC1 and RAB11 (A), LAMP1 (B), EEA1 (C) in SW480/e.v. and SW480/MACC1 cells after 15 
min stimulation of TfR internalization with h-Tf. Scale bar = 10 µm. Indicated regions are displayed enlarged 
(10x).  
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Supplementary Figure 5. CME-related domains of MACC1 mutants regulate the TfR distribution at the PM 
and the first steps of TfR endocytosis. A confluent monolayer of SW480/MACC1-GFP and SW480/MACC1ΔSH3-
GFP cells (1x104) has been seeded, serum starved and treated for 15 min with Tf-647 (25 µg/ml) in order to 
measure by immunofluorescence (SP5, Leica) changes in the protein distribution within the cell and in 
endosomal compartments (EEA1-maked, in particular). Scale bar = 10 µm. Indicated regions are displayed 
enlarged (10x). 
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Supplementary Figure 6.  MACC1 overexpression determines EGFR and TfR associated cargo selection in CCV, 
upon receptor-stimulated internalization. Single channel images are provided. A confluent monolayer of 
SW480/e.v. and SW480/MACC1 cells (1x104) has been seeded, serum starved and treated for 8 min with 20 
ng/ml EGF in presence or absence of the dynasore inhibitor (80 μM). The three fluorescent signals from CLTC, 
EGFR and TfR were measured by immunofluorescence distribution and detection (SP5, Leica). (A) Colocalization 
of EGFR, TfR and CLTC after triple-staining of SW480/e.v. cells treated (left panel) and untreated (right panel) 
respectively with EGF for 8 min or with EGF for 8 min after pretreatment with dynasore (80 μM). (B) 
Colocalization of EGFR, TfR and CLTC after triple-staining of SW480/MACC1 cells treated (left panel) and 
untreated (right panel) respectively with EGF for 8 min or with EGF for 8 min after pretreatment with dynasore 
(80 μM).  Single channel images are provided. Scale bar = 10 µm. 
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Supplementary Figure 7. Assessment of MACC1 and EGFR expression in MACC1 CME mutants. (A) MACC1 and 
EGFR mRNA and protein expression were determined in all the MACC1-mutant cells. Thus, 48 h after seeding 
cells (3x105), total RNA was extracted, reverse transcribed and quantified by real time PCR. Results are first 
normalized to GADPH and then represented as n-fold of the control cell line with respect to the gene of 
interest. Results are shown as means ± SEM of three independent experiments. *p < 0.05, **p < 0.01, ***p < 
0.001 (B) For the MACC1 and EGFR protein expression analysis, 48 h after seeding cells (3x105), cells were 
harvest and lysed in RIPA lysis buffer (See Material and Method for details). Proteins of cell lysates were 
quantified and each sample was immunoblotted on nitrocellulose membrane, for MACC1, EGFR and β-actin as 
loading control. A representative blot of three independent experiments is shown.  
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Supplementary Figure 8. MACC1 overexpression retains a sustained downstream ERK 1/2 signaling upon EGF 
stimulation and accumulation at endosomes. After cell seeding (3x105), serum-free starvation and treatment 
with Monensin (10 μM), HCT116-derived cell lines were stimulated with low concentration (20 ng/ml) of EGF 
for 0, 8 min, to induce EGFR-specific internalization. After stimulation, cells were harvested and lysed in RIPA 
lysis buffer (see Material and Method for details). Proteins of cell lysates were quantified and each sample was 
immunoblotted on nitrocellulose membrane, for ERK1/2 cascade antibodies and β-actin as loading control. A 
representative blot of three independent experiments is shown. Western blot quantification represents the 
ratio of the phosphorylated ERK1/2 / total protein. 
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Supplementary Figure 9. MACC1 migrates into SW480/MACC1 nucleus and at the PM in SW620 cells after 
HGF stimulation.  A confluent monolayer of SW480/MACC1 and SW620 cells (1x104) has been seeded, serum 
starved and treated for 5 min with 2 ng/ml HGF. The three fluorescence signals from CLTC, MET and MACC1 
were measured by immunofluorescence distribution and detection (SP5, Leica). Colocalization of MACC1, MET 
and CLTC triple-staining of cells untreated (A, B upper panel) and treated (A, B lower panel) respectively. 
Representative pictures of three independent experiments. All panels show merged images. Scale bar = 10 µm. 
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Supplementary Figure 10. KEGG pathway analysis via DAVID is screened, endocytosis interactors of 
MACC1 are indicated by red stars, useful to understand at which level of endocytic processes, MACC1 
might be involved and have putative interactors (the complete list is the Supplementary Figure 1). 
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5. Discussion
In 2018, CRC is still one of the heaviest and deadliest burdens for society207. The development of CRC 
is complex, due to a gradual accumulation of genetic and epigenetic changes and to environmental 
factors. If CRC progresses until the late stages this predicts, a poor outcome, while at early stages the 
disease is often curable. A key to preventing deaths and improving the survival of patients in later 
stages of CRC will surely be to gain an understanding of the molecular mechanisms associated with 
crucial steps in the genetic development of the disease.  Identifying new prognostic markers to 
predict CRC development and progression is an important milestone toward personalizing 
treatments.  
The gene MACC1 was identified in 2009 as a new marker in early stages of CRC that proved 
prognostic for the development of metastases. MACC1 has been linked to a number of signaling 
pathways, but its physiological functions have remained elusive. In this thesis we identified a 
complete new biological role for MACC1 during CME. 
Our data shed new light on the impact of MACC1-mediated CME on two distinct receptors, TfR and 
EGFR. In particular, MACC1 shows a clear involvement during internalization and increases TfR 
recycling during CME. MACC1 binds CLTC, DNM2 and TfR via all the predicted CME domains. 
Moreover, MACC1’s N-terminus CME domains and the SH3 domain are differently involved and 
influence both TfR and EGFR during CME. Our data show a predominant role for the SH3 domain. 
Surprisingly, after we observed an increased colocalization of TfR and EGFR in CCVs in MACC1 
overexpressing cells during EGF-stimulated CME, we hypothesized a MACC1-mediated increased 
recycling of EGFR. This thesis not only confirms our mechanistic hypothesis on the increase MACC1-
mediated recycling of EGFR but also characterize the functional impact of MACC1 CME domains on 
EGFR-mediated proliferation. Our functional studies also indicate that if MACC1 lacks its endocytic 
cassettes, both EGFR transactivation and downstream ERK/MAPK and PI3K/AKT signaling are 
deregulated.  
In summary, this work exposes a novel biological role for MACC1, that might lead in future to 
exploitation in the development of targeted treatments against metastasis and the progression of 
CRC. 
5.1 MACC1 and its homology with SH3BP4: protein structure, localization and 
interaction 
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The first insights into MACC1 functions were hypothesized from its homology to SH3BP4; they share 
43.7% homology in their amino acid sequence and predicted structural features. Both exhibit an SH3 
domain91,  in the C-terminus of the protein structure. These similarities suggested a role during CME 
(Fig. 19). In this thesis I first showed that MACC1’s interaction partners include a well-defined known 
set of proteins involved in CME. MACC1 shows interesting new dynamics with CME interactors 
including CLTC, AP-2, DMN2 and TfR (Fig.2-3). Our data reveal slight differences between the 
interactomes of MACC1 and SH3BP412289 but both proteins share interactions with proteins involved 
in endocytosis, as established through GO terms enrichment, which is highly indicative for a role in 
regulating CME122 (Fig.1).  
Among the overlap in the proteins’ interactomes, MACC1 predicted interactions with CLTC, DNM2, 
AP-2α and TfR were validated (Fig. 20, B-E). These validations suggest that MACC1 is part of the 
endocytic machinery and is probably involved in the process of CCV formation. In terms of cellular 
distribution, reports have placed SH3BP4 in punctate structures in the cytoplasm and at the 
periphery of the cells, and has also been detected in the nucleus121. In 2009, MACC1 was 
characterized for its distribution and shuttling from the nucleus to cytoplasm. Until the present work, 
however, neither its punctual distribution with CME proteins in the cytoplasm nor dynamic, stimulus-
dependent changes in localization had been observed.89 
Our colocalization studies reveal a distribution of MACC1 within CCV and the TfR (Fig. 21, A-B). This 
increases over time, after a specific stimulation that leads to TfR internalization. In contrast to CLTC 
and TfR, the colocalization of MACC1 and DNM2 decreases after TfR-specific stimulation (Fig. 21, C). 
This tendency toward an inverse correlation of MACC1 and DMN2, compared to TfR or CLTC, 
indicates that MACC1 associates in distinct ways with proteins that are involved in early and late 
stages of the CCV machinery.  
We speculate that MACC1 might play a role in the sequential recruitment of these endocytic 
proteins. Upon stimulation of TfR, MACC1’s CME binding domains might regulate a decisive and 
limiting step of cargo-containing vesicle excision from PM208–210. Our results also suggest that the 
interaction of MACC1 and AP-2α is indirect and probably mediated by CLTC or TfR, which form the 
main hub of the CCV (Fig. 21, D). Interestingly, SH3BP4 exhibited no codistribution with the endocytic 
markers RAB11 and EEA1, although a triple colocalization was found with TfR and CLTC121. In 
contrast, our data show that upon TfR-stimulated CME, MACC1 was found colocalizing with the TfR 
and CLTC or the endosomal marker EEA1 (Fig. 22). Since MACC1 was observed to colocalize with 
these two endocytic markers, we speculate that it might shuttle from the PM to the endosomes via 
TfR-loaded CCVs. 
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 In summary, the interactomes of MACC1 and SH3BP4 present similar endocytic protein signatures. 
Their common interactions with CME proteins and significant homology suggest similar functions. On 
the other hand, their distinctive traits are likely to give them different roles during CME. MACC1 
appears to be involved in the endocytic machinery at the steady state and after specific-receptor 
trigger confirmed by our observations in its dynamic changes in the distribution with endocytic 
proteins. Also, our data confirm MACC1 presence in TfR-marked vesicles and endosomes after CME 
initiation. These conclusions and preliminary results suggested that we should investigate a new 
aspect of MACC1, as a key player in endocytosis.  
5.2 MACC1 overexpression effect and the TfR endocytic cycle 
The present work shows a novel role for MACC1 in the process of CME. Our preliminary screen of 
MACC1 interactors suggested a role in endocytic trafficking (Fig. 19-22). To test this hypothesis, we 
studied the internalization of TfR in MACC1-overexpressing and -knockdown conditions. Differently 
from SH3BP4, which shows an accumulation of TfR at PM dependent on its interference during TfR 
internalization, upon overexpression, MACC1 does not mediated an accumulation of TfR at the PM 
instead, the TfR surface distribution decreases in MACC1 overexpressing cell lines (Fig. 24, A). Similar 
results and effect on TfR PM distribution were also obtained in SW480/SH3BP4 (Fig. 24, A)121. 
Overexpression of either SH3BP4 or MACC1 interferes with the internalization of Tf-647 compared to 
control cell lines (Fig. 24, B). These findings suggest that MACC1 is not only part of the endocytic 
machinery during the first steps of TfR internalization, but might regulate it. Regarding SH3BP4, its 
knowing role during TfR internalization and in the endocytic machinery, was used to compare MACC1 
behaviour and as a positive control.  
In contrast, our findings also show an unusual block in the endocytic trafficking of pHrodo-Tf (Fig. 25, 
A-B). This pH-sensitive compound was unable to progress towards and accumulate in strongly acidic
and degradative compartments, exhibiting a decrease in its fluorescent signal that stayed stably at
low levels, compared to the control (Fig. 25, A-B). A convincing clarification of the mechanism came
through the recycling assay, where the overexpression of MACC1 caused a faster loss of the Tf-647
signal compared to control cell line (Fig. 26, A-B). In line with previous data SH3BP4 is not showing
any effect on TfR recycling. These data suggested a dual and distinct role for MACC1 during the
internalization and the recycling of TfR. The colocalization of TfR within RAB11-marked recycling
compartments and decreased colocalization of TfR in LAMP1-marked degradative compartments in
SW480/MACC1, compared to the control cell line, provided further evidence (Fig. 27, A-B). We
concluded that the faster recycling of TfR toward RAB11-positive compartments might depend only
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on the recruitment of MACC1 to the tail of the TfR during CME, since TfR the tail does not contains 
docking sites for signaling adaptors.211 An alternative possibility is that the increase in recycling 
mediated by MACC1 might also depend on its interactions with TfR at the endosomal level with 
RAB11, or through a specific targeting of the receptor to ERC or TGN via interaction with ESCRT 
machinery (Supplementary Fig. 1 and Fig. 19). Our data reveal that MACC1 has a dual effect: on TfR 
distribution at the PM and internalization, and on the increased TfR recycling. Differently from 
SH3BP4’s previous data, which show an accumulation of TfR at PM and no effect on recycling, we 
concluded backwards that SW480/MACC1 cells might not need a rich pool of TfR on the PM, 
considering its increased effect on TfR recycling. That, might be an explanation of the altered the TfR 
amount at PM at steady state in SW480/MACC1.  
MACC1’s role in increasing the RAB11-recycling route for TfR is a key step in understanding its 
endocytic functions. MACC1 overexpression decreases the presence of the TfR into degradative 
compartments compared to the control cell line (Fig. 25-27). Thus, MACC1 has an impact at several 
steps of TfR endocytic trafficking, as shown from our data. Still needs to be clarified how MACC1 
directs the TfR receptor towards recycling or degradative routes.  
A similar situation has been observed for the Rab11 family-interacting protein Rip11/FIP5. This 
protein also enriches the endocytic recycling compartments and mediates the transport of TfR from 
endosomes to RAB11-marked compartments. In contrast to MACC1, a knockdown of Rip11/FIP5 
increases the uptake, recycling, and PM distribution of TfR212 .In contrast, MACC1 overexpression 
interferes with TfR uptake and blocks pHrodo-Tf trafficking towards late and degradative endocytic 
routes, but does not mediate and accumulation of TfR at PM.  
These observations suggest that MACC1 might act mainly at the endosomal or recycling 
compartments, after it has mediated the sorting of TfR at the PM through direct or indirect 
recruitment at the endocytic machinery. As a predicted RAB11-interacting protein, MACC1, might 
mediate the directional targeting of TfR through their association en route at the endosomes and by 
recruiting/excluding specific RABs.  
MACC1 blocks the targeting of pHrodo-Tf to degradative and late compartments (Fig. 25), thereby 
suggesting that its recruitment to the TfR-endocytic complex might exclude RAB12 or RAB7, which 
were not detected in the MACC1 interactome (Suppl. Fig. 1). The differential recruitment of RAB12 or 
RAB7 at the endosomal compartment has an important effect, by targeting TfR to the degradative 
pathway instead of along the recycling route, as happens with RAB11 (slow recycling route from ERC) 
or RAB4 (fast recycling route from endosomes).  
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Figure 41 Investigating MACC1’s role in the TfR endocytic traffic. (1) MACC1 was found colocalizing with 
DNM2 at PM before TfR-triggered internalization. (2) Upon TfR stimulated CME, its colocalization increases 
with CLTC and TfR. (3) After the endocytic machinery has loaded TfR on CLTC-marked vesicles, MACC1 travels 
(4) together with TfR from PM to endosomes. (5) Probably, at the endosomal compartment MACC1 might
mediates the TfR sorting into recycling compartments, by increasing the TfR targeting to RAB11-compartments,
instead of LAMP1-marked compartments or degradative routes.
5.3 MACC1 knockdown effect and the TfR endocytic cycle 
The present work assigns an endocytic role to MACC1. We previously showed how MACC1 
overexpression blocks the trafficking of TfR into degradative compartments, and how this influences 
the most commonly used model of TfR-CME (Fig. 41) Our next step was to dissect the effects of 
MACC1 knockdown (KD) on TfR endocytic trafficking. Interestingly, this does not alter the PM 
distribution of TfR from the situation seen in the overexpression studies (Fig. 28, A), but it alters 
equally the TfR internalization process, confirming MACC1 as a regulator of the TfR internalization 
(Fig.28, B).  
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These data, coupled with the results from the MACC1 overexpression experiments (Fig.25-27), 
suggested that the distribution of TfR on the PM might depend on downstream endocytic events 
such as endosomal sorting and TfR recycling in SW620 cells overexpressing MACC1 KD. We cannot 
exclude a connection between the activity of MACC1 and SH3BP4 during the TfR internalization and 
sorting phase, which might influence our results in this context. Our conclusion was that interference 
of MACC1 KD on TfR uptake confirms its endocytic role during the TfR internalization process. The 
effects of MACC1 KD on TfR routing and its accumulation in recycling or degradative compartments 
in SW620 cell lines were interesting and bear further investigation (Fig. 29, A-B)  
After 3 h of pHrodo-Tf trafficking, we observed that MACC1 KD clearly triggers and strengthens the 
accumulation of TfR in degradative and low pH compartments compared to the control (Fig. 29, B). 
This effect was visualized via live imaging as a red-fluorescent accumulation in SW620 cells (Fig.29, 1 
and 2) both panels). We could also confirm a MACC1-dependent effect of TfR routing into 
degradative compartments by measuring the decrease of total TfR protein level after 20 min of h-Tf 
stimulation (Fig. 30, A). Additionally, bafilomycin A1 caused a block of the degradative 
compartments, leading to a visible accumulation of the TfR receptor resembling that of the control 
(Fig. 30, B), as expected. We conclude that in contrast to SH3BP4, MACC1 is an endocytic protein 
both involved in the internalization and the recycling of the TfR. Still unclear but very intriguing is 
whether the MACC1-dependent effect on TfR sorting into recycling compartments is dependent on 
specific recruitments orchestrated by MACC1. Our data could not clarify whether such events take 
place during TfR internalization or at the endosomal compartment at the sorting machinery through 
an inclusion or exclusion of specific trafficking proteins.   
 
5.4 Biological impact of MACC1-mediated endocytic trafficking of TfR  
 
It has recently been shown that there is a relationship between TfR expression and the stages of 
colorectal carcinoma (Dukes A, B, C, D). In particular, differentiated colorectal carcinoma cells (Dukes 
A and B) present high expression of TfR while poorly differentiated cells (Dukes C and D)177 exhibit 
only weak TfR expression. This may be related to changes in the metabolic requirements of cancer 
cells at different stages of their development. Here, iron plays a role as a fundamental biological 
nutrient and cellular entity. It has particular importance in regulating DNA synthesis over the cell 
cycle. Iron depletion generally blocks the cell in G1/S phase and causes apoptosis213. Modulating iron 
transport and balancing cellular quantities are crucial in maintaining a healthy relationship between 
nutrients and cell growth213. Any deregulation in these processes can lead to unbalanced and 
aggressive proliferation, particularly in neoplasia214. Thus, by modulating TfR, MACC1 has a potential 
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to profoundly alter cell metabolism in ways that may be either supportive or detrimental to the 
progression of cancer. 
To define the MACC1 general impact on internalization and recycling of TfR we used SW480 (Dukes 
B) cell lines derived from the primary tumor and SW620 (Dukes C) from a lymph node metastasis
from the same CRC patient. The aim was to assess the biological impact of MACC1 on iron uptake in
primary tumours and in distant metastasis. MACC1 is endogenously overexpressed in SW620; in
SW480 there is virtually no expression. Interestingly, the mRNA expression of TfR in SW480 and
SW620 cells do not reflect the mentioned TfR mRNA expression. The expression of TfR mRNA is 2-
fold higher in SW620 cells than in SW480 (Fig. 23, E-F).
We confirmed a higher indirect membrane distribution for TfR/Tf-647 complexes in SW620 than in 
SW480 cells (Fig.13, A). We also confirmed that MACC1 weakly interferes with TfR uptake in SW620 
cells (Fig. 13, C). But we also showed that the endogenous expression of MACC1 in these cells causes 
TfR to accumulate in acidic compartments in a time-dependent manner (Fig. 13, D-E). We speculate 
that this effect depends not only on the increased distribution of TfR at the PM but also on enhanced 
MACC1-mediated endocytic recycling of TfR and consequent increase of TfR delivery to degradative 
compartments. In summary, these data suggest that in highly TfR expressing cells (SW620), MACC1 
mediates the regulation of TfR transport, ultimately leading to an increase in iron metabolism and we 
speculate, to subsequent cell proliferation.   
5.5 A role for TfR in novel approaches to CRC therapies 
Ultimately, the metastatic progression of CRC is the principal cause of deaths from the disease215. 
This makes preventing the formation of metastases in the early stages of tumours a key therapeutic 
goal. TfR is an expression marker for many cancer types, including CRC166,167,170, and is linked to the 
availability of iron, a nutrient crucial for cell growth and proliferation216. Here we present strong 
evidence that MACC1 has an impact on both TfR internalization and recycling. It has been shown that 
the progression to CRC is driven by an increased expression of iron import proteins which 
subsequently sustain increased proliferation178. Our data show that SW620 cells, which highly 
express MACC1 and increased TfR compared to SW480, (Fig. 23, E-F) exhibit an increase in TfR 
endocytic traffic through recycling compared to SW480 cells, which express virtually no MACC1. 
Overall, this leads to an increase in the import of TfR (Fig. 31, C-D).  
MACC1 has been indicated as a prognostic factor for many cancer types105,217–222, and our research 
sheds new lights on the MACC1 role during physiological processes. Our data reveal MACC1 as a 
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decisive driver of the switch of TfR fate from degradation to recycling. This suggests a potential 
handle for treatments.  
Because increased iron import is a prerequisite for highly proliferative cancer cells, a number of novel 
therapies are targeting this process. Very recently, TfR has become an attractive target for these 
approaches because it is upregulated in many drug-resistant and metastatic cancer entities in a 
highly specific way. Moreover, TfR is already being efficiently used to deliver therapeutic compounds 
and molecules into malignant cells173,223,224. Despite the fact that TfR is the most known and 
characterized receptor able to recycle to the PM after internalization171, a mechanistic involvement 
of MACC1 in its distribution had not been shown. 
Here we show that MACC1 has a striking impact on TfR’s distribution on the PM. MACC1 increases of 
TfR endocytic traffic towards recycling instead of degradation potentially makes it a potent player in 
the development of efficient therapies. Tf-conjugated/targeted compounds might be used in future 
for primary tumors and metastases, particularly aiming to develop highly selective cytotoxic 
strategies to target highly proliferative cancer cells. 
 
5.6 Impact of MACC1 CME domains during TfR trafficking 
 
Endocytosis is essential in mediating the transport of nutrients and molecules from the extracellular 
environment to the cell interior, integrates cellular signaling and regulates the composition of the 
PM225. CME regulates signal attenuation and the fates of receptors at the PM by internalizing them. 
Relatively disruptions of CME have been identified as drivers of cancer. Numerous proteins that act 
as endocytic modulators of receptor recycling enhance cancer-related cell signaling, which can lead 
to malignant progression122,226–228. Here we identify MACC1 as a new endocytic protein with a dual 
impact on TfR trafficking. As for many endocytic proteins, MACC1 exhibits predicted CME interacting 
domains at its N-Terminus and also contains a predicted interacting SH3 domain at the C-Terminus. 
To dissect the impact of MACC1 CME domains on endocytic traffic, we deleted them and observed 
the effects on distinct endocytic-limiting steps. Interestingly, we also found that deleting the SH3 
domain predominantly causes an accumulation of the indirectly stained TfR at the PM (Fig. 34, A) and 
also strongly impairs pH-Tf internalization (Fig 34, E). This led us to speculate on a stronger SH3-
dependent impact on MACC1-mediated TfR internalization compared to the ΔNT mutant MACC1 
protein. We observed a SH3 domain-dependent MACC1-mediated uptake of the TfR/Tf-647 complex 
using also confocal microscopy (Fig. 34, C). By quantifying the integrated density of fluorescence, we 
could confirm that the lack of the SH3 domain strikingly inhibits Tf-647 uptake into the cell (Fig. 34, C-
D). We also found that the MACC1 SH3 domain predominantly determines MACC1 distribution and 
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accumulation at the PM (Fig. 33, A), compared to the mutant harbouring the ΔNT deletions. The 
deleted cassettes (ΔNT and ΔSH3) caused the loss of the interaction between MACC1 and CLTC and 
DNM2 (Fig. 33, B-C).  
Moreover, MACC1 binding to TfR is SH3 domain-dependent and is lost when the SH3 domain is 
deleted (Fig. 33, D). TfR binds to MACC1 when the N-Terminus cassettes are deleted, suggesting that 
the MACC1/TfR complex might be mediated indirectly by other endocytic proteins such as CLTC after 
TfR-stimulated internalization (Fig. 33, D). We conclude that the impact of the SH3 domain of MACC1 
is clearly dominant over the N-Terminal interaction motifs and necessary for the uptake of TfR, as it is 
strikingly impaired in the ΔSH3 mutant compared to the ΔNT mutant cell lines. The MACC1 N-
Terminus CME cassettes and the SH3 domain might show synergistic effects during the process of 
TfR-stimulated internalization, but the TfR/Tf-647 accumulation at PM (Fig.33, A) clearly suggests 
that the MACC1 SH3 domain is involved in the rate-limiting step of the vesicle scission and TfR 
internalization.  
In contrast to all the other correlations between MACC1 and endocytic proteins we tested, MACC1 
exhibits a high inverse correlation with DNM2 (Fig. 21, A-D) before CME is triggered by h-Tf 
stimulation. In contrast to the MACC1/CLTC correlation, MACC1/DNM2 decreases after TfR 
stimulation. We speculate that MACC1 might bind to DNM2 before h-Tf triggers TfR. Alternatively, 
MACC1 might sequentially bind first to DNM2 and then TfR during the internalization step, and the 
two binding partners might compete for MACC1 SH3 domain during this process.  
In summary, MACC1 has an impact on the CME-based internalization and recycling of TfR. It is known 
that dynamin binds and initiates its GTPase activity after self-assembly via PRD/SH3 domain 
interactions and this regulates the rate-liming steps of CCV scission209,229–232. MACC1 seems to be 
involved in the first steps of this process. Further investigation will be needed to clarify whether the 
MACC1-dynamin interaction might also affect the budding of endosomal-derived recycling vesicles, a 
process which targets receptors to the PM233. We speculate that MACC1 might act in the manner of 
the “vesicle loading model” (Fig. 8, introduction), and mutually work with DNM2 to guarantee the 
correct sequential recruitment of endocytic proteins together with the receptor. This would 
hierarchically orchestrate their inclusion or exclusion from vesicles, predominantly via the MACC1 
SH3 domain. 
5.7 Discovery of the MACC1 impact on receptor tyrosine kinase endocytic traffic 
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Since MACC1 was identified in our lab in 200989, it has been characterized as a driver oncogene for 
metastasis in several other types of cancer105,234–238. So far biological evidence for a MACC1-
dependent mechanism of enforced signaling has not been presented. Here, for the first time, we 
introduce evidence for a role for MACC1 as an endocytic protein that can increase TfR recycling. 
Endocytic recycling has only recently been identified as a leading cause of sustained signaling for 
many receptors122,228,239.  
Our KEGG pathway analysis of the MACC1 interactome, predicted interactions with RTKs (Fig. 19, C), 
so we decided to validate MACC1’s binding with MET (Fig. 35, B). Mainly out of curiosity, we also 
examined whether MACC1 binds to EGFR, a well-known prognostic marker for CRC240. Unexpectedly, 
we confirmed their interaction (Fig. 35, A). In CRC, ligand-stimulated EGFR dimerizes and trans-
autophosphorylates specific tyrosine sites on its cytoplasmic tail. This enables numerous docking 
sites for signalosome adaptors (GRB2, GAB1, etc.) and activates signaling pathways such as PI3K/AKT, 
Jak/STAT, Src, and MAPK241. Furthermore, ligand-induced kinase activity of EGFR and subsequent 
tyrosines phosphorylation of SH3BP4 or dynamin during the internalization process prevent their 
interaction and probably mediates the exclusion of SH3BP4 from EGFR-containing CCP121.  
In contrast, a cooperation of TfR and EGFR in the cytoplasm has been found in lung cancer, and it is 
dependent on EGFR kinase activity that generates an increase of TfR membrane distribution187. Based 
on this finding from the literature, we tested whether MACC1 overexpression might have influenced 
the inclusion or exclusion of EGFR from TfR-marked CCVs upon its ligand-stimulated internalization 
and trans-autophosphorylation. In SW480/MACC1 cells, we could not confirm that EGFR is excluded 
from TfR-marked CCPs or CCVs (Fig. 36), but when dynamin was inhibited with dynasore, the two 
receptors could not be found in CCVs and CCPs. Taking this into account, we concluded that in CRC 
cell lines which overexpress MACC1, it does not mediate an exclusion of EGFR from CCPs and CCV 
upon EGFR kinase activation. This suggested that EGFR and TfR follow the same early endocytic 
pathway, as they are found in TfR-marked vesicles. Observing this we then speculated that TfR and 
EGFR could have been sorted after internalization to the recycling route and transported back to the 
PM. 
 
5.8 The impact of MACC1 on EGFR endocytic traffic 
 
MACC1’s role during CME was identified first by studying its impact on the endocytic trafficking of 
TfR. Our research shows two MACC1-mediated effects: the ligand-stimulated internalization of TfR 
and the faster release of the TfR-Tf-647 complex from the endosome to PM via RAB11-marked 
compartments. We further observed MACC1 binding to EGFR in three different cell lines (Fig. 35, A) 
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and showed that MACC1 overexpression includes EGFR in TfR-marked vesicles upon EGF stimulation. 
Our next step was to understand the impact of MACC1 during ligand-stimulated EGFR internalization. 
In SW480 cells, MACC1 overexpression mediates a significant increase of dynamin-mediated 
endocytic traffic of pH-EGF into acidic compartments after 3 h (Fig. 37).  
It has recently been shown that EGFR is targeted to degradative or recycling compartments in a 
ligand-concentration-dependent manner. At low EGF concentrations, ligand-stimulated EGFR is 
recycled back to the PM and only one-third of the pool is destined for degradation, which sustains 
EGFR signaling. At high EGF concentrations, with an involvement of both NCE and CME, the receptor 
is targeted preferentially to degradative compartments (40% cases). This has a differential impact on 
the EGFR signaling by decreasing its intensity130. In the most recent model of EGFR (Fig. 16, 
introduction), the recycled receptor needs to release the EGF-ligand in mild endocytic compartments 
such as endosomes/recycling endosomes before being disassembled. In turn it is transported back to 
the PM, increasing its availability and sustaining signaling182,183,242.  
Our data show that MACC1 overexpression causes an increased endocytic trafficking of the pH-
sensitive compound to low pH/acidic compartments in SW480 cells (Fig. 37). We cannot exclude that 
a sizable proportion of the receptor is destined to degradation, considering the high EGF 
concentration used (5 µg/ml), nor that the increased accumulation depends on the pH-EGF released 
in endosomes/recycling endosomes, which allows EGFR to be recycled182,183. In accordance with our 
data, the sequential deletion of MACC1 CME cassettes strongly increased endocytic traffic of pH-
EGF/EGFR complexes into low pH compartments in mutant cell lines. Together, these data suggest 
that the endocytic features of MACC1 are important to correctly ensure EGFR routing into CME, 
maintaining the balance of EGFR between recycling and degradation. To conclude, we speculate that 
the deletion of MACC1 CME domains might be the leading cause of the destabilization of the pH-
EGF/EGFR complex and its direct targeting into low pH and degradative compartments, compared to 
the full-length MACC1 and the control cell lines 
 
5.9 MACC1 overexpression increases EGFR recycling to the PM 
 
After focusing on the way by which MACC1 influences TfR recycling we were curious to investigated 
its impact on endocytic traffic of RTK receptors. Without evidence for one receptor over another, we 
first validated the indirect or direct binding of MACC1 to MET and EGFR (Fig. 35). Interestingly, the 
kinase activity of EGFR promotes Tf-internalization and increases the distribution of TfR at the PM in 
NLSC. Also, both EGFR and TfR colocalized in the cytoplasm after EGF-stimulated internalization187. 
133 
 
Considering this and our previous results into account (Fig. 36), and the MACC1-mediated increase of 
TfR recycling, we decided to test whether MACC1 overexpression could also affect EGFR recycling. At 
a low CME-inducing concentration of EGF (20 ng/ml), we found that MACC1 overexpression increases 
the pool of EGFR available on the surface after ligand-specific stimulation in two different expressing 
cell lines (Fig. 38, A, E). This finding suggests a first physiological role for MACC1 during EGF-
stimulated endocytic traffic leading us to hypothesized a MACC1-mediated in sustained signaling 
upon EGF-stimulated CME, dependent from its CME domains. 
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5.10 EGFR activation and trans-autophosphorylation is sustained by MACC1 
overexpression and affects two distinct downstream signaling cascades 
The structure of EGFR includes the extracellular region responsible for EGF ligand recognition and 
binding. EGFR also possesses the intracellular region including the juxtamembrane regulatory region, 
the kinase domain, and the intracellular C-terminal regulatory tail containing tyrosine residues which 
become phosphorylated upon EGF binding243. The binding of EGF, stabilizes EGFR monomers and 
induces EGFR dimerization. This, in turn, causes structural changes in the cytoplasmic domain, 
leading to the allosteric activation of the EGFR kinase domain244. In the active dimer, specific tyrosine 
residues in the cytoplasmic regions of each monomer trans-autophosphorylate, acting as a docking 
station for proteins and triggering the signaling cascade.  
To be recycled back to the PM, EGFR needs to effectively reach endosomes and must be routed into 
RE. There it disassembles into monomeric units and is targeted back to the PM, making it available 
for another round of transphosphorylation upon EGF binding183. Our data show that in line with the 
increased recycled EGFR pool, MACC1 overexpression in SW480 cells causes sustained trans-
autophosphorylation of the receptor at Y1068 for 30 min after stimulation. This confirms that 
MACC1-mediated increased recycling of EGFR sustains the activation of the receptor and its trans-
autophosphorylation. The effectiveness of this process depends on the MACC1 CME cassettes. Any 
MACC1 deregulation by deletion results in different effects on EGFR trans-autophosphorylation of Y-
1068; a decreased EGFR transphosphorylation as observed in the ΔNT mutant cell line, or decreased 
and prolonged transphosphorylation until 90 min after stimulation in the ΔSH3 and ΔNTΔSH3 mutant 
cell lines.  
Since its discovery in 2009, MACC1 has been implicated in driving sustained signaling in diverse 
molecular cascades including the HGF/c-Met245,246,76  pathway, the PI3K/AKT cascade98,247, and the 
Wnt/β-catenin248,and ERK/MAPK249 pathways. As previously shown for many cancer entities, the 
overexpression of MACC1 also drives sustained downstream signaling of ERK1/2 cascade (Fig. 40, A-
B). In contrast, in the ΔNT mutant cell line downstream ERK1/2 phosphorylation is weakly decreased 
while ΔSH3 and ΔNTΔSH3 mutant cell lines show a stronger decrease of ERK1/2 phosphorylation 
compared to the ΔNT mutant cell line. All the mutant cell lines harbouring MACC1 deleted versions 
show a general decrease of ERK1/2 phosphorylation compared to the full-length. Regarding the 
downstream activation of AKT, we observed some differences. MACC1 overexpression shows a mild 
increase AKT downstream phosphorylation compared to the control cell line. When we observed the 
MACC1 deletions effect on AKT phosphorylation we noticed an impairment in the signaling cascade 
in the ΔNT-deleted mutant cell line compared to the MACC1 full-length cell line. And indeed, we 
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observed an increase AKT downstream signaling for both ΔSH3 and ΔNTΔSH3 mutant cell lines. These 
data suggest that if the SH3 domain deletion causes a loss of MACC1 biological functions, in this 
context MACC1 might be temporarily replaced at PM by another protein (eg.SH3BP4). SH3BP4 may 
rescue the downstream activation of AKT. We further speculate that since SH3BP4 sustains AKT 
signaling during FGFR stimulation by interacting with the catalytic subunit (p85) of PI3K and 
promoting receptor recycling122, the SH3BP4 effect might overlap with MACC1 when studying AKT 
downstream phosphorylation.  
Considering these data, we suggest that MACC1 acts as an endocytic protein which is involved in 
physiological processes not only as an enhancer of receptor recycling, but also as a modulator of the 
process via its CME domains, which are necessary for effective downstream signaling. 
 
5.11 MACC1 CME domains ensure and efficient cell proliferation upon EGF stimulation 
 
Our current understanding of endocytosis has moved beyond seeing its functions in terminating 
ligand-induced signaling and the biological availability of surface receptors due to new insights and 
discoveries250. A deregulation of signaling is inherently connected to the development of cancer; 
sustained signaling in particular, is typical for RTKs during enforced recycling and is a major 
contributor to the continuous and uncontrolled growth of cancer cells. Since 2009, MACC1 has been 
identified as a prognostic marker for many solid entities, and as a key regulator of sustained 
proliferation76,236,247,251,252. MACC1 transcriptionally regulates the HGF receptor c-MET and promotes 
the HGF/c-MET axis as proliferative boost via ERK/MAPK and PI3K/AKT245. In this thesis, we identified 
a new role for MACC1 in relation to the EGFR-stimulated downstream pathways ERK/MAPK and 
PI3K/AKT. Data show that MACC1 participates during TfR endocytosis via its endocytic domains and 
substantially influences it, as seen in particular through the dominant effects of SH3 domain deletion. 
Conversely, any studied deletion of the MACC1 protein structure impairs the trans-
autophosphorylation of the EGFR receptor and the downstream signaling of both ERK/MAPK and 
PI3K/AKT pathways, but differently. This pattern of impairment was functionally confirmed by testing 
all the MACC1 cell lines harbouring CME-deleted domains (Fig. 40, F). The proliferation of cell lines 
containing these mutations only increased in the wild-type MACC1 cell line, compared to control and 
all the deletions. In conclusion, our data show a completely new biological role for MACC1 through 
its clear impact on CME, on EGFR downstream signaling and functionally on MACC1-mediated 
proliferation upon EGF stimulation.  
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Figure 42 Investigating MACC1’s role during EGFR endocytic traffic. (1) After EGF-triggered EGFR 
internalization, EGFR and TFR were found colocalizing in MACC1 overexpressing cell in CCPs and CCVs, (3-4) we 
speculate that MACC1 might travel together with the receptors after stimulation, probably via its interaction 
with TfR (established in the previous model) and its suggested shuttling in CCV-TfR marked vesicles and TfR-
marked endosomes. (4) Probably MACC1 recruitment to the TfR-EGFR multicomplex mediates a faster recycling 
of EGFR to PM after stimulated internalization. Further studies are needed to dissect where and how, MACC1 
intervenes during EGFR internalization to increase EGFR recycling to PM, probably decreasing its degradation 
(5) As result, MACC1 overexpression prolongs EGFR transphosphorylation for 30 minutes after EGF-stimulated
internalization. Furthermore, MACC1 increases AKT downstream activation and mildly also ERK1/2 downstream
activation, globally resulting in increased EGF-stimulated proliferation.
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5.12 Future outlook 
 
SH3BP4 has been characterized as taking part in TfR internalization and switching the fate of FGFR 
between degradation and recycling upon ligand-specific stimulation121,122. MACC1 is involved in CME 
and was found to regulate TfR internalization and recycling. We also found that in the presence of 
MACC1, EGF stimulation causes TfR and EGFR to follow the same early endocytic pathway, revealing 
an increased delivery of EGF to acidic compartments. We clarified that the overexpression of MACC1 
is able to increase the recycling of EGFR, which partially explains this increase in the delivery of EGF. 
More interestingly, MACC1 overexpression increases the transactivation of EGFR upon ligand 
stimulation and leads to sustained EGF-mediated proliferation (Fig. 40). MACC1 KD downregulates 
EGFR gene expression in SW620/sh MACC1 compared to SW620/sh control. We also detected 
(Supplementary Fig. 9) MACC1 and MET colocalizing at the PM after triggering the receptor with HGF 
for 5 min. MACC1’s regulation of the HGF/c-MET axis was first identified in our lab, and constitutes 
the key regulator of the prognostic and metastatic driving feature of MACC1. With our preliminary 
evidence on MACC1’s regulative role of TfR and EGFR, CME constitutes a new first line of 
investigation for the future, with a focus on the role of MACC1 during MET CME. Studying MACC1’s 
role in MET’s endocytic trafficking opens a potential field of research for new compounds and 
therapeutic strategies to intervene and target on MACC1-mediated endocytic signaling enforcement. 
Recycling in CME by coupling MACC1-targeted therapeutic strategies with those aiming to impair 
cancer-associated signaling may open an effective path toward improving the overall survival of CRC 
patients. 
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